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General introduction and outline of this thesis 
The kidneys play a vital role in excretion of waste products from the blood, regulating 
blood pressure, water, electrolyte and acid-base homeostasis, and production or 
activation of several hormones. The kidneys also prevent the leakage of plasma 
proteins into the urine. The functional units of the kidney are the nephrons, which 
consist of the glomerulus where the blood is primarily filtered and pro-urine is formed, 
and the renal tubule where solutes and water can be either reabsorbed or excreted 
into the pro-urine. These processes eventually form the urine, containing waste 
products. Filtration of the blood is a charge and size-dependent process that occurs 
in the glomerulus. The glomeruli are a network of capillary loops, enclosed by 
Bowman’s capsule. These capillaries are triple layered, from blood to pro-urine made 
up of glomerular endothelial cells, glomerular basement membrane (GBM) and 
glomerular epithelial cells or podocytes (Figure 1). 
 
Figure 1: Schematic representation of the glomerular capillary filter. 
The glomerular capillaries are coated with fenestrated endothelial cells which are attached to 
the glomerular basement membrane, while the foot processes of the podocytes cover the 
capillaries at the urinary aspect. The endothelium, GBM and podocytes constitute the three 
layers form the glomerular sieve. While the mesangial cells, interconnect the capillary loops 
and in part regulate blood flow into the glomerulus. Reproduced with permission from W. Kriz 
(Institute of Anatomy and Cell Biology, University of Heidelberg, Germany). 
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Podocytes are terminally differentiated and highly specialized epithelial cells that 
consist of 3 parts: a cell body, major processes and foot processes. The interdigitated 
foot processes are connected by the slit diaphragm that contain specific proteins. The 
slit diaphragms contribute to specific filtration slits that are of prime importance for the 
structural integrity and permselectivity of the glomerular filter. Important constituents 
of the slit diaphragm are the transmembrane protein nephrin, which interacts with 
CD2-associated protein (CD2AP), and podocin that connects to the podocyte 
cytoskeleton. Injury to the glomerulus, and the podocyte in particular, can induce 
structural changes that lead to podocyte foot process effacement, which is 
associated with proteinuria as the major clinical outcome. During foot process 
effacement slit diaphragms disappear and injured podocytes can eventually even 
detach from the glomerular capillary. A consequence of podocyte injury may be the 
occurrence of focal segmental glomerulosclerosis (FSGS) or scarring of the 
glomerulus, which can lead to progressive kidney function loss and eventually end 
stage renal failure. 
 
A novel role for the Transient Receptor Potential channel C6 (TRPC6) emerges 
from familial FSGS and acquired glomerular diseases 
Primary FSGS is a disease characterized by a circulating factor that is supposedly 
responsible for podocyte injury and specific glomerulosclerosis lesions. FSGS is also 
manifested secondary to a variety of other renal disease conditions, like minimal 
change disease, membranous nephropathy and diabetic nephropathy. In addition, 
mutations in structural slit diaphragm-associated proteins, like nephrin and podocin, 
cause hereditary forms of FSGS characterized by proteinuria [1-3]. In 2005, the 
groups of Winn and Reiser demonstrated that gain-of-function mutations in the gene 
encoding the six-transmembrane non-selective calcium-conducting ion channel 
Transient Receptor Potential Channel C6 (TRPC6) result in late-onset autosomal 
dominant FSGS [4, 5]. The involvement in glomerular disease of a TRP-type ion 
channel, which is normally expressed in cellular membranes thereby facilitating 
intracellular signaling processes or transcellular ion transport, was a break-through 
finding. The TRP protein superfamily is a diverse group of cation-permeable 
channels, subdivided into six protein subfamilies based on sequence identity [6-9]. 
Several TRP channels are expressed in the kidney, however, they are most 
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abundantly expressed in the tubular system [10, 11]. The human renal TRP 
channelopathies identified include hypomagnesaemia with secondary hypocalcaemia 
(TRPM6), polycystic kidney disease (TRPP1 and TRPP2) and as outlined primary 
FSGS (TRPC6) [4, 5]. 
TRPC6 is expressed in the glomerulus and more specifically at the slit diaphragm of 
the podocyte [12], however, the exact function of this ion channel has still to be 
elucidated (Figure 2). 
  
Figure 2: Schematic representation of the podocyte slit diaphragm. 
Podocyte foot processes are connected by nephrin which is bound to the podocyte by a 
protein complex consisting of amongst others podocin, zona occuldens 1 (ZO-1) and CD2-
associated protein (CD2AP). This protein complex is connected to the podocyte actin 
cytoskeleton which is regulated by synaptopodin and α-actinin 4. In this micro-domain, the 
non-specific calcium (Ca2+) conducting ion-channel Transient Receptor Potential Channel C6 
(TRPC6) is also expressed. TRPC6 dependent Ca2+ influx has been shown to induce 
rearrangement of the podocyte cytoskeleton, which is associated with podocyte foot process 
effacement and proteinuria. 
 
After demonstrating that TRPC6 might be a key factor in the initiation of podocyte 
injury, the attention in the research field of podocyte injury shifted towards TRPC6 
expression [4, 5]. In addition to the genetic gain-of-function mutation, an increased 
glomerular expression of TRPC6 in renal biopsies from patients with acquired non-
familial FSGS, minimal change disease and membranous glomerulopathy was found 
[12]. The glomerular TRPC6 expression pattern in patients with FSGS appeared to 
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be clustered and aggregated as well as segmental more intense, which is in line with 
the focal and segmental glomerular lesions normally observed in FSGS [12]. TRPC6 
expression was upregulated in animal models of membranous glomerulopathy and 
nephrotic syndrome as well [12]. Importantly, podocyte-specific transgenic 
overexpression of TRPC6 in mice induced proteinuria [12]. Moreover, animal models 
for human FSGS, e.g. adriamycin nephropathy, showed a podocyte-specific 
upregulation of TRPC6 expression [13]. Thus, while the exact (patho)physiological 
role of TRPC6 in the podocyte and the pathogenesis of proteinuria was still largely 
elusive, it appeared that TRPC6 overexpression and/or activity is involved in 
podocyte injury. 
 
A role for TRPC6 in deleterious intracellular signaling leading to podocyte 
injury 
TRPC6 had already been previously identified as part of the family of canonical TRP 
channels, in which the TRPC3/C6/C7 channels represent a subfamily by sharing 
approximately 75% amino acid identity and cation-gating by diacylglycerol (DAG) 
[14]. Cell surface receptors are suggested to activate TRPC6-mediated cation entry 
[14-16]. The proposed mechanisms include activation of phospholipase C isozymes 
by e.g. G-protein-coupled receptors and receptor tyrosine kinases to generate DAG 
[14, 17]. DAG is released when such G protein–coupled receptors (GPCRs) are 
activated by their agonist, including Angiotensin II (AngII) activating the AngII 
receptor. AngII has long been recognized as a major deleterious modulator of 
progressive kidney injury, and inhibition of the renin-angiotensin-aldosterone system 
(RAAS) is currently the most successful treatment strategy in reducing proteinuria 
and kidney function decline in patients with glomerular disease. Therefore, previous 
work in our laboratory showed that in the podocyte, AngII can activate TRPC6 
leading to TRPC6-mediated Ca2+ influx, which stimulates the calcineurin/Nuclear 
Factor of activated T-cells (NFAT) signaling pathway (Figure 3). This pathway was 
shown to lead to further TRPC6 transcription and expression, and could be 
successfully blocked by e.g. angiotensin receptor blockers, angiotensin converting 
enzyme inhibitors and calcineurin inhibitors, which are all used to treat proteinuria 
and glomerular disease [18]. Thus, the first experimental evidence emerged that 
could link TRPC6 to several other intracellular pathways leading to podocyte 
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cytoskeleton collapse, podocyte foot process effacement and eventually podocyte 
apoptosis. 
 
Figure 3: Schematic representation of downstream TRPC6 signaling in podocytes. 
Angiotensin II (ANGII) type 1 receptor (AT1R) activation induces phospholipase C (PLC) 
leading to generation of diacyl-glycerol (DAG) and inositol trisphosphate (IP3). DAG activates 
Transient Receptor Potential Channel C6 (TRPC6) leading to calcium (Ca2+) influx. This 
process is followed by activation of the calcineurin/Nuclear Factor of Activated T-cells (NFAT) 
pathway, which stimulates TRPC6 transcription. This feedforward mechanism constitutes a 
driving force for persistent TRPC6-mediated Ca2+ influx, which was also shown to induce 
cytoskeletal rearrangement and podocyte loss. Adapted from T. Nijenhuis. 
 
Aims and objectives addressed in this thesis 
As outlined above, TRPC6 might be a key pathogenic mediator in podocyte injury, 
the development of proteinuria, glomerulosclerosis and eventually loss of kidney 
function. TRPC6 could thereby be a novel treatment target for glomerular diseases. 
Notably, ion channels are generally amenable to pharmacological modulation. 
Therefore, the aim of the work presented in this thesis was to further elucidate the 
role of TRPC6 in the molecular pathophysiology of podocyte injury, 
glomerulosclerosis and proteinuria, as well as study the possibility of TRPC6 or 
TRPC6-mediated signaling as potential therapeutic target.  
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Outline of the thesis 
 
The AngII-TRPC6-Cn/NFAT pathway is operative in diabetic nephropathy (DNP). 
An important and prevalent cause of glomerular disease and proteinuria is diabetes 
mellitus (DM), which can result in diabetic nephropathy (DNP) and end stage kidney 
failure [19]. Currently, around 200 million people are diagnosed with DM and this 
number will exponentially rise in the coming years. Renal injury triggered by 
hyperglycemia, accumulation of advanced glycation end products, high intra-renal 
AngII levels, elevated insulin levels and hypertension-induced mechanical stress of 
mesangial cells, glomerular endothelial cells and podocytes, have all been suggested 
to play a role during development of DNP [20-22]. In both human and experimental 
models for DNP, podocyt injury was correlated with proteinuria, lower nephrin 
expression levels and an altered glomerular distribution of nephrin [23-25]. It was 
shown that AngII induces a reduced nephrin expression in DNP, which could be 
normalized by RAAS blockade [26, 27]. Podocyte injury due to high intrarenal levels 
of AngII and/or high ambient glucose concentrations due to hyperglycemia are 
suggested to play a crucial role in the initiation of DNP [23-25]. In chapter 2 of this 
thesis we will present several in vitro and in vivo experiments to test the hypothesis 
that both AngII and glucose affect TRPC6 in the context of DNP. 
 
Does calpain mediate TRPC6-induced podocyte injury and proteinuria? 
Upregulation of TRPC6 expression activity is associated with podocyte cytoskeleton 
rearrangements, podocyte injury and proteinuria. However, the pathways 
downstream of TRPC6 leading to breakdown of cytoskeletal and slit diaphragm 
associated proteins in the podocyte remain elusive. Members of the calpain family of 
non-lysosomal Ca2+-activated cystein proteases may be potential candidates 
mediating the cleavage of structural and slit diaphragm proteins in the podocyte. 
Calpains do not cleave at a specific amino-acid sequence, they rather cleave proteins 
with a certain tertiary structure [28]. Moreover, it was shown that calpain was able to 
cleave nephrin and the anchoring protein talin-1 [29, 30]. Importantly, levels of active 
calpain in the urine of FSGS patients were higher compared to normal healthy 
controls [30]. It was suggested that calpain-dependent cleavage of structural proteins 
in the podocyte could be a key mechanism for the initiation and progression of 
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podocyte injury. The underlying mechanisms that lead to activation of calpains 
remain elusive. Calpain 1 and 2 are the most well-characterized members of the 
calpain family. Calpain 1 is a µ-calpain, indicating that is activated by Ca2+ at micro 
Molar range, while calpain 2 is a m-calpain, which is activated at milli Molar Ca2+ 
concentrations [28]. Previously, it was described that calpain activation and secretion 
promote glomerular injury in experimental glomerulonephritis [29]. Anti-GBM nephritis 
led to increased calpain activity in the kidney cortex and increased urinary excretion 
of active calpain. This was associated with nephrin downregulation and proteinuria. 
When calpastatin (calpain inhibitor) was overexpressed in mice, a reduction in 
proteinuria and less severe glomerular injury was observed. In addition, when calpain 
was added to a podocyte culture, surface nephrin expression was downregulated 
[29]. Because TRPC6 is a calcium conducting ion-channel, we hypothesized that 
Ca2+ influx via this channel activates calpain. Subsequently, nephrin, talin-1 and 
possibly other structural proteins could be cleaved, which eventually might result in 
effacement of podocyte foot processes. In chapter 3 we addressed the hypothesis 
that TRPC6 activates calpain resulting in podocyte injury and proteinuria. 
 
Vitamin D (analogs) modulate TRPC6 and TRPC6-mediated signaling in 
proteinuric disease. 
Vitamin D (vitamin-D3) is a steroid hormone, which is taken up by the diet or 
synthesized in the skin upon exposure to ultra violet light. Hydroxylation of vitamin-D3 
in the liver leads to 25-hydroxy-vitamin-D3, followed by hydroxylation in the proximal 
tubule of the kidney to its active form 1,25-dihydroxy-vitamin-D3. Vitamin D has a 
crucial role in calcium/phosphate homeostasis, in which TRPV5 and 6 are central 
players. TRPV6, which absorbs Ca2+ from our diet, is abundantly expressed in the 
proximal small intestine. While, TRPV5 expressed in the tubuli of the kidney is 
responsible for the reabsorbtion of calcium from the pro-urine. It has been shown that 
vitamin D upregulates the expression of both TRPV5 and 6 [31, 32].  
During CKD both the glomeruli and the tubuli are injured, thereby gradually losing 
their capacity to activate vitamin D. As a result, 1,25-dihydroxy-vitamin-D3 deficiency 
is a well-known early consequence of CKD, but it is now recognized that vitamin D 
has pleiotropic actions and that its supplementation in CKD patients is directly 
associated with improved survival [33-35]. Importantly, vitamin D supplementation 
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was suggested to be anti-proteinuric in animals with CKD [36-38], possibly by 
preventing podocyte injury and loss. These findings led to our hypothesis that vitamin 
D might protect the podocytes via downregulation of TRPC6 expression, which was 
addressed in chapter 4. 
 
Indeed, studies showed that patients with renal disorders have lowered serum 
vitamin D levels [39, 40]. Several lines of evidence have suggested that vitamin D 
analogs are not only anti-proteinuric, but that vitamin D deficiency could also induce 
or contribute to the proteinuria. In chapter 5, we addressed this hypothesis using a 
mouse model which lacks 1α-hydroxylase, the enzyme in the tubuli of the kidney 
which activates vitamin D, as well as rats with acquired vitamin D deficiency. We 
determined the phenotype of this aforementioned animal models, which included 
addressing podocyte injury and proteinuria.  
 
Does vitamin D regulate heparanase expression and activity in proteinuric 
diseases? 
Heparanase is the only mammalian enzyme that is able to cleave heparan sulfate. 
Previously, we showed that decreased glomerular HS expression in proteinuric 
patients and experimental models for glomerular diseases was associated with 
proteinuria and the upregulation of heparanase expression and activity [41, 42]. 
Notably, we showed that heparanse is essential for the development of proteinuria 
and pathology in experimental diabetic nephropathy, whereas inhibition of 
heparanase activity in other experimental models for other glomerular diseases was 
beneficial [42-49]. Interestingly, both TRPC6 and heparanase expression are 
upregulated in proteinuric diseases [12, 42, 45]. Moreover, we and others showed 
that both heparanase and TRPC6 expression and activity are regulated by the RAAS 
and during diabetic conditions [13, 45, 50, 51]. Additionally, it has been shown that 
both TRPC6 and heparanase share the syndecan heparan sulfate proteoglycans in 
regulation [52-57]. Therefore,we hypothesize that vitamin D in analogy to TRPC6 
also regulates heparanase expression in proteinuric disease. In chapter 6 we have 
addressed this hypothesis, essentially as described in chapter 4 and 5 for TRPC6, 
using similar model systems. 
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Does Sildenafil (Viagra®) potentiates protection against TRPC6-mediated renal 
injury and proteinuria? 
Sildenafil, better known as Viagra® was primarily developed to treat hypertension and 
angina pectoris. However, the first clinical trials were disappointing and currently it is 
used to treat erectile dysfunction and pulmonary hypertension. Sildenafil inhibits the 
activity of phosphodiesterase 5A (PDE5), which breaks down cyclic guanosine 
monophosphate (cGMP) to GMP [58]. Increased cGMP levels will eventually lead to 
vasodilatation of the corpus cavernosum and the pulmonary arteries. In both, 
pulmonary hypertension and erectile dysfunction, a role of TRPC6 during vasodilation 
was shown. Gene therapy by inducing a TRPC6 dominant-negative gene in diabetic 
rats could restore erectile function [59]. The vasoconstriction involved in pulmonary 
hypertension is caused by TRPC6-mediated calcium influx into the pulmonary arterial 
smooth muscle cells (PASMC), and TRPC6 expression in PASMC is increased in 
pulmonary hypertension [60]. Sildenafil treatment reduces the TRPC6 expression in 
PASMC, lowering the pulmonary arterial tone. Interestingly, a possible renoprotective 
effect of sildenafil was described, although this was in ischemia/reperfusion models 
[61, 62]. We hypothesized that Sildenafil affects TRPC6 expression and actitvity in 
podocytes In chaper 7 we addressed this hypothesis using different in vitro and in 
vivo models.  
 
Finally, we have summarized our data in chapter 8, and we have identified future 
lines of research that eventually could lead to targeting of TRPC6 in human 
glomerular and proteinuric diseases. 
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Abstract 
Slit diaphragm and podocyte damage is crucial in the pathophysiology of proteinuria 
in diabetic nephropathy (DNP). Gain-of-function mutations in TRPC6, a slit 
diaphragm-associated ion-channel, cause glomerulosclerosis and TRPC6 expression 
is increased in acquired glomerular disease. Hyperglycemia and high intrarenal 
angiotensin II (AngII) levels could contribute to podocyte injury in DNP. We 
determined whether glucose regulates TRPC6 expression and TRPC6-mediated 
Ca2+ influx into the podocyte, and whether these effects are AngII-dependent. 
High glucose increased TRPC6 mRNA and protein expression in cultured podocytes, 
while TRPC1 and TRPC5 mRNA expression was unaltered. AngII and induced 
podocyte injury also specifically increased TRPC6 expression. Angiotensin receptor 
blockade (ARB) and inhibition of local AngII production through angiotensin-
converting-enzyme inhibition (ACEi) prevented the glucose-mediated increased 
TRPC6 expression. In addition, pre-treatment with high glucose enhanced Ca2+ influx 
in podocytes, which was prevented by concomitant ARB application and TRPC6 
knockdown. Studies with a TRPC6 luciferase promoter construct demonstrated a 
glucose concentration-dependent effect on TRPC6 promoter activity. In vivo, 
podocyte TRPC6 protein expression was increased in proteinuric streptozotocin-
induced diabetic rats. 
Our data suggests that glucose can activate a local renin-angiotensin system in the 
podocyte, leading to increased TRPC6 expression, which enhances TRPC6-
mediated Ca2+ influx. Regulation of TRPC6 expression could be an important factor 
in podocyte injury due to chronic hyperglycemia, and the anti-proteinuric effect of 
ARB or ACEi in DNP. 
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Introduction 
Diabetic nephropathy (DNP) is a major complication of diabetes mellitus and one of 
the leading causes of chronic renal failure, which especially in type 2 diabetes is 
epidemic [1, 2]. Podocytes are crucial constituents of the glomerular capillary filter [3, 
4]. These cells are situated on top of the glomerular basement membrane (GBM), 
where they connect to each other through podocyte foot processes. The latter are 
interconnected by the slit diaphragm complex of proteins, which provides both 
physical linkage and a signaling platform that regulates podocyte behavior [4]. 
Damage to the glomerular capillary filter, in particular at the level of the podocyte and 
the slit diaphragm, is of crucial importance in the pathophysiology of DNP, which 
eventually leads from microalbuminuria to overt proteinuria with renal function decline 
[1, 2, 4-6]. It was previously shown that several factors could contribute to the 
podocyte damage in DNP, including hyperglycemia and high intrarenal angiotensin II 
(AngII) levels [1, 5, 6].  
 
The Transient Receptor Potential channel C6 (TRPC6) has been identified as a slit 
diaphragm-associated protein in podocytes [7, 8]. Gain-of-function mutations in 
TRPC6 have been shown to cause autosomal dominant focal segmental 
glomerulosclerosis (FSGS) and enhanced podocyte TRPC6 expression leads to 
glomerular damage [7-10]. It is hypothesized that enhanced Ca2+ influx due to an 
increased number of functional TRPC6 channels or enhanced channel activity at the 
cell surface, compromises the structural integrity of the podocyte leading to 
proteinuria. The signaling complex is suggested to incorporate other crucial podocyte 
proteins such as nephrin, podocin and CD2AP, but also large-conductance Ca2+-
activated K+ (BKCa) channels, which could preserve the driving force for Ca2+ influx 
through TRPC6 [4, 7, 11, 12]. This slit diaphragm signaling complex is mechanically 
and functionally linked to the podocyte actin cytoskeleton [4, 11]. Overexpression of 
TRPC6 in cultured podocytes results in actin stress fiber loss and cytoskeletal 
rearrangement, which is a crucial early event in the pathophysiology of proteinuria 
[9]. 
 
TRPC6 is a receptor-operated cation channel, which can be activated in vitro by 
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AngII [8, 13-19]. AngII is a key contributor in the pathogenesis of glomerular disease, 
and the anti-proteinuric effects of angiotensin converting enzyme (ACE) inhibition and 
angiotensin type 1 receptor (AT1R) blockade (ARB) in DNP are undisputed [20, 21]. 
We, and others, have previously shown that TRPC6 expression in the podocyte is 
regulated by several hormones such as vitamin D and AngII [16, 18, 19, 22]. 
Activation of TRPC6 by AngII drives several intracellular pathways, including a feed-
forward pathway in which AngII-induced, TRPC6-mediated Ca2+ influx appears to 
activate the calcineurin/NFAT signaling, leading to enhanced TRPC6 expression [16, 
19]. In addition, AngII-dependent albuminuria is ameliorated in TRPC6 knockout mice 
[18]. Thus, AngII-induced TRPC6 expression plays a role in the pathogenesis of 
proteinuria. It was previously suggested that TRPC5, a related Ca2+-permeable ion 
channel, has antagonistic actions to TRPC6 in the podocyte [23-25]. However, a 
recent study actually suggested that TRPC5 inhibition would be anti-proteinuric [25, 
26]. Altering expression of either TRPC channel in AT1R-expressing podocytes led to 
distinct AngII-induced actin cytoskeletal changes. Thus, TRPC5 expressional 
regulation or the TRPC6/TRPC5 ratio, could also be relevant in podocyte injury. In 
addition, high glucose levels have been shown to induce several deleterious effects 
in podocytes, including reduced nephrin, podocin, synaptopodin and BKCa channel 
expression [5, 27]. Interestingly, glucose is also able to activate a local renin-
angiotensin-aldosterone system (RAAS) in the podocyte, leading to production of 
AngII by the podocyte itself as well as enhanced expression of the AT1R [6]. 
 
The aim of the present study was to determine whether the glucose concentration 
itself regulates TRPC(6) mRNA and protein expression and, thereby TRPC6-
mediated Ca2+ influx into the podocyte and, if so, whether this is an AngII-dependent 
effect. To this end, the effect of high glucose and AngII on the transcription of several 
TRPC channels expressed in the podocyte, as well as on Ca2+ influx, was 
determined in cultured podocytes. In addition, we evaluated whether the effect of the 
glucose concentration was a primary one, or secondary to the activation of a local 
RAAS. Eventually, we evaluated whether our in vitro results also occurred in a 
relevant in vivo situation, in hyperglycemic and proteinuric streptozotocin-induced 
diabetic (STZ-DM) rats. 
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Methods 
Cell culture 
Conditionally immortalized mouse podocytes (MPC-5), either untransfected or stably 
transfected with tetracycline-inducible TRPC6 knockdown (KD) or scrambled siRNA 
constructs, were cultured as described previously [16, 28]. After differentiation, the 
glucose concentration in the medium was varied by adding glucose to glucose-free 
RPMI (Life Technologies, Carlsbad, USA) to achieve the indicated glucose 
concentrations, and mannitol was used to control for osmotic strength. Depending on 
the exact experimental setup, AngII (1 µM), losartan (100 µM), captopril (1 mM), or 
chymostatin (100 µM) was added. Four days prior to the TRPC6 KD experiments, 
podocytes were treated with 5 µg/ml tetracyclin to induce the TRPC6 siRNA. 
 
Real-time quantitative RT-PCR analysis 
Total RNA was isolated from cultured podocytes and RNA was reverse transcribed 
(Transcriptor Kit Roche Diagnostics, Mannheim, Germany). Real-time quantitative 
PCR was performed using SYBR Green Supermix (Roche Diagnostics, Mannheim, 
Germany) on a MyiQ Real-Time PCR Detection System (Bio-Rad Laboratories, CA, 
USA). Expression of the respective genes was quantified by the delta-delta cycle 
time (Ct) method using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the 
house-keeping gene. RNA polymerase was used as a second house-keeping gene, 
to rule out regulation of GAPDH (data not shown). In these experiments, N=5-8 
separate mouse podocyte cultures were used per experimental condition per 
experiment, and all experiments were repeated at least twice for confirmatory 
purposes. 
 
Western blotting 
TRPC6 protein expression in cultured podocytes was assessed by Western blotting 
and semi-quantitative immunocytochemistry. Western blotting was performed as 
follows: podocytes were lysed in a 50 mM Tris pH 7.5 buffer containing 150 mM 
NaCl, 0.5% w/v SDS, 0.5% v/v Triton X-100, 2 mM EDTA, 1mM PMSF and the 
Complete Mini cocktail of protease inhibitors (Roche Diagnostics, Mannheim, 
Germany). Protein concentration was determined and samples containing equal 
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amounts of protein were resolved by 10% (w/v) SDS-PAGE and blotted to 
nitrocellulose membranes (Whatman, GE Healthcare, UK). Blots were incubated with 
rabbit polyclonal anti-mouse TRPC6 antibody (ACC-017, Alomone, Jeruzalem, Israel) 
and mouse anti-β-actin antibody (AC-15, Sigma-Aldrich, Zwijndrecht, the 
Netherlands) and subsequently with peroxidase-labeled secondary antibodies. 
Proteins were visualized using chemiluminescence and signal intensity was 
determined digitally. 
 
Intracellular Ca2+ imaging studies 
Intracellular Ca2+ was visualized using the fluorescent Ca2+ indicator Fura-2 as 
performed previously[29]. Cultured podocytes with or without the TRPC6 KD or 
scrambled construct were seeded on collagen A coated 96-wells plates and 
differentiated during 2 weeks. After induction of siRNA with tetracyclin, cultures were 
pre-treated with 5 mM glucose, 5 mM glucose with 35 mM mannitol or 40 mM 
glucose, with or without the ARB losartan (100 µM) for 24 hrs. Hereafter, the cells 
were washed and put in Ca2+-containing buffer. Subsequently, cells were treated with 
100 µM 1-oleoyl-2-acetyl-sn-glycerolin (OAG) (Sigma-Aldrich, St. Louis, USA) in the 
presence or absence of 100 µM 2-aminoethoxydiphenyl borate (2-APB) (Sigma-
Aldrich, St. Louis, USA) and intracellular Ca2+ was measured by fluorescence using a 
specialized microscope (Becton Dickinson’s Pathway 855, BD Biosciences, San 
Jose, USA). Data is presented as 340/380 nm ratio. Data from selected cell 
populations was averaged, and statistical analysis was performed on multiple 
experiments. 
 
Luciferase TRPC6 promoter activity assay 
The promoter region of the mouse TRPC6 gene (−1500/+32; +1 designates the 
transcription start site, NM_013838.2) was obtained after amplification of genomic 
DNA. The PCR product was cloned into the pGL3-Basic luciferase reporter vector 
and the promoter sequence was verified by Sanger sequence analysis. The pRL-
CMV vector encoding Renilla luciferase under control of a CMV promoter was used 
as control for transfection efficiency (Promega, Fitchburg, USA). HEK293 cells were 
cultured in DMEM/F12 medium supplemented with 10% (v/v) FCS, 15 mM HEPES, 
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2.5 mM L-glutamine at 37°C in a humidity-controlled incubator with 5% (v/v) CO2. 
Briefly, cells were seeded in a 12-well plate and transfected the following day in full 
medium. The transfection mixture was prepared in 60 µl Optimem (Invitrogen, 
Carlsbad, USA) and consisted of 1 µg of either TRPC6 -1500 promoter construct or 
empty pGL3-basic vector, 50 ng of pRL-CMV and 4 µl Lipofectamin2000 (Invitrogen, 
Carlsbad, USA). The glucose concentration in the medium was varied and mannitol 
was used to control for osmotic strength. Cells were harvested 48 hours post-
transfection and luciferase activity was determined using a dual luciferase reporter 
assay system (Promega, Fitchburg, USA).  
 
Animal studies 
Diabetes was induced in male Wistar–Münich rats (body weight 211 ± 12 g) by 
intravenous injection of STZ (55 mg/kg body weight) [30]. Sex- and age-matched 
control rats received saline injections. By treatment with 1.2 IU of bovine insulin 
(Ultralente; Novo, Copenhagen, Denmark) three times a week blood glucose levels 
were maintained around 20-25 mM. Body weight, blood glucose, urine production, 
and albuminuria were measured. Five months after the induction of diabetes, rats 
were sacrificed and kidneys were processed for analysis. Approval by the animal 
ethics committee of the Radboud University Nijmegen was obtained. 
 
Immunohistochemistry and immunocytochemistry  
Glomerular expression of TRPC6 was determined by semi-quantitative scoring of 
immunofluorescence staining in 2 µm kidney cryosections as described previously 
[16]. Double staining with nephrin was performed to evaluate whether the increased 
TRPC6 expression occurred in podocytes. Glomerular TRPC6 expression was 
scored semi-quantitatively from 0 to 5 based on the extent of TRPC6 
immunofluorescence staining in the glomerulus. Scoring was performed 
independently by two investigators, which scored 35-50 glomeruli per animal on 
blinded sections. Immunocytochemistry on cultured podocytes was performed as 
previously described [16]. Immunocytochemical staining intensity was quantified 
using Image J software (version 1.47). 
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Statistical analysis 
Data are expressed as means ± SEM. All statistical analyses were conducted by two-
tailed student’s t-test when comparing 2 treatment groups or experimental conditions, 
and ANOVA when comparing 3 or more treatment groups or conditions, using SPSS 
(IBM, New York, USA). P values less than 0.05 were considered significant. 
 
Results 
Glucose specifically increased TRPC6 expression in cultured podocytes 
TRPC6 mRNA expression was significantly upregulated in podocytes when glucose 
concentration in the culture medium was increased from 5mM to 25mM and 40mM, 
and compared to respective osmotic controls (Figure 1A). However, the mRNA 
expression of TRPC5, which has been suggested to play an antagonistic role to 
TRPC6 in the podocyte, remained unaltered (Figure 1B). In addition, TRPC1 mRNA 
expression, which is a Ca2+-permeable ion channel to which no specific role has 
been attributed in the podocyte as yet, was unaltered by increasing the glucose 
concentration in the culture medium (Figure 1C). When expressed as individual ratio 
per culture sample, the TRPC6 over TRPC5 ratio was significantly higher under high 
glucose conditions (Figure 1D). As previously reported, high glucose concentration 
significantly reduced nephrin mRNA expression in these podocytes (Figure 1E). BKca 
channel expression was not altered when compared to osmotic controls, but was 
reduced when compared to normal glucose conditions (Figure 1F). 
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Figure 1: Effect of high glucose on TRPC6, TRPC5, TRPC1, nephrin and BKCa expression in 
podocytes.  
The effect of medium with a glucose concentration of 5, 25 and 40 mM during 24h on (A) 
TRPC6, (B) TRPC5, (C) TRPC1, nephrin (E) and BKCa (F) mRNA expression by 
differentiated podocytes was determined by real-time quantitative RT-PCR analyses. As 
osmotic controls, medium with 5mM glucose and either 20 or 35 mM mannitol was used. In 
addition, TRPC6/TRPC5 ratios were quantified (D). * p < 0.05 compared to 5 mM glucose. † p 
< 0.05 compared to 5 mM glucose + 20 mM mannitol. ‡ p < 0.05 compared to 5 mM glucose 
+ 35 mM mannitol. 
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TRPC6 promoter activity is enhanced by high glucose  
To study whether the observed effect of high glucose on TRPC6 expression was 
mediated by stimulation of TRPC6 promoter activity, the -1500 bp region upstream to 
the TRPC6 start codon was cloned into a luciferase reporter construct. Figure 2 
demonstrates that glucose significantly enhances TRPC6 promoter activity in a 
concentration-dependent manner. 
 
Figure 2: High glucose enhances TRPC6 promoter activity in a concentration-dependent 
manner. 
 The effect of increasing glucose concentrations on TRPC6 promoter activity was determined 
by luciferase assay in HEK293 cells transiently transfected with a TRPC6 promoter or the 
empty vector as control construct, driving Firefly luciferase expression. A Renilla luciferase 
construct was co-transfected to correct for transfection efficiency and the Firefly/Renilla ratio 
was determined as a measure of promoter activity. Ratios were normalized to the mean of 
HEK293 cells transfected with the TRPC6 promoter construct at 5mM glucose. * p < 0.05 
compared to 5 mM glucose. 
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Regulation of podocyte TRPC6 promoter activity, mRNA and protein 
expression by glucose is AngII-dependent 
We previously showed that TRPC6 expression in podocytes was regulated by AngII 
[16]. Previous studies suggest that some effects of high glucose in the podocyte are 
mediated via AngII [5, 6]. Figure 3 shows that AngII increases the expression of 
TRPC6 mRNA expression (Figure 3A). In contrast, it did not alter expression of 
TRPC5 (Figure 3B) or TRPC1 (Figure 3C) in podocytes. Accordingly, the 
TRPC6/TRPC5 ratios were significantly increased by AngII treatment (Figure 3D). 
BKCa channel expression was not altered by AngII treatment (Figure 3E). Previously, 
we demonstrated that the effect of PAN- and Adriamycin-induced podocyte injury on 
TRPC6 expression in podocytes is AngII-mediated [16]. In line with the above results, 
TRPC6 mRNA levels were increased by PAN as well as by adriamycin treatment 
(Figure 3F). Again, TRPC5 (Figure 3G) and TRPC1 (Figure 3H) mRNA expression 
was not affected in these podocyte injury models. TRPC6/TRPC5 ratios (Figure 3I) 
were increased in both podocyte injury models, which were ameliorated by 
application of the ARB losartan (Figure 3F and 3I). 
 
To evaluate whether the effects of glucose concentration described above are also 
mediated through AngII/AT1R signaling, we blocked the AT1R under high glucose 
conditions by co-incubation with the ARB losartan. ARB treatment prevented the 
upregulation of TRPC6 mRNA expression in high glucose medium (Figure 4A). The 
expression of TRPC5 (Figure 4B) and TRPC1 (Figure 4C) remained unaltered, 
either at normal or high glucose concentration. In addition, ARB treatment normalized 
the TRPC6/TRPC5 expression ratios (Figure 4D).  
 
 
 
 
 
 
 
Chapter 2 
 
 
 
 
  
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glucose affects podocyte TRPC6 via angII 
 
 
 
 
 
33 
 
 
 
Figure 3: AngII/AT1R signaling specifically regulates TRPC6 expression in podocytes.  
The effect of 1 µM AngII on (A) TRPC6, (B) TRPC5, (C) TRPC1 and (E) BKCa mRNA 
expression was determined by real-time quantitative RT-PCR analyses. Panel D depicts 
TRPC6/TRPC5 ratios in control (CTR) and AngII-treated (AngII) podocytes. In addition, the 
effect of angiotensin receptor blockade (ARB) by 100 µM losartan in podocyte injury induced 
by 100 µg/ml puromycin aminonucleoside (PAN) or 0.25 µg/ml adriamycin (ADRIA) on (F) 
TRPC6, (G) TRPC5 and (H) TRPC1 mRNA expression and (I) TRPC6/TRPC5 ratios were 
determined. * p < 0.05 compared to control (CTR). † p < 0.05 compared to PAN-treated 
podocytes. ‡ p < 0.05 compared to ADRIA-treated podocytes. 
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Figure 4: Angiotensin receptor blockade prevents the induction of TRPC6 mRNA expression 
by high glucose.  
The effect of 100 µM losartan (ARB) on (A) TRPC6, (B) TRPC5 and (C) TRPC1 mRNA 
expression in medium with 5 mM glucose and 40 mM glucose was determined by real-time 
quantitative RT-PCR analyses. Panel D shows TRPC6/TRPC5 ratios the respective 
treatment groups. * p < 0.05 compared to 5 mM glucose. † p < 0.05 compared to 40 mM 
glucose. 
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Accordingly, luciferase activity assays demonstrated that the enhanced TRPC6 
promoter activity under high glucose conditions is also AngII/AT1R-responsive 
(Figure 5). These data suggest that regulation of TRPC6 expression by glucose in 
podocytes is indeed AngII-dependent. 
 
Figure 5: Angiotensin receptor blockade prevents high glucose-induced TRPC6 promoter 
activity.  
The effect of 100 µM losartan (ARB) on high glucose-induced TRPC6 promoter activity was 
determined by luciferase assay in HEK293 cells as previously described. * p < 0.05 
compared to 5 mM glucose. † p < 0.05 compared to 40 mM glucose. 
 
To ascertain whether the above described effects of glucose and AngII on TRPC6 
promoter activity and mRNA expression also resulted in alterations of TRPC6 protein 
levels, we performed semi-quantitative immunocytochemistry (Figure 6A and B) and 
Western blot analyses (Figure 6C and D). Indeed, high glucose increased TRPC6 
protein expression in podocytes, and ARB treatment prevented the upregulation of 
TRPC6 protein expression.  
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Figure 6: Angiotensin receptor blockade prevents the induction of TRPC6 protein expression 
by high glucose.  
The effect of medium with a glucose concentration of 5 and 40 mM, including the appropriate 
osmotic control (5 mM glucose and 35 mM mannitol) during 24h on TRPC6 protein 
expression in podocytes was determined by immunofluorescent staining (A, semiquantified in 
B) and Western blotting (C, quantified in D). In addition, the effect of 100 µM losartan (ARB) 
on high glucose-induced TRPC6 expression was determined. * p < 0.05 compared to 5 mM 
glucose. † p < 0.05 compared to 40 mM glucose. 
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High glucose induces enhanced Ca2+ influx in the podocyte 
To determine whether the upregulation of TRPC6 protein expression results in 
increased intracellular Ca2+ influx in the podocyte, Fura-2 ratiometry secondary to 
stimulation by the diacylglycerol (DAG) analogue 1-oleoyl-2-acetyl-sn-glycerol (OAG) 
was performed. In a previous publication we already showed that the majority of 
OAG-induced Ca2+ influx into podocytes appears mainly to be mediated by TRPC6 
[16]. After pretreatment of cells in an identical way as described above, we 
subsequently tested Ca2+ influx under normal and similar glucose concentrations, to 
prevent measuring direct effects of glucose concentration on Ca2+ influx. 
Pretreatment with 40mM glucose increased the OAG-activated Ca2+ influx into the 
podocyte (Figure 7A), which could be normalized by concomitant pretreatment with 
the ARB losartan, compared to 5 mM glucose and its osmotic control (5mM glucose 
with 35mM mannitol). Addition of the TRPC channel inhibitor 2-aminoethoxydiphenyl 
borate (2-APB) abolished the Ca2+ influx in all groups (Figure 7B). Since the 
inhibitory action of 2-APB is not TRPC6-specific, we studied whether TRPC6 
specifically mediated the increased Ca2+ influx by comparing Ca2+ influx in podocytes 
in which we induced expression of scrambled siRNA and TRPC6 siRNA resulting in 
65±3% KD of TRPC6 expression. These experiments demonstrated that TRPC6 KD 
significantly reduced the Ca2+ influx in cells treated with 40mM glucose (Figure 7C). 
Moreover, addition of ARB in these TRPC6 KD cells did not lead to a significant 
further reduction in Ca2+ influx. TRPC6 KD completely abolished Ca2+ influx in cells 
cultured under normal glucose concentration and under osmotic control conditions 
(Figure 7D). 
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Figure 7: High glucose increases Ca2+ influx into podocytes, which is abolished by 
angiotensin receptor blockade.  
Intracellular Ca2+ concentration was determined by Fura-2 ratiometry. Cells were 24h pre-
treated with 5 mM glucose, 5mM glucose with 35 mM mannitol or 40 mM glucose with or 
without 100 µM losartan (ARB). After removal of the specific media, cells were exposed to 
100µM OAG to activate the TRPC6 ion-channel (A). In the same setup, cells were treated 
with 100 µM 2-APB to inhibit TRPC mediated Ca2+ influx (B). A similar experiment was 
performed using podocytes transfected with a TRPC6 siRNA or scrambled siRNA control 
construct after pre-treatment with 40mM glucose, with or without ARB (C), and 5mM glucose 
and 5mM with 35mM mannitol (D). * p < 0.05 compared to 5 mM glucose. † p < 0.05 
compared to 40 mM glucose treated TRPC6 KD siRNA transfected podocytes. ‡ p < 0.05 
compared to 5 mM glucose treated TRPC6 KD siRNA transfected podocytes. 
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Durvasula et al. previously reported that a high glucose concentration results in 
enhanced AT1R expression as well as AngII production by the podocyte itself [6]. 
The above-described data, showing the effect of ARB, is in line with either TRPC6 
expression being enhanced by either glucose-induced AT1R expression or activation 
of local RAAS leading to AngII production. Therefore, we evaluated whether inhibition 
of AngII production by either blocking ACE by captopril (ACEi) or inhibiting the non-
ACE-mediated pathway by chymostatin application (nonACEi) affected glucose-
induced TRPC channel regulation. Both ACEi as well as nonACEi prevented the high 
glucose-induced TRPC6 expression (Figure 8A). Whereas high glucose 
concentration did not affect TRPC5 expression, captopril, but not chymostatin, 
enhanced TRPC5 expression (Figure 8B). ACEi as well as nonACEi reduced 
podocyte TRPC1 expression (Figure 8C). The increased TRPC6/TRPC5 ratio was 
reduced by both ACEi and nonACEi (Figure 8D). 
 
Glomerular TRPC6 expression is enhanced in streptozotocin-induced diabetic 
rats 
To study whether our in vitro results also occurred in a relevant in vivo situation, we 
determined TRPC6 expression in hyperglycemic and proteinuric STZ-induced 
diabetic rats. Before sacrifice, five months after STZ injection, rats showed a 
significant hyperglycemia (21.2 ± 0.7 mM versus 3.9 ± 0.6 mM in untreated, non-
diabetic controls) (Figure 9A). Diabetic rats demonstrated a significant albuminuria 
(44.0 ± 7.0 mg/24h versus 0.4 ± 0.2 mg/24h in non-diabetic controls) (Figure 9B). 
Immunohistochemistry studies showed an increased glomerular TRPC6 expression 
in diabetic rats, as semi-quantified in Figure 9C. An increased TRPC6 expression in 
podocytes was confirmed by TRPC6/nephrin co-staining (Figure 9D; representative 
images). Most of the TRPC6 signal appears to be present in the podocytes, although 
some staining can be appreciated that does not co-localize with nephrin. 
Chapter 2 
 
 
 
 
  
40 
 
 
Figure 8: Inhibition of local AngII production by the podocyte prevents the induction of 
TRPC6 expression by high glucose.  
The effect of 1 mM captopril (ACEi) or 100 µM chymostatin (nonACEi) on (A) TRPC6, (B) 
TRPC5 and (C) TRPC1 mRNA expression in medium with 5 mM glucose and 40 mM glucose 
was determined by real-time quantitative RT-PCR analyses. Panel D shows TRPC6/TRPC5 
ratios the respective treatment groups. * p < 0.05 compared to 5 mM glucose. † p < 0.05 
compared to 40 mM glucose. 
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Figure 9: Glomerular TRPC6 expression in hyperglycemic and proteinuric streptozotocin-
induced diabetic rats. 
 (A) Serum glucose levels in non-diabetic control rats (CTR) and rats in which diabetes 
mellitus was induced by streptozotocin injection (STZ-DM). (B) Urinary albumin excretion in 
CTR and STZ-DM rats. (C) Glomerular TRPC6 expression was determined by semi-
quantitative analyses of immunofluorescence signals by scoring performed independently by 
two investigators, which scored 35-50 glomeruli per animal on blinded sections. (D) To 
confirm increased TRPC6 expression in podocytes, TRPC6/nephrin co-staining was 
performed. * p < 0.05 compared to control rats. 
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Discussion 
This study showed that high glucose specifically increases TRPC6 transcription and 
TRPC6 protein expression, resulting in increased Ca2+ influx into podocytes, in an 
AngII-dependent manner. Increasing the glucose concentration in the medium 
enhanced TRPC6 expression in cultured podocytes, while the expression of TRPC1 
and TRPC5 was unaltered. In particular, we could demonstrate that high glucose 
stimulates TRPC6 promoter activity. The increased TRPC6 expression was 
functionally accompanied by an increased Ca2+ influx into podocytes, which was 
inhibited by inducible TRPC6 KD, therefore suggesting that the high glucose-induced 
TRPC6 overexpression leads to increased numbers of functional TRPC6 channels at 
the podocyte cell membrane. Addition of AngII specifically enhanced expression of 
TRPC6, but not the other tested TRPC channels, a finding that was also confirmed in 
the primarily AngII-mediated PAN- and adriamycin-induced podocyte injury models. 
The ARB losartan prevented the high glucose-induced TRPC6 promoter activity, 
TRPC6 expression and Ca2+ influx into podocytes, which suggests that the effect of 
glucose concentration on TRPC6 transcription is AngII-dependent. Indeed, inhibition 
of local AngII production diminished high glucose-mediated TRPC6 expression. In 
vivo, glomerular TRPC6 expression was significantly increased in hyperglycemic and 
proteinuric STZ-DM rats, predominantly in podocytes. While the latter data do not 
prove the regulation of TRPC6 by glucose and AngII in vivo, recurrent or chronic 
hyperglycemia in diabetes could activate a local RAAS in the podocyte, leading to 
increased transcription of TRPC6. Chronic enhanced TRPC6 expression could be an 
important factor in inducing persistent podocyte injury in the pathogenesis of 
proteinuria, and reducing this expression by ARB or ACEi could be part of their 
beneficial role in DNP. 
 
High glucose has been previously shown to regulate several proteins suggested to 
be involved in the slit diaphragm signaling complex, including downregulation of 
nephrin, podocin and CD2AP, but also reduction of the cell surface expression of 
large-conductance Ca2+-activated K+ BKCa channels [5, 27, 31, 32]. These regulatory 
effects are all suggested to be deleterious to the podocyte, and have also been 
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confirmed in in vivo diabetic animal models including the STZ-DM model. In this 
study we demonstrated that TRPC6 expression is increased in podocytes in STZ-DM 
rats. Although this model has been used extensively to study DNP in the past, we 
cannot rule out that other factors apart from hyperglycemia and AngII, or the STZ 
itself might be responsible for the podocyte injury and TRPC6 upregulation. However, 
as gain-of-function mutations or increased expression of TRPC6 in the podocyte are 
generally suggested to lead to podocyte damage, glucose-induced TRPC6 
expression is in line with the current literature on high glucose-induced pathological 
effects in podocytes, as well as with the in vitro data presented in this work. 
 
Importantly, our data suggest that the effect of high glucose on TRPC6 expression in 
the podocyte is mediated by local AngII production and AngII/AT1R signaling. 
Indeed, Durvasula et al. showed that high glucose activates a local RAAS in these 
cells [6]. In addition, they demonstrated that exposure to high glucose increases 
AngII production by the podocyte itself, which could be blocked by application of 
ACEi or chymostatin. Our data suggest that a high glucose-induced upregulation of 
TRPC6 expression leads to an AngII-dependent increased OAG-stimulated Ca2+ 
influx into podocytes through TRPC6 channels specifically. However, when TRPC6 
KD cells were treated with 40mM glucose, a residual Ca2+ influx remained, while in 
podocytes treated with the non-specific TRP-channel blocker 2-APB Ca2+ influx was 
absent. This could be due to the remaining TRPC6 expression as TRPC6 KD was 
not complete, but also leaves the theoretical possibility that another TRP channel 
might be responsible. 
 
Recently, we have shown that AngII contributes to podocyte injury by increasing 
TRPC6 expression via a mechanism in which TRPC6-mediated Ca2+ influx, 
stimulates a calcineurin/NFAT-dependent pathway, resulting in enhanced TRPC6 
transcription [16]. In this way, a putatively deleterious feedback mechanism is 
activated which, when continuously stimulated, could eventually perpetuate podocyte 
injury. We, and others, showed that activation of NFAT signaling in podocytes 
increases glomerular TRPC6 expression and causes glomerulosclerosis and 
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proteinuria [16, 33, 34]. Furthermore, the involvement of MAPK, ERK, JNK and NF-
κB pathways in AngII-induced TRPC6 expression has been previously suggested 
[19]. The clinical relevance of AngII-mediated TRPC6 regulation was also shown in 
studies by Eckel et al., which demonstrated reduced AngII-induced albuminuria and 
attenuated AngII-mediated Ca2+ influx into podocytes in TRPC6 knockout mice [18]. 
A very attractive hypothesis that has been put forward suggests that the AngII-
mediated Ca2+ influx through TRPC6, via calcineurin activation, would also induce 
cathepsin L-mediated synaptopodin degradation leading to disorganization of the 
podocyte cytoskeleton [16, 35]. Both synaptopodin downregulation and podocyte 
cytoskeletal changes were previously shown in DNP. Alternatively, other pathways 
including RhoA activation could link TRPC6 function and expression to cytoskeletal 
changes in the podocyte. Furthermore, regulation of TRPC6 activity by e.g. nephrin in 
the slit diaphragm signaling complex could be impaired, as absence of nephrin 
causes increased TRPC6 expression in podocytes of nephrin knockout mice [36]. In 
line with this mechanism, this and other previous studies have consistently shown 
reduced nephrin expression in DNP and during high glucose in cultured podocytes. 
Whatever the mechanisms secondary to TRPC6 upregulation, our data show that the 
concerted actions of two pathogenic factors believed to be implicated in DNP, 
hyperglycemia and high intrarenal AngII levels, result in deleterious TRPC6 
overexpression in podocytes. 
 
In addition to TRPC6 expression, we determined TRPC1 and TRPC5 mRNA 
expression, which were both not altered by high glucose or AngII. Previously, TRPC6 
and TRPC5 were suggested to function as antagonistic regulators of actin 
remodeling in podocytes, while TRPC5 inhibition was recently suggested to be 
antiproteinuric [24, 26]. Both channels were proposed to activate, secondary to 
generating Ca2+ microdomains, specific Rho GTPases that are spatially restricted to 
these respective channel proteins. Altering expression of either TRPC channel in 
AT1R-expressing podocytes led to distinct actin cytoskeletal changes induced by 
AngII. This would suggest that regulation of TRPC5 expression, or possibly even 
more importantly the TRPC6/TRPC5 ratio, could also be relevant in podocyte injury 
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[24, 25]. However, while TRPC6 was highly regulated in podocyte injury, by AngII 
and glucose, TRPC5 expression was strikingly stable under these conditions. As a 
result of this, TRPC6/TRPC5 ratios were consistently increased by glucose, AngII, 
and in the PAN and Adriamycin-induced podocyte injury models. While, as indicated 
above, our functional data do not preclude the contribution of another TRP channel to 
the high glucose-induced Ca2+ influx in the podocyte, these data suggest that high 
glucose- and AngII-induced regulation of TRPC channel expression is specific for 
TRPC6, and that direct regulation of TRPC5 transcription does not occur.  
 
DNP is a diabetic complication that takes years to develop. This suggests that 
hyperglycemia and high AngII levels do not lead to immediate podocyte injury and 
proteinuria in vivo. The question then arises how the podocyte is able to protect itself 
from persistently high expression of TRPC6. An explanation by which the podocyte 
could counteract deleterious TRPC6 expression, was recently eluted by Kim et al. 
These authors had previously shown that TRPC6 is co-localized with BKCa channels 
in podocytes, and that increasing TRPC6 expression in podocytes enhances BKCa 
channel surface expression, whereas knockdown of TRPC6 resulted in the opposite 
[12]. It was hypothesized that enhanced TRPC6 expression and, thereby, Ca2+ influx 
would lead to depolarization of the podocyte cell membrane, which would 
theoretically lead to blockade of TRPC6 pores by Ca2+ at more positive potentials. 
Thus, in order to sustain Ca2+ influx through TRPC6, depolarization needs to be 
limited, which could be brought about by coordinated activation of these Ca2+-
activated K+ channels upon increasing TRPC6 expression. Importantly, it was 
recently shown that high glucose actually reduces BKCa expression at the podocyte 
cell surface, without altering BKCa total expression [27]. Our data demonstrated that 
total BKCa mRNA levels were not changed by high glucose when compared to 
osmotic controls. However, levels were reduced compared to normal glucose per se. 
Reducing BKCa total and/or cell surface expression could protect against unlimited 
Ca2+ influx through an increased amount of TRPC6 channels, which would mitigate 
the direct deleterious effect of high glucose-induced TRPC6 expression in the 
podocyte. This hypothesis asks for follow-up studies that determine the TRPC6-
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mediated Ca2+ influx into podocytes in the situation where BKCa cell surface 
expression is reduced.  
 
Insulin plays a pivotal role in glucose metabolism and diabetes. Interestingly, it was 
recently shown that insulin affects TRPC6 cell surface expression and function in the 
podocyte, without altering total TRPC6 expression [23]. The authors argued that this 
could be part of a mechanism to maintain podocyte and slit diaphragm stability in 
response to e.g. transient hyperglycemia secondary to a high carbohydrate meal. 
While an interesting hypothesis, the same authors showed that insulin enhances 
BKCa cell surface expression both in normal and high glucose medium, which would 
further enable deleterious TRPC6-mediated Ca2+ influx [27]. Thus, insulin release 
due to hyperglycemia, at least in the early stages of type 2 diabetes, could very well 
also contribute to TRPC6-mediated podocyte injury. Since insulin stimulates glucose 
entry into cells via stimulation of the GLUT-type glucose transporters, and podocytes 
express both GLUT1 and GLUT4, our data suggest that enhanced glucose influx can 
be involved in the response to insulin [37]. Future studies should elucidate whether 
combinations of high concentrations of insulin and glucose, resembling type 2 
diabetes, possibly lead to an even more increased TRPC6 expression and 
functionality in podocytes. If so, this might stimulate the accelerated progression of 
diabetic nephropathy. 
 
Taken together, whereas we currently lack a full comprehensive understanding of 
TRPC6 regulation by all pathogenic factors implicated in DNP, our data add new 
information to this field of research. The data presented here demonstrate that high 
glucose increases TRPC6 mRNA and protein expression in podocytes in an AngII-
dependent manner, leading to an increased OAG-responsive Ca2+ influx carried by 
TRPC6 channels into the podocyte. AngII-mediated TRPC6 expression appears to 
be an important factor inducing continued podocyte injury in the pathogenesis of 
proteinuria. Therefore, reducing TRPC6 expression by ARB or ACEi, as we have 
shown in this and previous studies, could be part of the known beneficial effects of 
RAAS inhibition on proteinuria in DNP. 
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Abstract 
The hallmark of Focal Segmental Glomerular Sclerosis (FSGS) is podocyte injury 
resulting in glomerular scarring and protein excretion in the urine. Transient Receptor 
Potential channel C6 (TRPC6) is calcium-conducting ion channel that is expressed at 
the slit-diaphragm that interconnects the foot processes of the podocyte. TRPC6 
gain-of-function mutations and glomerular TRPC6 overexpression are associated 
with proteinuric diseases. However, the underlying mechanisms that link TRPC6 to 
podocyte injury remain elusive. Previously, calcium-dependent calpain activation was 
shown to mediate renal injury in ischemia reperfusion and anti-glomerular basement 
membrane glomerulonephritis. We hypothesize that calpain is involved in TRPC6-
mediated renal injury. Here, we showed that calpain-1 is activated by TRPC6-
dependent calcium influx leading to talin-1 cleavage, podocyte injury, proteinuria and 
renal injury in FSGS. Calpain activation in podocytes was inhibited by silencing 
TRPC6 and calpain-1. In a model for human FSGS, increased calpain activity in 
urine, glomeruli and tubuli were associated with increased proteinuria, which could be 
prevented by calpain inhibition. Finally, increased TRPC6 expression leading to more 
calpain activity and podocyte injury, was found in kidneys of FSGS patients. In 
conclusion, we have elucidated a novel mechanism that links TRPC6 activity to 
calpain-1 activation, talin-1 cleavage and podocyte injury. Calpain-1 and/or TRPC6 
inhibition could be a novel therapeutic option to treat FSGS patients. 
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Introduction 
Podocytes in the glomerular filtration barrier play a vital role in the blood filtration 
process in the kidneys. Podocytes are terminally differentiated epithelial cells with 
interdigitating foot processes that are interconnected by the slit diaphragm protein 
complex, with nephrin and Neph1 as important constituents. Podocin and CD2AP 
anchor these proteins to the actin cytoskeleton of the podocyte, and play an 
important role in cell signaling [1-5]. Podocyte injury is associated with proteinuria, 
the hallmark of glomerular injury, and can eventually lead to end stage renal disease 
(ESRD) [2]. It has been suggested that induction of podocyte injury is central in the 
pathogenesis of most inherited and acquired glomerular diseases, including diabetic 
nephropathy (DNP) and focal segmental glomerular sclerosis (FSGS), which are all 
associated with decreased expression of the aforementioned slit diaphragm proteins 
[6-9]. 
 
Transient Receptor Potential channel C6 (TRPC6) is a non-specific calcium (Ca2+)-
conducting ion channel, which is expressed at the slit diaphragm of the podocyte 
[10]. TRPC6 gain-of-function mutations lead to heredity FSGS, while acquired 
glomerular proteinuric diseases are associated with TRPC6 overexpression [10-14]. 
Therefore, it is suggested that TRPC6 plays an important role during the initiation of 
podocyte injury. Downstream of the TRPC6 dependent Ca2+ influx calcineurin is 
activated, which subsequently activates the transcription factor nuclear factor of 
activated T-cells (NFAT) in the cytoplasm, which thereafter translocates to the 
nucleus [13]. One of the important transcriptional targets of NFAT is TRPC6, thereby 
creating a deleterious feed forward loop. Moreover, TRPC6 specific Ca2+ influx 
activates RhoA, thereby promoting formation of stress fibers and focal contacts, 
which results in a contractile podocyte phenotype that eventually may lead to 
apoptosis [15-17]. The antagonistic pathway for TRPC6 mediated signaling, is 
activation of the TRPC5-ras-related C3 botulinum toxin substrate 1 (Rac1) and cell 
division control protein 42 homolog (Cdc42)-pathway, leading to formation of 
lamellipodia and filopodia, respectively [4, 16]. Although TRPC6 upregulation is 
associated with cytoskeleton rearrangements in the podocyte, podocyte foot process 
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effacement, podocyte injury and proteinuria, the underlying molecular pathway 
leading to breakdown of the (structural) proteins like nephrin remains elusive. 
 
Calpains are a family of non-lysosomal cysteine proteases, which cleave proteins 
with a specific tertiary structure. Calpains can be directly activated by binding Ca2+. 
The best characterized calpain family members are calpain-1 and 2, which are 
activated at different Ca2+ concentrations, namely, at micro molar and milli molar 
levels, respectively [18]. In the kidney, active calpain was previously associated with 
renal ischemia reperfusion and anti-glomerular basement membrane (anti-GBM) 
injury, which both could be prevented by blocking calpain activation [19-21]. 
Moreover, it was shown that calpain was able to cleave nephrin and the podocyte 
anchoring protein talin-1 [21]. Talin-1 is an integrin-actin binding protein that plays a 
vital role in the adhesion of podocytes to the GBM [22]. Importantly, recently it has 
been reported that Talin-1 loss led to loss of podocyte integrity and severe proteinuria 
[23]. It has been suggested that calpain-dependent cleavage of (structural) proteins 
in the podocyte could be a key mechanism for the initiation and progression of 
podocyte injury [23]. The mechanism by which calpains are activated in the slit-
diaphragm micro-domain of the podocyte remain elusive. 
 
Taken together, we hypothesizethat calpain is activated by TRPC6-dependent Ca2+ 
influx, which would ultimately lead to degradation of talin-1 and other structural 
proteins in the podocyte. This study aims to elucidate the mechanism of calpain 
activation, to determine which calpains are activated during podocyte injury, and to 
evaluate the potential renoprotective effect of calpain inhibition during experimental 
FSGS, and to determine whether calpain activation plays a role in human FSGS 
patients as well. 
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Results 
Different calpains are expressed in the kidney and podocytes 
Since nothing is known about the expression pattern of calpains in the renal cortex 
and podocytes, we first determined which calpains are expressed in mouse kidney 
cortex. We found mRNA expression of calpain 1, 2, 4, 6, 7, 10, 12, 15 and the calpain 
inhibiting protein calpastatin (Figure 1a). In conditionally immortalized cultured 
mouse podocytes we observed a similar expression profile as in renal cortex, except 
for calpain 7 and 12 (Figure 1b). 
 
 
 
Figure 1: Different calpains are expressed in mouse renal cortex and podocytes.  
mRNA of the renal cortex of mice was isolated and PCR was used to determine which 
calpains were expressed (A). mRNA of cultured mice podocytes was isolated and PCR was 
used to determine which calpains were expressed (B). The numbers correspond to the 
calpain family member. C = calpastatin. Notably, for calpain 14 there is no ortholog present in 
the mouse genome.  
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Calpain-1 is activated by TRPC6 in injured podocytes 
Since calpain-1 has been associated with renal injury in previous studies, we started 
to address the question whether there was a link between TRPC6 and calpain-1. 
Cultured mouse podocytes transfected with calpain-1 siRNA (cpn-1sil), resulting in a 
72 ± 3 % down-regulation. Cpn-1sil or non-targeting siRNA (cpn-1scram), were injured 
using adriamycin or activated by OAG as described previously [24]. Cells were 
treated with a synthetic calpain inhibitor, calpeptin, or the TRP-channel blocker 2-
aminoethoxydiphenyl borate (2-APB) or vehicle. Adriamycin and OAG increased 
cellular calpain activity in cpn-1scram cells compared to vehicle-treated podocytes 
(Figure 2). However, calpain-1 mRNA levels did not differ between adriamycin-
treated and control cpn-1scram podocytes (Figure 3a). Moreover, adriamycin and 
OAG-treated control podocytes treated with calpeptin or 2-APB, and adriamycin or 
OAG-exposed cpn-1sil cells did not show increased calpain activity (Figure 2a). After 
Adriamycin or OAG stimulation also enhanced excretion of active calpain into the 
culture medium was detected, which could be prevented by treatment with 2-APB or 
calpeptin, and by silencing of calpain-1 (Figure 3b). Previously, we have shown that 
TRPC6 expression was upregulated during adriamycin-induced podocyte injury [12, 
24]. Thus, we hypothesized that TRPC6-mediated Ca2+ influx activates calpain-1. 
TRPC6 was overexpressed after adriamycin application in both cpn-1scram and cpn-
1sil podocytes (Figure 3c), suggesting that calpain-1 is downstream of TRPC6. Using 
stably transfected TRPC6 knock-down (KD) or scrambled cells we demonstrated that 
the increased Ca2+ influx after adriamycin pre-treatment in podocytes is TRPC6-
dependent (Figure 3d). Importantly, calpain activation was prevented in TRPC6 KD 
podocytes treated with adriamycin or OAG (Figure 2b). Previously, it was shown that 
an unidentified calpain was able to break down talin-1 in the podocyte, causing 
severe proteinuria [23]. We reasoned that podocyte injury-induced calpain-1 activity 
leads to talin-1 degradation. Indeed, adriamycin or OAG incubation both led to talin-1 
protein degradation, which was prevented in the TRPC6 KD podocytes compared to 
podocytes transfected with a scrambled control construct (Figure 2c-d). 
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Figure 2: Calpain-1 is activated via TRPC6 during podocyte injury. 
Differentiated immortalized cultured podoyctes were transfected with non-targeting (CPN-
1scram) or calpain-1 siRNA (CPN-1sil), subsequently, they were treated with vehicle, 
adriamycin (ADRIA) for 24 hours or 1-oleoyl-2-acetyl-sn-glycerol (OAG) for 20 seconds. 
Proteins were isolated and a calpain activity assay was performed (A).To confirm that 
TRPC6 activates calpain-1, podocytes with an inducible stably transfected TRPC6 
knockdown (TRPC6 KD) or scrambled construct (TRPC6 Scram) were used. After activation 
of the construct we treated the cells with vehicle, ADRIA for 24 hours or OAG for 20 seconds 
and measured calpain activity (B). Western Blot assay for talin-1 in extracts of TRPC6 KD 
(TRPC6scram) or scrambled (TRPC6KD) cells treated with adriamycin (C) or OAG (D) for 24 
hours or 30 minutes respectively. * p < 0.05 compared to vehicle treated scrambled or non-
targeted transfected cells. $ p < 0.05 compared to non-targeted transfected ADRIA-treated 
podocytes. † p < 0.05 compared to non-targeted transfected OAG-treated podocytes. ‡ p < 
0.05 compared to scrambled transfected vehicle-treated podocytes.  
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Figure 3: Calpain activation depends on TRPC6-mediated calcium influx.  
The effect of adriamycin (ADRIA) on calpain-1 expression compared to vehicle treated cells 
(Vehicle) was detemined in mouse podocytes using real-time quantitative RT-PCR analyses 
(A). Differentiated immortalized cultured podoyctes were transfected with non-targeting 
(CPN-1scram) or calpain-1 siRNA (CPN-1sil), subsequently, they were treated with vehicle, 
adriamycin (ADRIA) for 24 hours or 1-oleoyl-2-acetyl-sn-glycerol (OAG) for 20 seconds. A 
calpain activity assay was performed in the medium (B). Differentiated immortalized cultured 
podoyctes CPN-1scram and CPN-1sil were treated with vehicle or adriamycin (ADRIA). TRPC6 
mRNA expression was determined using real-time quantitative RT-PCR analyses (C). 
Intracellular Ca2+ concentration was determined by Fura-2 ratiometry. Stably transfected 
TRPC6 knockdown (TRPC6 KD) and scrambled (Scrambled) cultured podocytes were 24h 
pre-treated with vehicle (Control) or ADRIA. After removal of medium, cells were exposed to 
100 µM OAG to activate the TRPC6 ion-channel and calcium influx was measured (D). * p < 
0.05 compared to healthy controls. $ p < 0.05 compared to non-targeted transfected ADRIA-
treated podocytes. † p < 0.05 compared to non-targeted transfected OAG-treated podocytes. 
‡ p < 0.05 compared to scrambled transfected vehicle-treated podocytes. 
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Inhibition of calpain in a model for human FSGS improves renal outcome 
Next we addressed the question whether calpain inhibition would be beneficial in 
experimental FSGS. To this end, we treated adriamycin-induced nephropathy rats, a 
well defined model for human FSGS, with the calpain inhibitor calpeptin. Adriamycin 
treatment resulted in an increased urinary protein excretion compared to non-injured 
rats as we described previously [24]. Importantly, calpeptin treatment reduced urinary 
albumin and IgG excretion in adriamycin-treated animals (Figure 4a). Calpeptin 
specifically reduced proteinuria, which could be attributed to glomerular origin as 
determined of urinary IgG (Figure 5a). Importantly, the increased calpain activity in 
the renal cortex (Figure 4b) and in the urine (Figure 5b) of proteinuric rats was 
normalized by calpeptin treatment. Serum calpain activity showed no difference 
between groups, ruling out that a possible increased active calpain concentration in 
the blood resulted in a higher calpain activity in the urine. (Figure 5c). In line with the 
in vitro experiments, increased TRPC6 mRNA (Figure 5d) and TRPC6 protein 
expression (Figure 5e) in the renal cortex and podocytes of adriamycin-treated rats, 
was, as expected, not affected by treatment with calpeptin. In contrast, the decreased 
talin-1 (Figure 4c) and nephrin expression induced in adriamycin nephropathy was 
normalized by calpeptin treatment (Figure 5f). Expression of the podocyte injury 
marker desmin was upregulated during adriamycin nephropathy, while treatment with 
calpeptin normalized desmin expression (Figure 5g). In situ zymography showed 
that calpain activity in the glomeruli and tubuli of adriamycine nephropathy rats was 
greatly enhanced, which was completely normalized by calpeptin treatment (Figure 
4d, quantified in Figure 5h). The calpain activity in the supernatant of the in situ 
zymography on renal sections revealed similar results (Figure 5i).  
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Figure 4: Calpain inhibition is renoprotective in a model for human FSGS. 
Wistar rats were injected with vehicle (control) or adriamycin (ADRIA) to induce adriamycin 
nephropathy, a model for human FSGS. Subsequently, animals were treated with vehicle or 
calpeptin for 6 weeks after which they were sacrificed. As a measure of renal injury, the 
albumin/creatinin ratio was determined (A). Protein of the renal cortex was isolated and a 
calpain activity assay was performed (B). Western Blot analysis for talin-1 was executed (C). 
Sections of the cortex were cut and an in situ zymography assay was performed, 
representative images are shown (D). * p < 0.05 compared to vehicle treated control rats. $ p 
< 0.05 compared to vehicle treated ADRIA rats. † p < 0.05 compared to calpeptin treated 
vehicle rats.  
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Figure 5: Inhibition of calpain improves renal outcome in a model for human FSGS. 
Wistar rats were injected with vehicle (Control) or adriamycin (ADRIA) to induce adriamycin 
nephropathy, a model for human FSGS. Animals were treated with vehicle or calpeptin for 6 
weeks after which they were sacrificed. As measure of glomerular injury urinary IgG 
excretion was determined (A). Urinary (B) and serum (C) calpain activity was assessed. 
Cortical mRNA was isolated and TRPC6 expression was determined using real-time RT-
qPCR (D). Sections of the renal cortex were cut, stained and glomerular expression of 
TRPC6 (E), nephrin (F) and desmin (G) was determined. Sections of the cortex were cut and 
an in situ zymography assay was performed, quantification is shown (H). In addition, a 
calpain activity assay was performed on the supernatant of the sections, normalized for 
surface of the slide (I). * p < 0.05 compared to vehicle treated control rats. $ p < 0.05 
compared to vehicle treated ADRIA rats. † p < 0.05 compared to calpeptin treated vehicle 
rats.  
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Calpain plays an important role during podocyte injury in human FSGS 
Next we addressed the question whether calpain activity could be associated with 
FSGS in patients. To this end, we determined calpain activity in urine of FSGS 
patients and healthy controls from our medical center, which revealed an increased 
calpain activity in urine of patients with FSGS (Figure 6a). In addition, calpain activity 
in renal cortical protein extracts from nephrectomy samples of FSGS patients was 
increased compared to healthy donor kidneys not suitable for transplantation (Figure 
6b). Calpain activity in the glomeruli was strikingly enhanced in FSGS patients 
compared to control kidneys using in situ zymography, which was in line with data of 
the experimental FSGS animal model, (Figure 6c, quantified in Figure 7a). The 
calpain activity of the supernatant of the in situ zymography revealed similar results 
(Figure 7b). 
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Figure 6: Calpain is activated in the kidneys of FSGS patients. 
Calpain activity in the urine of nephrectomized focal segmental glomerular sclerosis patients 
(FSGS) and healthy individuals (Control) was determined (A). Protein of the renal cortex of 
FSGS patients and healthy non-suitable donor kidneys (Control) was isolated and a calpain 
activity assay was performed (B). Sections of the cortex were cut and an in situ zymography 
assay was performed, representative images are shown (C). * p < 0.05 compared to controls. 
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Figure 7: Calpain is activated in the kidneys of FSGS patients. 
Sections of the renal cortex of nephrectomized focal segmental glomerular sclerosis (FSGS) 
patients were cut and an in situ zymography assay was performed for calpain (A). Also the 
activity in the supernatant was determined (B). * p < 0.05 compared to healthy controls. 
 
 
It has been extensively described that calpains are expressed in mitochondria [25]. 
To evaluate the subcellular the origin of activated calpains in our systems, 
mitochondria were isolated from vehicle, adriamycin or OAG-treated mouse 
podocytes, from kidneys of control and adriamycin-induced nephropathy rats, as well 
as from healthy human and FSGS patients. Subsequently, we performed a calpain 
activation assay and found no differences between groups (Figure 8a-c). The 
activated calpain seems thus from a non-mitochondrial origin. 
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Figure 8: Active calpain in podocytes, experimental and human FSGS is not of mitochondrial 
origin. 
Mitochondria of cultured podocytes treated with vehicle (Vehicle), adriamycin (ADRIA) and 1-
oleoyl-2-acetyl-sn-glycerol (OAG) was isolated and a calpain activity assay was performed 
(A). Mitochondria from the kidney cortex of vehicle treated (Control) and ADRIA treated (B), 
and from FSGS patients and healthy non-suitable donor kidneys (Control) was isolated and a 
calpain activity assay was performed (C). 
  
Calpain-1 links TRPC6 activity to podocyte injury 
 
 
 
 
 
65 
Discussion 
In the current study we describe a novel mechanism by which enhanced TRPC6 
activity causes podocyte injury. We demonstrated that upon podocyte injury, TRPC6 
ion channels are upregulated and activated, which was associated with an increased 
TRPC6-dependent Ca2+ influx into the podocyte. The latter activated calpain-1, 
leading to degradation of talin-1, a process which may be the cause of podocyte 
cytoskeleton rearrangement and play an important role in the pathogenesis of 
glomerular injury and proteinuria. Moreover, in a rat model for podocyte injury and 
human FSGS, we showed that glomerular and urine calpain activity is increased. 
Importantly, inhibition of calpain activity significantly reduced proteinuria, suggesting 
that this pathway could be a potential treatment target for patients. Indeed, 
glomerular and urinary calpain activity were also increased in patients with FSGS, 
along with increased calpain-1 expression and reduced talin-1 abundance. Taken 
together, we show that TRPC6-mediated Ca2+-dependent calpain activation plays an 
important role in the pathophysiology of podocyte injury, and could be a future 
treatment target in proteinuria. 
Increased activity and expression of TRPC6 in the podocyte is associated with 
podocyte injury and proteinuria [26]. Several intracellular signaling pathways 
downstream of TRPC6-mediated Ca2+ influx were suggested. However, it appeared 
difficult to show whether and how deleterious intracellular TRPC6-dependent 
signaling actually induces loss of structural or cytoskeleton-associated podocyte 
proteins. This study now shows that TRPC6-mediated Ca2+ influx, through activation 
of calpain-1, leads to subsequent loss of the cytoskeletal protein talin-1. Talin-1 is an 
important anchoring molecule expressed by the podocyte. Recently, increased 
calpain activity in the urine of FSGS patients was shown, as we confirm in this study 
[23]. This implies that active calpain not only plays a role during ischemia reperfusion 
and anti-GBM injury, but also during acquired glomerular injury. However, they it 
remained unclear which calpain was excreted, whereas the origin of the calpain and 
the mode of calpain activation were not evaluated.. In our current study we showed 
that specifically calpain-1 is activated via TRPC6 dependent Ca2+ influx leading to 
podocyte injury. Moreover, in our rat model, we found that calpain was more 
activated compared to the healthy controls, which we also found in our FSGS 
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patients. Previously, it was shown in neurons that calpain was able to cleave the 
TRPC6 protein, thus inhibition of calpain will increase TRPC6 protein levels [27]. This 
mechanism explains the increased glomerular TRPC6 protein levels in the control 
treated animals compared to the vehicle treated rats. Notably, this mechanism could 
be the negative feedback loop for TRPC6 expression. 
Previously, it was shown that anti-GBM nephritis leads to increased calpain activity in 
the kidney cortex and increased urinary excretion of active calpain. This was 
associated with nephrin downregulation and proteinuria. When the natural calpain 
inhibitor calpastatin was over-expressed in transgenic mice a reduction in proteinuria 
and less severe glomerular injury was found. The authors concluded that activated 
and secreted calpains participate in the development of immune-mediated glomerular 
injury [21]. Now, we have shown that calpain also plays an important role in the 
initiation and progression of experimental FSGS, which could be counteracted using 
calpain inhibitors.The beneficial effects of calpain inhibition are also described in 
ischemic reperfusion models in which renal function was preserved, and it was 
suggested that calpain inhibition might be used to prevent renal injury associated with 
aortovascular surgery or renal transplantation [19, 20]. However, extracellular calpain 
inhibition was shown to lead to a reduced tubular regeneration after renal ischemia 
reperfusion injury, suggesting that secretion of (active) calpain might be protective 
against tubular injury [28]. Interestingly, during complement-mediated glomerular 
disease, disruption of the podocyte actin microfilaments and focal adhesions could 
not be prevented by calpain inhibition [29]. This is in line with the finding of Kistler et 
al. which suggested that TRPC6 was protective during complement-mediated injury 
[30]. Thus, it seems that active calpain plays an important role during different types 
of renal injury induced by TRPC6. 
Interestingly, one of the substrates of calpain is calcineurin, which irreversibly 
activates this calcineurin. We and others previously demonstrated that Ca2+ influx 
through TRPC6 activates calcineurin in a angiotensin II-induced, TRPC6-mediated 
calcineurin/NFAT feed forward mechanism enhancing TRPC6 expression [13]. 
Possibly, calpain could also be responsible for the activation of calcineurin. Of note, 
angiotensin II activates calpain in cardiomyocytes, which led to activation of 
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calcineurin and dephosphorilation of NFAT [31]. Moreover, calpain was able to 
activate calcineurin in the podocyte [32].  
In conclusion, we have elucidated a novel mechanism that links deleterious Ca2+ 
influx through the slit diaphragm-associated ion channel TRPC6, via calpain-1 
activation, to podocyte cytoskeletal changes possibly mediated by talin-1 loss. 
However, the exact downstream targets that are cleaved by this protease, which 
subsequently initiate or propagate podocyte (cytoskeletal) injury mechanisms 
requires further investigation. Nevertheless, our data highlight that TRPC6-dependent 
activation of calpain-1 might be a key mechanism in the initiation and progression of 
podocyte injury in glomerular diseases. This identifies both TRPC6 as well as 
calpain-1 as possible future therapeutic targets in the treatment of proteinuria and 
prevention of further glomerular injury. 
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Methods 
FSGS patients 
Snap-frozen kidneys of three nephrectomized FSGS patients and five healthy 
controls were available for the present study. Urine of 7 FSGS patients and five 
healthy controls was frozen without addition of proteinase inhibitors and thawed on 
ice before measuring calpain activity. Inform consent was received from all 
applicants. 
 
Adriamycin nephropathy (AN) rats  
The AN model for human FSGS was induced in 8 week old Wistar rats (Charles 
River, Wilmington, USA) by a single tail vein injection with 5 mg/kg body weight 
adriamycin (Sigma-Aldrich, St. Louis, USA). Hereafter, rats were treated three times 
a week with intraperitoneal injections of 1 mg/kg bodyweight calpeptin (Sigma-
Aldrich) or vehicle (1% ethanol) for 6 weeks. At the end of the experiment, rats were 
housed in metabolic cages to collect 24 hour urine samples. Subsequently, animals 
were sacrificed, kidneys and blood samples were collected.  
All animals were kept at the Central Animal Facility of the Radboud University 
Nijmegen in a standard room at a temperature of 21°C and controlled humidity. 
Animals were exposed to a 12 hours light/dark cycle with ad libitum access to food 
and water. All procedures involving animals were approved by the Animal Ethics 
Committee of the Radboud University Nijmegen, The Netherlands, in accordance 
with the guidelines of the Dutch Council for Animal Care and the European 
Communities Council Directive (86/609/EEC). 
 
Cell culture 
Cultured conditionally immortalized mouse podocytes (MPC-5) were transfected with 
calpain-1 siRNA (cpn-1sil) or non-targeting siRNA (cpn-1scram). MPC-5, either 
untransfected or stably transfected with tetracycline-inducible TRPC6 knockdown 
(KD) or scrambled siRNA constructs were cultured as described. Four days prior to 
the TRPC6 KD experiments, podocytes were treated with 5 µg/mL tetracycline to 
induce the TRPC6 siRNA as described previously [24]. Subsequently, podocytes 
were injured using adriamycin (0.25 µg/ml) for 24 hours or activated using OAG (100 
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µM) for 20 seconds prior to a calpain activity assay, otherwise 30 minutes. Cells were 
simultaneously treated with calpeptin (1 µM), 2-APB (100 µM) or vehicle. 
Intracellular Ca2+ was visualized using the fluorescent Ca2+ indicator FURA-2. 
Cultured podocytes with or without the TRPC6 KD or scrambled construct were 
seeded on collagen A–coated 96-well plates and differentiated for 2 weeks. After 
induction of siRNA with tetracycline, cultures were pretreated with adriamycin (0.25 
µg/ml) or vehicle for 24 hours. Thereafter, the cells were washed and put in Ca2+-
containing buffer. Intracellular Ca2+ was measured by fluorescence using a 
specialized microscope (Pathway 855; BD Biosciences, San Jose, CA). Data are 
presented as 340/380 nm ratios. 
 
Real-time Quantitative RT-PCR Analysis 
Total RNA was isolated from cultured podocytes, cortex of mouse, rat and human 
kidneys and RNA was reverse transcribed (transcriptor kit; Roche Diagnostics GmbH, 
Mannheim, Germany). RT-qPCR was performed using SYBR Green SuperMix 
(Roche Diagnostics) on a CFX96 C1000 Touch real-time PCR detection system (Bio-
Rad Laboratories, Hercules, CA) with gene-specific primers (Table 1). 
Glyceraldehyde-3-phosphate dehydrogenase was used as housekeeping gene. 
 
Immunofluorescent analysis 
Immunofluorescent staining were performed on frozen kidney cortex of rats and 
humans which were cut in 2 µm cryosections and stained for TRPC6 (Abcam, 
Cambridge, UK), talin-1 (Acris antibodies, Herford, Germany) nephrin (R&D, 
Minneapolis, USA), calpain-1 (Santa cruz, Santa Cruz, USA) and desmin (Santa 
Cruz). Subsequently, the appropriate fluorescent secondary antibody was added and 
the mean fluorescent intensity in 30-40 glomeruli per slide was determined. 
 
  
Chapter 3 
 
 
 
 
 
70 
Table 1: Primers used in study. 
Gene 
(mouse) 
Forward Reverse 
Calpain-1 CCCTCCGGTTTCTCATAGCC CTGAAAGCTCTGGCCGTAGG 
Calpain-2 GGCAAATCTAACCGAACGGC GCCTCCAGTTCCCATCCATC 
Calpain-3 CAGCCGCAATTTTCCGATCA CAGCAGTCCCCTAGATCTCCT 
Calpain-4 CGAGACCGGGAACATGGATT 
 
GCAGGTCTGTGACTTCCACT 
 
Calpain-5 GGTGGAAGCGGCCTTTTGA 
 
AGTCTGGGATGACCTTTTGCC 
 
Calpain-6 CATTGAGTCTCCCAGCCAGG 
 
TTCTCCAAGACGGAGCTTGC 
 
Calpain-7 CCTCAGTTCTCCTCGCAGTG 
 
CTTGGGCAGCTTCCTTGTAG 
 
Calpain-8 GGTGACTTCTGCTTGAGGGT 
 
GATGTGGCTCATGAGGGTGTC 
 
Calpain-9 GGGCTGCTCCATAGATACCC 
 
TCTGGCCGTGGAAGTTTACC 
 
Calpain-10 GAAAATCTCCCTCAGTGCCGT 
 
AGCACCCTCAGGAACAGAGA 
 
Calpain-11 GTCGTCTTCTCGGTCCCAAA 
 
TGTTCACCTCCCTCGTGTTG 
 
Calpain-12 TGATGCCCTTGGCTATGACA 
 
CTAGAAGCCAGCAGTTTCCCAAG 
 
Calpain-13 CAGAGGACACAGAAAGAAAGG
AC 
 
AGATGCCTCAGCAGGGAATG 
 
Calpain-15 GCTCGCTAAGCCACACTCAT 
 
GATCTGGCTTATGTCGGGGG 
 
Calpastatin CAGAGAAGCCACTTGACAAAG
AA 
 
GGGGCAGCTATCCAAGTCTTC 
 
TRPC6 CTGTGATTTCCAAGTGCTCATT
G 
GACTCAAGGCCCCAAAGAATACT 
GAPDH AGAAACCTGCCAAGTATGATGA
C 
TCATTGTCATACCAGGAAATGAG 
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Western blot analysis 
Talin-1 protein expression in cultured podocytes and kidney cortex was assessed by 
Western blot analysis. Western blot was performed as follows: podocytes were lysed 
in a 50-mmol/L Tris (pH 7.5) buffer containing 150 mmol/L NaCl, 0.5% w/v SDS, 
0.5% v/v Triton X-100, 2 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, and 
the complete mini cocktail of protease inhibitors (Roche Diagnostics GmbH). Protein 
concentrations were determined, and samples containing equal amounts of protein 
were resolved by 10% (w/v) SDS-PAGE and were blotted to nitrocellulose 
membranes (Whatman, GE Healthcare, Little Chalfont, UK). Blots were incubated 
with mouse polyclonal anti-human talin-1 antibody (Novusbio, Littleton, USA) and 
mouse anti–β-actin antibody (AC-15; Sigma-Aldrich, Zwijndrecht, The Netherlands) 
and subsequently with peroxidase-labeled secondary antibodies. Proteins were 
visualized using chemiluminescence, and signal intensity was quantified digitally. 
 
Calpain activity analysis 
Calpain activity in the tissue, urine and serum was determined by a calpain activity 
assay according to the manufactures protocol (Abcam, Cambridge, UK). In situ 
zymography was performed by incubating the substrate of the calpain activity assay 
diluted in the appropriate buffer as described in the manufactures protocol, on 10 µm 
slides of cryo-cut slides for 24 h at 37°C. The slides were then fixed for 10 minutes 
using 1% paraformaldehyde, and examined using a fluorescent microscope. The 
mean fluorescent intensity in 30-40 glomeruli per slide was determined. The 
supernatant of the slides was harvested and calpain activity was determined as 
outlined, and activity was normalized for volume and the surface area of the slide. 
 
Analytical procedures 
Urinary albumin and creatinin levels were determined by radial-immunodiffusion and 
the Architect C16000 (Abbott Diagnostics, Chicago, USA), respectively. Urinary IgG 
levels were measured using ELISA according to the manufactures protocol 
(Antibodies-online, Aachen, Germany).  
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Mitochondrial isolation 
Mitochondria were isolated using a potter-Elvehjem (8 strokes at 1800 rpm on ice). 
Subsequently, 1.5M sucrose was added and the solution was centrifuged for 10 
minutes at 600g at 4°C. After replacing the buffer, protein concentration was 
measured and a calpain activity assay was performed. 
 
Statistics 
All results are depicted as mean ± SEM. Student t-test or ANOVA was used to test 
for significance using SPSS software (IBM, New York, USA) followed by a Bonferroni 
post-hoc test. P values less than 0.05 were considered significant. 
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Abstract 
The cation channel Transient Receptor Potential channel C6 (TRPC6) is a slit 
diaphragm protein expressed by podocytes. TRPC6 gain-of-function mutations cause 
autosomal dominant focal segmental glomerulosclerosis. In acquired proteinuric renal 
disease, glomerular TRPC6 expression is increased. We previously demonstrated 
that acquired increased TRPC6 expression is ameliorated by anti-proteinuric 
angiotensin receptor blockers and angiotensin converting enzyme inhibitors. Vitamin 
D also has an anti-proteinuric effect. We hypothesized that vitamin D reduces 
proteinuria by affecting TRPC6 expression in podocytes. 
Adriamycin-induced nephropathy increased TRPC6 mRNA and glomerular TRPC6 
protein expression, and induced proteinuria in rats. Treatment with 1α,25-dihydroxy-
vitamin D3 (1,25-D3) normalized TRPC6 expression and reduced proteinuria. In vitro, 
podocyte injury was induced by adriamycin exposure in cultured mouse podocytes, 
which increased TRPC6 expression. Treatment of injured podocytes with 1,25-D3 
resulted in a dose-dependent reduction of adriamycin-induced TRPC6 expression. Of 
note, Chromatin Immunoprecipitation analysis demonstrated that the vitamin D 
receptor directly binds to the TRPC6 promoter, and 1,25-D3 reduced TRPC6 
promoter activity in a luciferase reporter assay. In 1,25-D3-deficient 25-hydroxy-1α-
hydroxylase knockout mice, TRPC6 mRNA and glomerular TRPC6 protein 
expression were increased, accompanied by podocyte foot process effacement and 
proteinuria. Importantly, 1,25-D3 supplementation normalized TRPC6 expression, 
podocyte morphology and proteinuria in these mice. 
We demonstrated that vitamin D downregulates the enhanced TRPC6 expression in 
in vivo and in vitro podocyte injury, possibly through a direct effect on TRPC6 
promoter activity. Thus, our results suggest that this TRPC6 downregulation could 
contribute to the anti-proteinuric effect of vitamin D. 
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Introduction 
Podocytes play a crucial role in the glomerular filtration barrier. Podocyte foot 
processes are connected by specialized proteins, such as nephrin and neph1, to 
form the glomerular slit diaphragm complex. This structure is closely connected to the 
actin skeleton through proteins like podocin and CD2AP, and plays an important role 
in cell signaling in podocytes [1-5]. Injury to the podocyte and its slit diaphragm can 
lead to proteinuria and eventually chronic renal function decline [2]. Various studies 
suggest that podocyte injury plays a crucial initiating role in several hereditary and 
acquired proteinuric diseases, including focal segmental glomerulosclerosis (FSGS) 
and diabetic nephropathy [6-9]. 
 
Transient receptor potential cation channel, subfamily C, member 6 (TRPC6) is a 
calcium-conducting ion channel, which is expressed in podocytes and suggested to 
function as a slit diaphragm-associated protein [10]. TRPC6 is thought to play a role 
in signaling processes at the slit diaphragm complex which, in turn, might influence 
the cytoskeleton of the podocyte [10, 11]. TRPC6 gain-of-function mutations are 
associated with a hereditary form of FSGS [10, 12]. Moreover, in several acquired 
proteinuric diseases, an increased glomerular TRPC6 expression was demonstrated. 
Therefore, it appears that TRPC6 plays a role in the pathogenesis of podocyte injury 
in both hereditary and acquired proteinuric diseases [13]. Previously, we described a 
correlation between TRPC6 expression and severity of FGS score in an animal 
model for acquired FSGS [14]. Furthermore, we demonstrated that angiotensin II 
activates TRPC6 and increases TRPC6 expression via a nuclear factor of activated 
T-cells (NFAT)-mediated positive feedback signaling pathway, which contributes to 
podocyte injury. Moreover, we demonstrated that angiotensin converting enzyme 
inhibitors (ACEi) and angiotensin receptor blockers (ARBs), pivotal therapies to 
reduce proteinuria, decrease TRPC6 expression in injured podocytes as well as in 
animal models for proteinuric disease. Thus, enhanced TRPC6 activity and/or 
expression appears to mediate podocyte and glomerular injury, whereas decreasing 
TRPC6 expression is associated with reduced injury and amelioration of proteinuria.  
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In addition to ACEi and ARBs, new anti-proteinuric therapies have recently emerged, 
including treatment with vitamin D analogs [15]. Cholecalciferol (vitamin-D3) is taken 
up in the gastrointestinal tract or synthesized by the effect of sunlight in the skin, after 
which it can be converted by the liver into 25-hydroxyvitamin D3 and, subsequently, 
to 1,25-dihydroxyvitamin D3 (1,25-D3) in the proximal tubule of the kidney. 1,25-D3 is 
classically defined as the active form of vitamin D, which plays a central role in Ca2+ 
and PO43- metabolism. With the progression of renal insufficiency, deficiency of 1,25-
D3 ensues [16]. However, 1,25-D3 deficiency may not only be a consequence of, but 
recent studies indicated that 1,25-D3 deficiency itself could also be the cause of renal 
injury. Clinical and pre-clinical studies demonstrated that treatment with vitamin D 
analogs reduces proteinuria and podocyte loss [17-22]. It was demonstrated that 
podocytes express the vitamin D receptor (VDR) and undergo ultrastructural changes 
when exposed to 1,25-D3 [23, 24]. More recently, it was shown that 1,25-D3 regulates 
the expression of several key podocyte proteins, like nephrin and podocin [25, 26]. 
Other TRP channel family members, such as TRPV5 and TRPV6, are also regulated 
by 1,25-D3 [27, 28]. 
 
Taken together, this suggests a role for 1,25-D3 in the regulation of TRPC6 
expression in podocyte injury and proteinuric disease. Therefore, we investigated 
whether vitamin D regulates TRPC6 expression in cultured podocytes as well as in 
animal models for FSGS or 1,25-D3 deficiency.  
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Methods 
Adriamycin nephropathy (AN) rats 
The AN model for human FSGS was induced in 8 week old Wistar rats (Charles 
River, Wilmington, USA) by a single tail vein injection with 5 mg/kg body weight 
adriamycin (Sigma-Aldrich, St. Louis, USA). Hereafter, rats were treated with daily 
intraperitoneal injections of 2.5 µg/kg bodyweight 1,25-D3 or vehicle for 6 weeks. At 
the end of the experiment, rats were housed in metabolic cages to collect 24 hour 
urine samples. Subsequently, animals were sacrificed, and kidneys and blood 
samples were collected.  
 
All animals were kept at the Central Animal Facility of the Radboud University 
Nijmegen in a standard room at a temperature of 21°C and controlled humidity. 
Animals were exposed to a 12 hours light/dark cycle with ad libitum access to food 
and water. All procedures involving animals were approved by the Animal Ethics 
Committee of the Radboud University Nijmegen, The Netherlands, in accordance 
with the guidelines of the Dutch Council for Animal Care and the European 
Communities Council Directive (86/609/EEC). 
 
Podocyte cell culture 
Conditionally immortalized mouse podocytes (MPC-5) were cultured at 33°C/5% CO2 
and differentiated at 37°C in Roswell Park Memorial Institute (RPMI) Dutch modified 
medium (Invitrogen, Carlsbad, USA) supplemented with 10% v/v fetal calf serum 
(FCS), 1% w/v glutamine, 10 units/ml interferon-gamma and 1% 
penicillin/streptomycin as described previously [29]. Depending on the exact 
experimental set-up, differentiated podocytes were treated with 0.25 µg/ml 
adriamycin and 100 nM 1,25-D3 or vehicle for 24 hours (Sigma-Aldrich, St. Louis, 
USA). In these experiments, N=4-5 separate podocyte cultures were used per 
experimental condition per experiment, and all experiments were repeated at least 
twice for confirmatory purposes. 
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Construction of TRPC6 promoter luciferase reporter construct and luciferase 
activity assay 
The 5′-promoter region of the mouse TRPC6 gene (−1500/+32; +1 designates the 
transcription start site, NM_013838.2) was obtained by amplification of genomic DNA 
using primers 5′-GACGCTCGAGTGTTGCTTCTGCAGCCCGAGTG-3′ and 5′-
GATCAAGCTTAGC CGCGAAAGGAACCTTGACC-3′. The PCR product was cloned 
into the pGL3-Basic luciferase reporter vector and the cloned promoter sequence 
was verified by sequence analysis. The pRL-CMV vector encoding Renilla luciferase 
under control of a CMV promoter was used as control for transfection efficiency 
(Promega, Fitchburg, USA). 
 
Opossum kidney (OK) cells were cultured in DMEM/F12 (1:1) medium supplemented 
with 10% FCS, 15 mM Hepes, 2.5 mM L-glutamine and 1% penicillin/streptomycin at 
37°C in a humidity-controlled incubator with 5% (v/v) CO2 [30]. Briefly, cells were 
seeded in a 12-well plate and transfected the following day in serum free medium. 
The transfection mixture was prepared in 60 µl Optimem (Invitrogen, Carlsbad, USA) 
and consisted of 1 µg of either TRPC6 promoter construct or empty pGL3-basic 
vector, 50 ng of pRL-CMV and 1.25 µl Lipofectamin2000 (Invitrogen, Carlsbad, USA). 
Four hours after transfection, cells were washed with PBS and incubated with culture 
medium containing 1% FCS, in the presence of 100 nM 1,25-D3 or vehicle. Cells 
were harvested 48 hours post-transfection and luciferase activity was determined 
using a dual luciferase reporter assay system (Promega, Fitchburg, USA). In these 
experiments, N=4-5 separate cultures were used per experimental condition per 
experiment, and all experiments were repeated at least twice for confirmatory 
purposes.  
 
Chromatin immunoprecipitation (ChIP) 
ChIP analysis was performed using OK cells transfected with the TRPC6 promoter 
luciferase reporter construct or the empty pGL3-basic vector without promoter. Cells 
were treated with 100 nM 1,25-D3 as described above. Cells were harvested 4 hours 
after transfection and a Magna ChIP A assay was performed according to the 
manufacturer’s protocol (Merck Millipore, Billerica, USA). Briefly, proteins were cross-
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linked to the DNA with formaldehyde, subsequently cells were lysed and samples 
were sonicated two times for 30 seconds on ice at 22µm amplitude using a Soniprep 
150 (MSE, London, UK). Samples were incubated with 5.0 µg of rabbit polyclonal 
anti-vitamin D receptor antibody (ab3508, Abcam, Cambridge, USA) or with rabbit 
IgG isotype antibodies as control. Immunoprecipitates were enriched with protein A 
magnetic beads. Subsequently chromatin complexes were eluted, the cross-links 
reversed, and the DNA was isolated. The presence of TRPC6 promoter DNA was 
evaluated in real-time PCR with specific primers corresponding to the TRPC6 
promoter region (5’-CTCAACGCATGTCCCCATAC-3’ and 5’-
GTAACACCAAGGGAGGGC-3’). Subsequently, samples were loaded on a 2% 
agarose gel and visualized using Proxima C16 (Isogen, De Meern, the Netherlands).  
 
1,25-D3-deficient 25-hydroxy-1α-hydroxylase KO mice 
The 1,25-D3-deficient 25-hydroxy-1α-hydroxylase KO mice were previously 
generated by targeted ablation of exon 8 encoding the heme binding domain of the 
enzyme. Mice were genotyped using PCR and Southern blot analysis, as described 
previously [31]. Five-week-old WT and KO mice were given daily intraperitoneal 
injections with 500 pg 1,25-D3 (Sigma-Aldrich, St. Louis, USA) or vehicle for 6 weeks. 
At the end of the experiment mice were housed in metabolic cages to collect 24 hour 
urine samples. Subsequently, animals were sacrificed, kidneys and blood samples 
were collected.  
 
Analytical procedures 
Urinary albumin and creatinine levels were determined by radial-immunodiffusion and 
enzymatic colorimetry, respectively. Serum Ca2+ levels were measured by 
spectrophotometry [32]. 
 
Real-time PCR analysis 
RNA was isolated from cultured podocytes or kidney cortex and reverse transcribed 
(Transcriptor Kit, Roche Diagnostics, Mannheim, Germany). Real-time quantitative 
PCR was performed using SYBR Green Supermix (Roche) on a MyiQ Real-Time 
PCR detection system (Bio-Rad Laboratories, CA, USA) as described previously[14]. 
Chapter 4 
 
 
 
 
 82 
TRPC6 expression was quantified by the delta-delta cycle threshold (Ct) method 
using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the housekeeping 
gene. In these experiments, N=4-5 separate cultures were used per experimental 
condition per experiment, and all experiments were repeated at least twice for 
confirmatory purposes.  
 
Immunohistochemistry 
Glomerular expression of TRPC6 and desmin was determined by semi-quantitative 
scoring of immunofluorescence staining in 2 µm cryosections as described previously 
[14]. In rat kidneys, TRPC6 was probed using a rabbit polyclonal antibody against the 
C-terminal tail of rat TRPC6 (Abcam, Cambridge, USA). TRPC6 expression in mice 
kidneys was detected by a rabbit polyclonal antibody against the N-terminal tail of 
mouse TRPC6 (Alomone, Jerusalem, Israel). Desmin expression was detected using 
a goat polyclonal antibody against the C-terminus of mouse and rat desmin (Santa 
Cruz, Santa Cruz, USA). Alexa-conjugated secondary antibodies were used 
subsequently. Glomerular TRPC6 and desmin expression was scored semi-
quantitatively on a scale from 0 to 5 based on the extent of TRPC6 
immunofluorescence staining and 0 to 10 for desmin staining in the glomerulus as 
described previously [14]. Scoring was performed independently by two investigators, 
who scored 35 to 50 glomeruli per animal on blinded sections.  
 
Transmission Electron Microscopy 
For electron microscopy, we used immersion fixation. Small fragments of cortex were 
fixed in 2.5% glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer, pH 7.4, 
overnight at 4°C and washed in the same buffer. The tissue fragments were postfixed 
in palade-buffered 2% OsO4 for 1h, dehydrated, and embedded in Epon812, Luft's 
procedure (Merck, Darmstadt, Germany). Ultrathin sections were contrasted with 4% 
uranyl acetate for 45 min and subsequently with lead citrate for 5 min at room 
temperature. Podocyte effacement was analysed by blinded scoring of the glomeruli 
in a Jeol 1200 EX2 electron microscope (JEOL, Tokyo, Japan). 
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Statistical analysis 
All results are depicted as mean ± SEM. All statistical analyses were conducted by 
two-tailed student’s t-test when comparing 2 treatment groups or experimental 
conditions, and ANOVA when comparing 3 or more treatment groups or conditions, 
using SPSS (IBM, New York, USA). P values less than 0.05 were considered 
significant.  
 
Results 
Effect of 1,25-D3 on TRPC6 expression in an in vivo FSGS model 
To study the in vivo effects of vitamin D on TRPC6 expression and proteinuria in an 
animal model for FSGS, control and adriamycin-exposed rats (adriamycin 
nephropathy; AN) were treated with 1,25-D3 or vehicle. Vehicle-treated AN rats 
exhibited an increased albumin/creatinine ratio compared to vehicle-treated control 
rats, which was significantly ameliorated by 1,25-D3 treatment (Figure 1A). 1,25-D3 
treatment did not alter urinary albumin/creatinine ratio in control rats. AN rats showed 
increased TRPC6 mRNA (Figure 1B) and glomerular TRPC6 protein expression 
(Figure 1C). By co-staining for TRPC6 and nephrin, we could demonstrate that the 
enhanced TRPC6 expression occurs primarily in podocytes (data not shown). 
Importantly, 1,25-D3 treatment significantly reduced adriamycin-induced TRPC6 
mRNA as well as protein expression. Furthermore, TRPC6 expression was not 
significantly altered by 1,25-D3 in control animals. In addition, glomerular desmin 
expression, as a measure of podocyte damage, was increased in AN rats, but 
significantly reduced upon treatment with 1,25-D3 (Figure 1D). 
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Figure 1: Effect of 1,25-D3 on TRPC6 expression and proteinuria in the rat adriamycin-
induced nephropathy (AN) model for FSGS. 
AN was induced in Wistar rats by a single injection of adriamycin (1 mg/ml). Subsequently, 
AN or control (CTR) rats were treated with 1,25-D3 (2.5 µg/kg) or vehicle (VEH) for 6 weeks. 
Proteinuria is depicted as albumin/creatinine ratio (A), TRPC6 mRNA expression (B) was 
determined by real-time qPCR and glomerular TRPC6 protein expression (C) and desmin 
protein expression (D) were determined by semi-quantitative immunohistochemistry. 
Representative immunohistochemical images are shown (C and D) * p < 0.05 vs VEH-
treated controls, † p < 0.05 vs VEH-treated AN. 
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Effect of 1,25-D3 on TRPC6 expression in podocyte injury in vitro  
In the adriamycin-induced podocyte injury model, TRPC6 expression was 
significantly increased when compared to vehicle-treated control cells (Figure 2A). 
When injured podocytes were treated for 24 hours with 100 nM 1,25-D3, TRPC6 
expression was similarly reduced. Furthermore, a dose-dependent reduction of 
adriamycin-induced TRPC6 expression was observed when adriamycin-injured 
podocytes were treated with increasing concentrations of 1,25-D3 (Figure 2B). In 
contrast, no effect of 1,25-D3 on TRPC6 expression was seen in uninjured control 
podocytes. 
 
 
 
Figure 2: Dose-dependent effect of 1,25-D3 on TRPC6 expression in podocyte injury. 
Cultured podocytes were exposed to adriamycin (ADRIA) or vehicle (VEH) in absence or 
presence of 1,25-D3 (100nM) for 24 hours (A). Cultured podocytes were treated with 
adriamycin (ADRIA-treated) or vehicle (VEH) and subsequently treated with different 
concentrations of 1,25-D3 (100 pM – 1 µM) or vehicle (VEH) for 24 hours (B). TRPC6 mRNA 
levels were determined by real-time qPCR and quantified by the delta-delta cycle threshold 
(Ct) method using GAPDH as the house-keeping gene. Results are shown as percentage 
compared to vehicle-treated control podocytes. * p < 0.05 vs VEH/VEH-treated, † p < 0.05 vs 
ADRIA. 
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Effect of 1,25-D3 on TRPC6 promoter activity 
In order to evaluate whether 1,25-D3 directly regulates TRPC6 transcription, possibly 
through vitamin D-responsive elements (VDRE) in the TRPC6 promoter, the 1500 bp 
upstream of the mouse TRPC6 transcription start site were cloned upstream of the 
luciferase reporter gene. Opossum kidney (OK) cells were subsequently transfected 
with either the mouse TRPC6 promoter luciferase reporter construct or an empty 
vector that does not contain transcriptionally active elements, and treated for 48 
hours with 100 nM 1,25-D3 or vehicle. Treatment with 1,25-D3 significantly reduced 
the activity of the TRPC6 promoter by about 25%, compared to the vehicle-treated 
cells (Figure 3). Luciferase activity was not altered by 1,25-D3 in cells expressing the 
empty vector.  
 
Figure 3: Effect of 1,25-D3 on TRPC6 promoter activity. 
A luciferase assay was performed in OK cells transiently transfected with a Firefly luciferase 
TRPC6 promoter construct or empty vector, after 48 hours of treatment with 100 nM 1,25-D3 
or vehicle (VEH). A Renilla luciferase construct was co-transfected to correct for transfection 
efficiency. Firefly/Renilla luciferase ratios were determined as a measure of promoter activity. 
Results are depicted as percentage compared to vehicle-treated cells transfected with the 
TRPC6 promoter construct. * p < 0.05 vs VEH-treated empty vector, † p < 0.05 vs VEH-
treated TRPC6 construct. 
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ChIP analyses of VDR binding to the TRPC6 promoter region 
To determine whether the above described effect of 1,25-D3 on TRPC6 promoter 
activity is mediated by direct binding of the VDR to the TRPC6 promoter, we 
performed a ChIP analysis. OK cells were transfected with the mouse TRPC6 
promoter luciferase construct (TRPC6) or empty vector (Empty) and treated with 100 
nM 1,25-D3 for 4 hours. After the ChIP assay, we performed a real-time PCR 
analysis, which showed a 16-fold enrichment of the TRPC6 promoter when 
precipitated with the anti-VDR antibody (Figure 4: anti-VDR lane) compared to the 
rabbit IgG isotype control (Figure 4; IgG lane) Two percent of the chromatin used for 
immunoprecipitation was included as a control (Figure 4; input lane). Using the 
empty vector no significant difference was seen between both antibodies (data not 
shown). 
 
 
Figure 4: Vitamin D receptor (VDR) binds to the TRPC6 promoter region. 
To determine whether the VDR directly binds the TRPC6 promoter region we performed a 
chromatin immunoprecipitation (ChIP) analysis. OK cells were transfected with the mouse 
TRPC6 promoter luciferase construct or the empty vector without promoter, and treated with 
100 nM 1,25-D3. After chromatin immunoprecipitation using an anti-VDR antibody or a rabbit 
IgG isotype control antiserum, DNA was isolated and a (real-time) PCR with specific primers 
designed for the TRPC6 promoter was performed. Real-time PCR showed a 16-fold 
enrichment of signal using the anti-VDR antibody (anti-VDR lane) compared to the isotype 
control (IgG lane) in the presence of the TRPC6 promoter construct, whereas this enrichment 
was absent using the empty vector (not shown). As a control 2% of the chromatin used for 
the immunoprecipitation is shown (input lane) 
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TRPC6 expression and glomerular injury in 1,25-D3-deficient mice 
To study the in vivo effect of 1,25-D3 deficiency, we used 25-hydroxy-1α-hydroxylase 
knockout (KO) mice, which are unable to synthesize 1,25-D3 [33]. These KO mice 
showed a significantly increased albumin/creatinine ratio compared to their wildtype 
(WT) littermates (Figure 5A). Subsequently, 1,25-D3 supplementation in 25-hydroxy-
1α-hydroxylase KO mice reduced albumin/creatinine ratio to WT levels, without 
restoring the hypocalcemia in these mice. At sacrifice, serum Ca2+ concentrations 
were 2.09±0.01mM, 1.37±0.03mM and 1.39±0.04mM for WT, KO and KO 
supplemented with 1,25-D3, respectively. Importantly, 25-hydroxy-1α-hydroxylase KO 
mice demonstrated an increased TRPC6 mRNA (Figure 5B) and glomerular TRPC6 
protein expression (Figure 5C). By co-staining for TRPC6 and podocin, we could 
demonstrate that the enhanced TRPC6 expression occurs in podocytes (data not 
shown). Furthermore, 1,25-D3 treatment normalized TRPC6 mRNA and protein 
expression in these mice. Expression of desmin was significantly increased in 25-
hydroxy-1α-hydroxylase KO mice, which was restored to normal levels by 1,25-D3 
treatment (Figure 5D). Electron microscopy analysis clearly demonstrated more, and 
in some segments total, podocyte foot process effacement in proteinuric 1,25-D3-
deficient mice. Hardly any effacement could be detected in their WT non-proteinuric 
littermates, as shown in the representative images in Figure 5E. The extent of 
podocyte effacement was quantified as 1.9±0.1% in WT versus 15.3±2.9% in the 25-
hydroxy-1α-hydroxylase KO animals. When treated with 1,25-D3, the podocyte foot 
process effacement in 25-hydroxy-1α-hydroxylase KO animals completely recovered 
to 2.2±0.7%, and glomerular ultrastructure was not distinguishable from WT mice. 
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Figure 5: TRPC6 expression, proteinuria and podocyte foot process effacement in 1,25-D3-
deficient 25-hydroxy-1α-hydroxylase KO mice. 
25-hydroxy-1α-hydroxylase KO mice were supplemented daily with 1,25-D3 (500 ng) or 
vehicle for 6 weeks. Proteinuria is depicted as albumin/creatinine ratio (A), TRPC6 mRNA 
expression (B) was determined by real-time qPCR and glomerular TRPC6 protein 
expression (C) and desmin protein expression (D) were determined by semi-quantitative 
immunohistochemistry. * p < 0.05 vs VEH-treated controls, † p < 0.05 vs VEH-treated AN. 
Representative images showing podocyte morphology as determined by electron microscopy 
(E). 
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Discussion 
The present study demonstrated that 1,25-D3 downregulates TRPC6 expression both 
in injured podocytes as well as in animal models for FSGS and 1,25-D3 deficiency. 
The increased glomerular TRPC6 expression and proteinuria in the AN rat model for 
human FSGS, were both significantly ameliorated by 1,25-D3 treatment. In vitro, the 
enhanced TRPC6 expression in injured podocytes was dose-dependently reduced by 
1,25-D3 application. We demonstrated that the VDR binds directly to the TRPC6 
promoter region and, accordingly, 1,25-D3 inhibits TRPC6 promoter activity. 
Interestingly, 25-hydroxy-1α-hydroxylase KO mice, which are 1,25-D3 deficient, 
showed significantly enhanced glomerular TRPC6 expression levels along with a 
remarkable proteinuria associated with podocyte foot process effacement. In line with 
the aforementioned results, 1,25-D3 supplementation reversed both the increased 
TRPC6 expression as well as the proteinuria, and normalized podocyte morphology. 
Taken together, we demonstrated that vitamin D downregulates the enhanced 
TRPC6 expression in in vitro and in vivo podocyte injury, possibly through a direct 
effect on TRPC6 promoter activity.  
 
The present study is the first to show that TRPC6 promoter activity and expression is 
regulated by means of a nuclear hormone receptor, the VDR. TRPC6 was generally 
regarded to be a primarily receptor-operated channel, regulated by cell surface 
receptors like the angiotensin II type 1 receptor (AT1R) [14] [34]. The TRP channel 
family members TRPV5 and TRPV6 are also transcriptionally regulated by vitamin D. 
However, these channels are not regarded as primarily receptor-mediated signaling 
proteins, but rather involved in transcellular Ca2+ transport across the gastrointestinal 
and renal epithelia, processes known to be governed by vitamin D [35-37].  
 
While the TRPC6 promoter activity can be inhibited by 1,25-D3 in uninjured OK cells, 
in cultured podocytes and in vivo in the rat kidney 1,25-D3 appears to reduce TRPC6 
expression only in injured podocytes, but not in uninjured podocytes. One 
explanation could be the length (~1500bp) of the cloned TRPC6 promoter region for 
the luciferase reporter construct. In this cloned region there could be less 
transcription sites compared to the native promoter in its chromatin context. 
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Therefore the native TRPC6 gene in the cultured or in vivo podocytes might be 
regulated more strictly by other (transcription) factors, which are unable to affect our 
1500 bp promoter construct or are not even present, like higher order chromatin 
structures. A second explanation could be that the kinetics of the turnover and 
relative expression of the luciferase protein is different from the TRPC6 mRNA and 
protein. A third explanation could be, that the basal TRPC6 promoter activity is 
regulated by another transcriptional complex in a specific chromatin context in 
uninjured cultured or in vivo podocytes compared to the TRPC6 promoter activity in 
injured podocytes and/or OK cells.  
 
In general, transcriptional regulation of vitamin D-responsive genes occurs through 
interaction of the nuclear VDR complex with vitamin D responsive elements (VDRE) 
in the promoter region of these target genes [38]. In this study, we demonstrated that 
the VDR indeed binds to the TRPC6 promoter region. For positively regulated genes, 
a VDRE consensus sequence is available. Genes that are negatively regulated by 
vitamin D are sparse and, next to TRPC6, include the genes encoding parathyroid 
hormone and renin [39-41]. When the negative vitamin D-responsive promoter 
sequences (nVDRE) in these genes were identified, they did not comply with the 
consensus sequence [42, 43]. Similarly, the TRPC6 promoter region did not contain 
sequences complying with the VDRE consensus sequence (data not shown). Thus, 
TRPC6 appears to be part of a select group of genes that are negatively regulated by 
vitamin D. 
 
The relationship between proteinuria and increased TRPC6 activity and/or 
expression was demonstrated in several acquired human proteinuric diseases and 
animal models [10, 12, 13, 44-46]. In addition, downregulation of TRPC6 expression 
by e.g. ARBs, ACEi or calcineurin inhibitors correlated with reduced proteinuria in 
proteinuric animal models [14, 47, 48]. Recently, Eckel et al. illustrated the potential 
beneficial anti-proteinuric effect of downregulating TRPC6 expression by showing 
reduced AngII-mediated albuminuria in TRPC6 KO compared to WT mice [49]. In the 
present study, we demonstrated that 1,25-D3 treatment significantly reduces 
glomerular TRPC6 expression and proteinuria, as well as expression of the podocyte 
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injury marker desmin in the rat AN FSGS model. To further evaluate the importance 
of 1,25-D3, we used the 25-hydroxy-1α-hydroxylase KO model, which displays 
undetectable levels of 1,25-D3 [33, 50]. Glomeruli showed increased TRPC6 
expression, which was paralleled by a similarly increased expression of the podocyte 
damage marker desmin. Electron microscopy showed podocyte foot process 
effacement in the KO mice. To confirm that the enhanced TRPC6 expression was 
1,25-D3-mediated and to test whether damage could be prevented, mice were 
supplemented with 1,25-D3, which normalized glomerular TRPC6 expression and 
proteinuria. Theoretically, the observed effects could also result from e.g. the striking 
hypocalcemia interfering with TRPC6 function in the podocytes of 25-hydroxy-1α-
hydroxylase KO mice, but the relatively low dose of 1,25-D3 supplementation did not 
significantly increase serum Ca2+ levels in these mice. The current study is the first to 
describe the glomerular and proteinuric phenotype in this animal model of 1,25-D3-
deficiency. However, our results by no means prove a causal relationship between 
increased TRPC6 expression and the glomerular phenotype in this particular model. 
Taken together though, our data do show that 1,25-D3 downregulates the enhanced 
TRPC6 expression in FSGS, while 1,25-D3 deficiency results in increased TRPC6 
expression, which was proven 1,25-D3-sensitive. 
 
While our TRPC6 promoter luciferase reporter and ChIP analyses suggested that 
TRPC6 promoter activity is a specific target of vitamin D, this does not rule out that in 
vivo, other mechanisms could also contribute to the downregulation of TRPC6 
expression by vitamin D. Importantly, the gene encoding renin, important in AngII 
biosynthesis, is negatively regulated by vitamin D. As we previously showed that 
AngII enhances TRPC6 expression by stimulating a calcineurin/NFAT-mediated feed-
forward pathway in adriamycin-induced podocyte injury, this could certainly be an 
additional mechanism reducing TRPC6 expression [14]. Interestingly, recent studies 
in mice with cardiomyocyte-specific deletion of the VDR demonstrated that vitamin D 
inhibits the calcineurin/NFAT signaling pathway in the cardiomyocyte, which also 
includes TRPC6 [51]. Thus, the demonstrated vitamin D-mediated inhibition of 
TRPC6 promoter activity could serve to counteract the effect of the transcription 
factor NFAT on the TRPC6 promoter. Furthermore, TRPC6 will certainly not be the 
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only mediator of the effect of vitamin D on glomerular injury and proteinuria. Several 
studies described the protective role of 1,25-D3 in different proteinuric disorders such 
as FSGS and diabetic nephropathy, in which the authors hypothesized that 1,25-D3 
acts on various pathways [18-20]. For example, 1,25-D3 upregulates expression of 
various structural podocyte proteins such as podocin and nephrin [52, 53]. Nephrin 
was shown to inhibit TRPC6-phospholipase C complex formation, surface expression 
and activation [54]. Therefore, in addition to inhibiting TRPC6 expression directly, 
1,25-D3 could also affect TRPC6 indirectly via nephrin. 
 
Altogether, our results add important new data to our understanding of the regulation 
of TRPC6 expression in podocytes. The transcriptional regulation of TRPC6 by 1,25-
D3 demonstrated in cultured podocytes and illustrated in a rat FSGS model as well as 
in 1,25-D3-deficient mice, suggests that TRPC6 downregulation could indeed 
contribute to the anti-proteinuric effect of vitamin D. 
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Abstract 
Vitamin D
 
plays an important role in renal (patho)physiology. Patients with glomerular 
diseases have an injured renal filtration barrier leading to proteinuria and, eventually, 
reduced renal function. An impaired renal function also leads to 1,25-vitamin D3 
deficiency as a result of reduced renal 1α-hydroxylase (1α-OHase) activity. Vitamin D 
treatment to reduce proteinuria remains controversial, although an inverse correlation 
between vitamin D levels and the occurrence of proteinuria exists. 
In this study we showed that 1,25-vitamin D3-deficient 25-hydroxy-vitamin-D3-1α-
hydroxylase knockout (KO) mice and 1,25-vitamin D3-deficient rats develop renal 
injury and renal dysfunction. Glomerular injury was characterized by proteinuria and 
partial podocyte foot process effacement. Podocytes, are crucial cells of the 
glomerular filtration barrier, and expression of nephrin, podocin, desmin and TRPC6 
in the podocyte was significantly altered in 1,25-vitamin D3 deficient animals. 
Supplementation with 1,25-vitamin D3 or 1,25-vitamin D2 prevented podocyte 
effacement or reversed glomerular and tubulointerstitial damage in 1,25-vitamin D3-
deficient animals, thereby respectively preserving and restoring renal function. The 
curing effect of 1,25-vitamin D3 and 1,25-vitamin D2 was serum calcium-, PTH- and 
FGF23-independent. 
This study demonstrates that 1,25-vitamin D3 deficiency directly leads to renal injury 
in rodents. When translated to human subjects, this would underscore the need for 
early vitamin D supplementation in patients with glomerular disease and chronic renal 
insufficiency, which might inhibit or could even reverse renal injury.  
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Introduction 
Vitamin D is a steroid hormone with important physiological roles in several organs 
and tissues [1]. 1,25-vitamin D3 is the active form of vitamin D, and known for its role 
in calcium and phosphate homeostasis. However, the pluripotent 1,25-vitamin D3 
also influences processes in growth and development [2, 3], cardiovascular disease 
[4, 5], cancer [6, 7] and the immune system [8]. Vitamin D analog treatment seems to 
delay renal function decline and reduce proteinuria in patients and animals with 
chronic kidney disease [9-11]. However, the literature on this topic is not conclusive 
and the therapeutic effect of vitamin D remains heavily debated [12]. Interestingly, 
scarce literature data describes an association between low serum vitamin D levels 
and morbidity, mortality and renal damage as well as increased albuminuria [4, 13] 
[14]. These studies do not prove causality, and the exact molecular mechanisms by 
which vitamin D deficiency would cause these effects are unknown. 
Podocytes and the interconnecting slit diaphragm in the glomerular filtration barrier 
can be injured in glomerular diseases such as focal segmental glomerular sclerosis 
(FSGS) and diabetic nephropathy, leading to renal dysfunction and proteinuria [15-
18]. Persisting renal injury can lead to chronic kidney disease and end stage renal 
disease (ESRD). In renal insufficiency, renal proximal tubular cells show reduced 1α-
hydroxylation capacity resulting in 1,25-D3 deficiency [19]. Renal patients are treated 
with vitamin D analogs, but often only after secondary hyperparathyroidism has 
developed with the goal to correct calcium-phosphorus homeostasis. We suggest 
that vitamin D deficiency itself induces or aggravates glomerular injury. Podocytes 
express the vitamin D receptor (VDR), and undergo ultrastructural changes when 
exposed to vitamin D [20, 21]. Vitamin D is known to regulate vital proteins in the slit 
diaphragm, such as nephrin, and podocin, and we recently demonstrated the direct 
regulation of the Transient Receptor Potential channel C6 (TRPC6) by vitamin D [22-
26]. Thus, in addition to being a consequence of renal insufficiency, we hypothesize 
that 1,25-D3 deficiency itself can also cause renal injury.  
In our study on regulation of TRPC6 by vitamin D, we demonstrated a previously 
unreported proteinuria in 1,25-D3 deficient 25-hydroxy-vitamin-D3-1α-hydroxylase 
knockout mice (CYP27B1 or 1α-OHase KO)[25]. In the present study, we assessed 
the renal phenotype of these animals by studying in detail the effects of this inherited 
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1,25-D3 deficiency on the glomerulus, in particular the podocyte, and the 
tubulointerstitium. In addition, we studied glomerular, tubular and podocyte injury in 
rats with acquired 1,25-vitamin D3 deficiency. Elucidating the renal phenotype of 
these 1,25-vitamin D3 deficient animal models provides new insights into the complex 
relationship between renal injury and 1,25-vitamin D3 deficiency, and increases our 
understanding of the pluripotent effects of vitamin D. 
  
1,25-D3 deficiency induces reversible kidney injury 
 
 
 
 
 
101 
Methods 
Animal studies 
All animal procedures were approved by the Animal Ethics Committee of the 
Radboud University or the VU Medical Center, in accordance with the guidelines of 
the Dutch Council for Animal Care and the European Communities Council Directive 
(86/609/EEC). 
1α-OHase (CYP27B1) KO mice were created as previously described [26]. From an 
age of five weeks, mice received either a 2.0% calcium diet as performed previously 
[27], or daily intraperitoneal injections with 1000 pg/g bodyweight 1,25-D2; 500 (high 
dose) or 25 pg/g bodyweight (low dose) 1,25-D3 (Sigma-Aldrich, St. Louis, USA) or 
vehicle for 6 weeks (n=8 per group). These animals and untreated 5-week-old WT 
and KO mice were housed in metabolic cages for 24 hours to collect urine samples. 
Subsequently, animals were sacrificed and kidney, heart and blood were sampled for 
analysis. 
Wistar rats (Charles River WU, Sulzfeld, Germany) weighing 275-300 g were injected 
with 32 ng 1,25-D2 at day 0, 2, 4, 7, 9 and 11 to deplete the endogenous pool of 
vitamin D3. In addition, rats received a vitamin D deficient diet (TD.120503 Brown 
C.C. Vitamin D Deficient Diet with Lactose). From day 21 the animals were orally 
treated 3 times weekly with vehicle, 1,25-D2 (100 ng/kg), or 1,25-D3 (30 ng/kg) (n=8 
animals per group) as described before [28]. The choice of particularly these two 
vitamin D analogs was based on our in vitro experimental data (see results section). 
After eight weeks of treatment rats where sacrificed, and urine, blood and kidneys 
were harvested. 
 
Serum and urine chemistry 
Urinary NGAL (R&D, Minneapolis, USA) and IgG (Roche, Basel, Switzerland for 
mouse; Antibodies-online, Aachen, Germany for rat) levels and serum FGF-23 C-
terminal (Immunotopics, San Clemente, USA) and PTH 1-84 (Immunotopics, San 
Clemente, USA) concentrations were measured in ELISA. All ELISAs were 
performed according to manufactures protocol. Sodium, potassium, calcium and 
phosphate were determined by the Architect C16000 (Abbott Diagnostics, Chicago, 
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USA). Serum vitamin D levels were assessed by radioimmunoassay after 
immunoextraction (IDS, Tyne and Wear, UK) 
 
Transmission Electron Microscopy 
Immersion fixation was used for EM. Cortex was fixed in 2.5% v/v glutaraldehyde 
dissolved in 0.1 M sodium cacodylate buffer, pH 7.4, overnight at 4°C. The tissue 
was post-fixed in palade-buffered 2% w/v OsO4, dehydrated, and embedded in 
Epon812, Luft's procedure (Merck, Darmstadt, Germany). Ultrathin sections were 
contrasted with 4% w/v uranyl acetate and subsequently with lead citrate. Podocyte 
effacement was analyzed using a Jeol 1200 EX2 electron microscope (JEOL, Tokyo, 
Japan). 
 
(Immuno)histochemistry 
Frozen kidney cortex of 5-8 animals per group was cut into 2 µm cryosections and 
stained for several proteins (see Table 1 for primary antibodies). Alexa-conjugated 
secondary antibodies were used for detection and sections were embedded in 
vectashield (Vector Labs, Burlingame, USA). The antibody against granulocytes was 
directly labeled and therefore no secondary antibody was used. Analysis was 
performed on 30 glomeruli per animal using ImageJ software (National Institutes of 
Health, Bethesda, USA). We used a standard periodic acid-Schiff (PAS) staining on 
paraffin sections to study glomerular and tubulointerstitial morphology by light 
microscopy. 
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Table 1: Primary antibodies used for immunofluorescent staining. 
  
Antigen  Antibody  Description  Dilution  Manufacturer  
TRPC6  ACC-017  Rabbit-anti-
mouse  
1:1600  Alomone, Jeruzalem, Israel  
TRPC6 AB62999 Rabbit-anti-rat 1:500 Abcam, Cambridge, UK 
Desmin  SC-7559  Goat-anti-mouse  1:200  Santa Cruz, Santa Cruz, USA  
Nephrin  AF-3159  Goat-anti-mouse  1:200  R&D, Minneapolis, USA  
Podocin  SC-22298  Goat-anti-mouse  1:50  Santa Cruz, Santa Cruz, USA  
Caspase 3  9661-S  Rabbit-anti-
mouse  
1:200  Cell Signaling Technology, Boston, 
USA  
Granulocytes  LY-6G  Rat-anti-mouse  1:100  eBioscience, Inc., San Diego, USA  
NGAL   Rat-anti-mouse 1:50  R&D, Minneapolis, USA 
Synaptopodin  65194  Mouse-anti-rat  1:5  Progen Pharmaceuticals Ltd., 
Toowong, Australia  
IgG A11001 Goat-anti-mouse 1:200 Invitrogen, Carlsbad, USA 
IgM A21044 Goat-anti-mouse 1:200 Life technologies, Carlsbad, USA 
IgA 556978 Rat-anti-mouse 1:100 BD Pharmingen, San Diego, USA 
C3 14631 Goat-anti-mouse 1:40 Nordic, Tilburg, The Netherlands 
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Cell culture studies 
Conditionally immortalized mouse podocytes (MPC-5) cells were cultured as 
described previously [29]. After 2 weeks of differentiation, cells were treated with 0.25 
µg/ml adriamycin in combination with vehicle or a vitamin D analog (cholecalciferol 
(D3); calcidiol (25-D3); alphacalcidiol (1α-D3); calcitriol (1,25-D3); ergocalciferol (D2); 
doxercalciferol (1α-D2) or paricalcitol (1,25-D2)) at a concentration of 0.1 or 1 µM. 
After 24 hours cells were harvested. 
The TRPC6 promoter activity assay was performed as described previously [25]. 
Briefly, after transfection, cells were treated with vehicle or a vitamin D analog D3, 25-
D3, 1α-D3, 1,25-D3, D2, 1α-D2 or 1,25-D2 at a concentration of 0.1 or 1 µM. After 24 
hours, cells were harvested and a luciferase reporter assay (Promega, Madison, 
USA) was performed. 
 
Real-time quantitative PCR analysis 
RNA was isolated from kidney cortex or cultured MPC-5 cells. cDNA synthesis and 
real-time quantitative PCR was performed as described previously [30].  
 
Statistical analysis 
Results in the text and figures are depicted as mean ± SEM. ANOVA was used to 
test for significance using SPSS software (IBM, New York, USA) followed by a 
Bonferroni post hoc test. P values less than 0.05 were considered significant.  
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Results 
Inherited 1,25-D3 deficiency induces glomerular and tubulointerstitial injury and 
proteinuria 
A significant proteinuria was already detected in 4-week-old 1α-OHase KO mice 
(Figure 1A), with increased urinary IgG excretion suggesting a glomerular origin 
(Figure 1B). Urinary neutrophil gelatinase-associated lipocalin (NGAL) excretion, a 
measure of tubular damage, was also increased in the KO mice (Figure 1C). 
Treating KO animals from week 5 onwards with a low dose of 1,25-D3 for 6 weeks 
normalized urinary protein (Figure 1D) and reduced urinary IgG (Figure 1E) 
excretion to wildtype (WT) levels, without affecting NGAL excretion (Figure 1F). 
Immunohistochemistry demonstrated increased tubular NGAL expression in the KO 
mice, which remained unchanged by supplementation with 1,25-D3 (Figure 1G). 
Tubulointerstitial staining for cleaved caspase-3 was increased in KO mice, and was 
reduced but not normalized by 1,25-D3 (Figure 1H).  
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Figure 1: Renal injury in 1α-OHase KO mice. 
Renal injury was assessed by urinary albumin/creatinine ratio (µg/mg) (A) IgG/creatinine 
ratio (ng/mg) (B) and NGAL/creatinine ratio (ng/mg) excretion (C) in 4-week-old 1α-OHase 
KO and WT mice. Five-week-old 1α-OHase KO mice were given daily injections with low 
dose 1,25-D3 or vehicle, after 6 weeks, mice were sacrificed. Renal injury was assessed by 
urinary albumin/creatinine ratio (mg/µg) (D), IgG/creatinine ratio (ng/mg) (E) and 
NGAL/creatinine ratio (ng/mg) excretion (F). Tubulointerstitial NGAL protein expression (G) 
and cleaved caspase 3 expression (H). Protein and mRNA expression are depicted as 
percentage of vehicle-treated WT mice. * p < 0.05 vs WT, † p < 0.05 vs KO. 
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Podocyte injury in inherited 1,25-D3 deficiency  
Periodic acid–Schiff (PAS) staining showed no visible abnormalities in the glomerulus 
or tubulointerstitium of 4 or 11-week-old 1α-OHase KO mice (results not shown). 
Electron microscopy (EM) analysis detected no podocyte foot processes effacement 
in the 4-week-old KO mice (results not shown). However, glomerular desmin and 
TRPC6, as measures of podocyte injury, were increased in the KOs when compared 
to WT animals (Figure 2A + B). Moreover, nephrin expression was downregulated in 
the KO mice (Figure 2C). To determine the progression and reversibility of podocyte 
injury, we also examined KO mice treated with a low dose of 1,25-D3 for 6 weeks. EM 
revealed partial foot processes effacement in the untreated 11-week-old KO animals, 
which was reversed by 1,25-D3 treatment (Figure 2D). This was accompanied by a 
downregulation of desmin and TRPC6 expression in the 1,25-D3 supplemented mice 
compared to the 11-week-old KOs to WT levels (Figure 2E and F). Nephrin (Figure 
2G) and podocin expression (Figure 2H) were upregulated to WT levels by 1,25-D3 
administration compared to the KO animals. No difference in the expression of the 
actin cytoskeleton scaffolding protein CD2AP was found (Figure 2I). The 
calcineurin/nuclear factor of activated T cells (NFAT) pathway was identified as a 
pathway enhancing podocyte injury. Next to TRPC6, myocyte-enriched calcineurin-
interacting protein (MCIP) is an NFAT target [31]. MCIP expression was increased in 
1α-OHase KO mice and restored to WT levels when mice were supplemented with 
1,25-D3 (Figure 2J). Calcineurin activation might induce breakdown of the podocyte 
cytoskeletal protein synaptopodin. However, no significant differences in 
synaptopodin expression between groups were found (Figure 2K). 
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Figure 2: Podocyte injury and altered expression of key podocyte proteins in 1α-OHase KO 
mice. 
Expression of podocyte damage markers desmin (A), TRPC6 (B), and nephrin (C) was 
determined in 4-week-old 1α-OHase KO and WT mice. Five-week-old 1α-OHase KO mice 
were given daily injections with 1,25-D3 or vehicle for 6 weeks. Renal ultrastructural was 
assessed by EM (D). Expression of desmin (E), TRPC6 (F), nephrin (G), podocin (H), 
CD2AP (I), MCIP (J) and synaptopodin (K). Results are shown as percentage of vehicle-
treated WT mice. * p < 0.05 vs WT, † p < 0.05 vs KO. 
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Glomerular basement membrane (GBM) composition is altered in 1,25-D3 
deficiency 
EM analysis showed some variation in GBM width in 11-week-old 1α-OHase KO 
mice, where within one glomerular capillary loop thinner sections were present, 
reminiscent of GBM changes sometimes encountered in focal segmental 
glomerulosclerotic (FSGS) lesions (Figure 3). However, there was no clear global 
thinning or thickening, heterogeneity or multiplication of the GBM. 
 
 
Figure 3: Minor glomerular basement membrane (GBM) changes and extracellular matrix 
protein expression in 1α-OHase KO mice. 
Five-week-old 1α-OHase KO mice were given daily intraperitoneal injections with 1,25-D3 or 
vehicle for 6 weeks. Ultrastructural analysis by EM revealed thinning of the GBM (indicated 
by the arrows), without global GBM alterations. 
 
Endocrine alterations in inherited 1,25-D3 deficiency 
Endocrine alterations secondary to 1,25-D3 deficiency could be involved in the renal 
phenotype in these mice. Serum parathyroid hormone (PTH) levels were significantly 
elevated in the KO mice, as well as in the vitamin D-supplemented mice (Table 2). 
No differences were observed in renal cortical PTH receptor expression. In contrast  
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to PTH, serum levels of FGF-23 were not detectable in KO and vitamin D 
supplemented mice. Renal VDR expression was strongly reduced in the KO mice, 
but was even lower in the 1,25-D3 supplemented 1α-OHase KO group. The male as 
well as female KO mice had a decreased body weight and lowered serum calcium 
and phosphate concentration compared to their WT littermates.  
Table 2: Clinical parameters 1α-OHase KO mice. 
 WT  KO  KO + Vit D  
Serum PTH (pg/ml) 315±68 1907±353 * 1540±174 * 
PTH receptor 
expression (% vs 
WT) 
 
100±12.1 81.5±5.6 89.0±28.0 
VDR expression (% 
vs WT) 
100±12.5 27.0±4.6 * 10.4±2.8 * † 
Serum FGF23 
(pg/ml) 
225±66 Not detectable Not detectable 
Body weight (g) 23.4±1.7 males  17.4±0.6 males *  19.0±1.3 males  
 18.5±0.8 females  13.9±0.7 females *  14.3±0.2 females  
Serum calcium 
(mmol/L) 
2.12±0.08  1.41±0.05 *  1.45±0.02 *  
Serum phosphate 
(mmol/L) 
2.58±0.09  2.02±0.08  2.27±0.05 * †  
Five-week-old 1α-OHase KO mice were given daily intraperitoneal injections with 1,25-D3 or 
vehicle for 6 weeks. Weight of the mice was determined and blood samples were analyzed. * 
p < 0.05 vs WT, † p < 0.05 vs KO.  
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1,25-D3 deficiency does not lead to immune-mediated glomerular injury  
Because vitamin D affects the immune system, immune-mediated renal injury was 
examined. However, no IgG (Figure 4A), IgA (Figure 4B), IgM (Figure 4C), 
complement C3 (Figure 4D), or granulocyte influx (Figure 4E) could be shown in KO 
mice. 
 
Figure 4: No signs of immune-mediated glomerular injury in 1α-OHase KO mice. 
Five-week-old 1α-hydroxylase KO mice were given daily intraperitoneal injections with 1,25-
D3 or vehicle for 6 weeks. Renal IgG (A), IgA (B), IgM (C), complement factor C3 (D) and 
granulocyte influx (E). 
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In vitro, 1,25-D3 and 1,25-D2 downregulate expression of podocyte damage 
marker TRPC6  
Cultured MPC5 podocytes were injured using Adriamycin and treated with a wide 
range of vitamin D analogs, and podocyte injury was assessed by TRPC6 
expression. We previously showed that the classical activated 1,25-D3 analog 
downregulates TRPC6 expression. Adriamycin-injured podocytes showed increased 
TRPC6 expression when compared to control cells (Figure 5A). In Adriamycin-
injured cells treated with 1,25-D3 and 19-nor-1,25-dihydroxyvitamin-D2 (1,25-D2) at a 
concentration of 100 nM, TRPC6 expression was downregulated. At a concentration 
of 1.0 µM, all hydroxylated vitamin D3 analogs and 1,25-D2 were able to 
downregulate TRPC6 expression (Figure 5A). Moreover, we measured TRPC6 
promoter activity using a luciferase TRPC6 promoter reporter construct. TRPC6 
promoter activity showed a similar pattern when compared to the TRPC6 expression 
data, with the exception that treatment with 0.1 µM 1,25-D2 did not result in a 
decreased TRPC6 promoter activity (Figure 5B). 
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Figure 5: In vitro, 1,25-D3 and 1,25-D2 downregulate the expression of the podocyte damage 
marker TRPC6. 
Cultured podocytes were injured by adriamycin application and treated with several vitamin D 
analogs at a concentration of 0.1 and 1 µM, and TRPC6 mRNA expression was measured 
(A). The effect of vitamin D analogs on TRPC6 promoter activity was examined using a 
luciferase promoter assay. Cells were treated with several vitamin D analogs at a 
concentration of 0.1 and 1 µM. Firefly/Renilla ratio was calculated and normalized for vehicle 
treated cells (B). * p < 0.05 vs vehicle treated cells, † p < 0.05 vs control but adriamycin-
treated cells. 
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Both 1,25-D3 and 1,25-D2 supplementation reverse glomerular injury in 1α-
OHase KO mice  
Our in vitro data suggested that, in analogy to the classical role of vitamin D in 
mineral metabolism, the hydroxylation state of vitamin D analogs is also important for 
its protective effect in podocytes. Therefore, we treated 1α-OHase KO mice with 
1,25-D3 and 1,25-D2, which were in our in vitro experiments the most potent 
downregulators of TRPC6 expression, at concentrations that restored serum calcium 
to WT level (WT: 2.24±0.04 mM, KO: 1.67±0.12 mM, 1,25-D2: 2.18±0.13 mM, 1,25-
D3: 2.26±0.02 mM). KO mice showed albuminuria (Figure 6A) and increased IgG 
excretion (Figure 6B), which were completely corrected by both vitamin D analogs. 
Moreover, tubulointerstitial damage was partly and completely reversed by 1,25-D2 
and 1,25-D3, respectively (Figure 6C). EM showed that the partial podocyte foot 
process effacement in the KO mice was absent after treatment with both vitamin D 
analogs (Figure 6D). Expression of podocyte injury markers desmin and TRPC6 was 
increased in KO animals and normalized by 1,25-D2 and 1,25-D3 supplementation 
(Figure 6E + F). However, only normalizing serum calcium did not reverse renal 
injury in 1α-OHase KO mice as shown by albumin/creatinine ratio (Figure 6G), 
urinary IgG (Figure 6H) and NGAL (Figure 6I) excretion. Moreover, glomerular 
desmin (Figure 6J) and TRPC6 (Figure 6K) expression between mice with high and 
low calcium diets was comparable. 
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Figure 6: High dose 1,25-D3 and 1,25-D2 supplementation reverses glomerular injury in 
1αOHase KO mice. 
Five-week-old 1α-OHase KO mice were given daily intraperitoneal injections with 1,25-D2, 
1,25-D3 or vehicle for 6 weeks. Renal injury was assessed by urinary albumin/creatinin ratio 
(µg/mg) (A), IgG/creatinine ratio (ng/mg) (B) and NGAL ratio (ng/mg) (C). Renal 
ultrastructural was assessed by EM (D). Expression of podocyte damage markers desmin 
(E) and TRPC6 (F). Five-week-old 1α-OHase KO mice received a 0.8% or 2.0% calcium diet 
for 6 weeks. Renal injury was assessed by urinary albumin/creatinin ratio (mM/mM) (G), IgG 
(H) and NGAL excretion (I). Expression of podocyte damage markers desmin (J) and TRPC6 
protein (K). Expression levels are depicted as percentage of vehicle-treated WT mice. * p < 
0.05 vs WT. * p < 0.05 vs WT, † p < 0.05 vs KO. 
1,25-D3 deficiency induces reversible kidney injury 
 
 
 
 
 
117 
Acquired 1,25-vitamin D3 deficiency also leads to glomerular and 
tubulointerstitial injury and proteinuria 
In addition to genetic 1,25-vitamin D3 deficiency, we also studied acquired 1,25-
vitamin D3 deficiency in rats. After depleting the endogenous vitamin D pool, 1,25-D3 
serum levels were lower compared to control animals (control: 295±58pmol/L, 
deficient: 35±9pmol/L, p<0.05), thus rendering these animals 1,25-vitamin D3 
deficient. After 5 weeks, albuminuria (Figure 7A) and increased urinary IgG excretion 
(Figure 7B) were observed, which could be prevented by supplementation with 1,25-
D2 and 1,25-D3. Urinary NGAL excretion was also increased in the 1,25-vitamin D3 
deficient animals and reduced with 1,25-D2 and 1,25-D3 supplementation (Figure 
7C). EM revealed no ultrastructural alterations (results not shown). However, the 
expression of desmin (Figure 7D) and TRPC6 (Figure 7E) was upregulated in 
vitamin D deficient rats compared to either control or 1,25-D2 and 1,25-D3 
supplemented groups. 
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Figure 7: Acquired 1,25-vitamin D3 deficiency leads to glomerular and tubulointerstitial injury 
and proteinuria. 
Wistar rats were made vitamin D deficient and, subsequently, treated with 1,25-D2 or 1,25-D3 
for 5 weeks. Renal injury was assessed by urinary albumin/creatinin ratio (µg/mg) (A), 
IgG/creatinine ratio (ng/mg) (B) and NGAL/creatinine ratio (ng/mg) excretion (C). Expression 
of podocyte damage markers desmin (D) and TRPC6 (E). Protein and mRNA expression are 
depicted as percentage of control. * p < 0.05 vs control, † p < 0.05 vs untreated rats. 
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Discussion 
The present study demonstrated that hereditary as well as acquired 1,25-vitamin D3 
deficiency leads to reversible glomerular injury and albuminuria, as well as 
tubulointerstitial damage in 1,25-D3 deficient 1α-OHase KO mice. Moreover, KO mice 
showed partial podocyte foot process effacement, altered expression of functionally 
relevant slit-diaphragm-associated proteins, and activation of the deleterious 
calcineurin/NFAT pathway. Acquired 1,25-vitamin D3 deficiency in rats also induced 
proteinuria, in combination with an increased expression of podocyte injury markers. 
In vitro, we determined that the fully hydroxylated 1,25-D3 and 1,25-D2 analogs were 
most potent in preventing the upregulation of the podocyte injury marker TRPC6. In 
vivo, 1,25-D3 and 1,25-D2 supplementation indeed largely reversed glomerular injury 
and above described expressional changes. Thus, this study provides important 
evidence that vitamin D treatment is not only able to ameliorate, but also to reverse 
podocyte injury, at least in 1,25-vitamin D3 deficient animal models. Reversal of 
podocyte injury would be consistent with the debated anti-proteinuric effect of vitamin 
D analogs in clinical practice. 
In this study, we showed that loss of 25-hydroxy-vitamin-D3-1α-hydroxylation 
capacity, which also occurs in patients with renal insufficiency, as well as acquired 
1,25-vitamin D3 deficiency, leads to renal injury. An association between low 25-
hydroxyvitamin D levels and an increased prevalence of albuminuria was previously 
described in a population-based survey [13]. A causal relationship between both 
could not be proven. In the present study, we show that 1,25-vitamin D3 deficiency 
indeed results in glomerular proteinuria and partial podocyte foot process effacement. 
Vitamin D analogs have been suggested to ameliorate proteinuria in several 
glomerular diseases [9-11]. Although overt podocyte effacement was not yet present 
in 4-week-old 1α-OHase KO mice, proteinuria and glomerular injury markers were 
already detectable. Moreover, a significant progressive urinary albumin loss was 
found when 4-week-old and 11-week-old 1,25-vitamin D3 deficient mice are 
compared, the latter showing clear podocyte effacement. 
Both in the inherited and acquired vitamin D deficient model, we demonstrated 
downregulation of the expression of structural slit diaphragm-associated proteins 
nephrin and podocin and upregulation of TRPC6 expression. In proteinuric 
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glomerular diseases such as acquired FSGS, membranous nephropathy and diabetic 
nephropathy, decreased expression of podocin and nephrin as well as TRPC6 
overexpression were reported [32-34]. Loss-of-function mutations in nephrin and 
podocin, as well as TRPC6 gain-of-function mutations lead to (congenital) nephrotic 
syndrome and hereditary FSGS [35-38]. Previous studies already suggested that 
vitamin D regulates nephrin and podocin expression [24, 39]. In accordance, diabetic 
VDR KO mice and rats that constitutively express CYP24A1, the enzyme breaking 
down 1,25-D3, displayed proteinuria accompanied by podocyte effacement and 
decreased nephrin expression [40, 41]. Wang et al. demonstrated that 
overexpression of the VDR in podocytes protects the kidney from diabetic injury [24]. 
We previously demonstrated that 1,25-D3 specifically binds to the TRPC6 promoter 
region, thereby downregulating TRPC6 expression [25]. The combination of podocin 
expressional loss and TRPC6 upregulation in 1,25-Vitamin D3 deficient animals is 
particularly significant because podocin regulates TRPC6 channel gating in 
podocytes. It was recently demonstrated that podocin knockdown markedly increases 
TRPC6 mechanosensitivity and would lead to a profound TRPC6 overactivation in 
podocyte foot processes, leading to a situation of Ca2+ overload [42]. In addition, the 
channel appears to function in a deleterious AngII-induced positive feedback TRPC6-
calcineurin/NFAT-TRPC6 signaling loop in the podocyte, which might be enhanced 
by 1,25-vitamin D3 deficiency [12, 30]. MCIP expression, as a measure of 
calcineurin/NFAT activity, was indeed increased in kidneys of 1α-OHase KO animals. 
Calcineurin activation was also shown to lead to dephosphorylation of the podocyte-
specific actin-binding protein synaptopodin, which is crucial for maintaining the 
podocyte actin cytoskeleton [43, 44]. However, enhanced synaptopodin degradation 
does not appear to have occurred in these mice. Of note, while an attractive 
hypothesis, the proof for TRPC6-activated and subsequent calcineurin-mediated 
synaptopodin degradation has yet to be delivered.1,25-vitamin D3 deficiency in the 
KO mice also increased tubulointerstitial damage, as exemplified by detection of 
increased NGAL as tubular injury marker and caspase-3 as measure of apoptotic 
tubular cells. While a low dose of vitamin D did not alter urinary NGAL, a higher dose 
of 1,25-D3 normalized NGAL excretion, which was also partially accomplished by 
1,25-D2. In contrast to NGAL, cleaved caspase 3 expression was already decreased 
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by a low dose of vitamin D treatment, indicating less apoptotic cells. Whether the 
interstitial damage is a direct cause of 1,25-vitamin D3 deficiency, or secondary to the 
glomerular injury is unknown. VDR KO mice showed increased tubular atrophy and 
interstitial fibrosis when subjected to unilateral urethral obstruction [45]. Inoue and 
colleagues found that the vitamin D analog maxacalcitol prevented tubulointerstitial 
fibrosis in urethral obstructed rats [46]. A beneficial effect of vitamin D on caspase 3 
expression was shown in several renal injury models [11, 47]. The reversal of the 
interstitial damage in our study by 1,25-vitamin D might need higher vitamin D 
supplementation doses, or more time to recover when it is secondary to the 
glomerular injury. 
Taken together, regulation of nephrin, podocin and TRPC6 expression by 1,25-D3 in 
inherited as well as acquired 1,25-vitamin D3 deficiency appear to be involved in the 
glomerular injury and proteinuria in 1,25-vitamin D3 deficient animals. The reversal of 
these effects by 1,25-D2 and 1,25-D3 treatment demonstrated that vitamin D can 
reverse podocyte injury and prevent foot process effacement, and that the phenotype 
is indeed vitamin D-dependent. An important additional mediator that could be partly 
responsible for the described effects is the renin-angiotensin system, which is 
regulated by 1,25-vitamin D3. It was previously shown that administration of 1,25-
vitamin D3 reduces blood pressure, plasma renin activity and AngII levels. In line with 
this, 1α-OHase KO mice have a 1,25-vitamin D3-dependent increased blood 
pressure, renin and AngII level, and particularly the latter is known to be an important 
pathogenic factor in glomerular injury [48]. However, as outlined, the direct 
transcriptional regulation of e.g. nephrin, podocin and TRPC6 was previously 
demonstrated [22-26]. Hypothetically, the Ca2+/PO43- homeostasis, or the hormonal 
regulation thereof, could be mediating the deleterious effect of 1,25-vitamin D3 
deficiency. However, our data did not demonstrate a correlation between the 
proteinuric phenotype and serum levels of FGF23, PTH, phosphate and calcium, nor 
did Ca2+ supplementation itself correct the phenotype. To further study the 
contribution of possible mechanistic contributors, the generation of kidney- or even 
podocyte-specific 1α-OHase KO mice would represent valuable tools for future 
research.  
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In conclusion, we demonstrated that 1,25-D3 deficiency leads to glomerular and 
tubulointerstitial damage. When translated to human subjects, this has clear 
implications for clinical practice. Patients with glomerular diseases and/or proteinuria 
should be tested for (1,25-)vitamin D3 deficiency, and supplementation of 1,25-D3 or 
1,25-D2 should be considered. Furthermore, our data add mechanistic evidence to 
the debate on the anti-proteinuric and renoprotective effects of vitamin D, suggesting 
that vitamin D supplementation might be indicated in patients with renal function 
decline in an earlier phase, before the development of overt hyperparathyroidism. 
However, this strategy would have to be based on solid clinical trials showing that 
early vitamin D treatment indeed reduces the rate of renal function decline in human 
patients, which are not available in literature as yet. In general, these data provide 
new input into the debate on the pluripotent effects of vitamin D, at a moment when 
the initial excitement seems to be fading.  
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Abstract 
The glomerular filtration barrier consists of podocytes, the glomerular basement 
membrane, and endothelial cells covered with a glycocalyx. Heparan sulfate (HS) 
expression in the glomerular filtration barrier is reduced in patients with proteinuria, 
which is associated with an increased expression of the HS-degrading enzyme 
heparanase. Previously, we showed that heparanase is essential for the 
development of proteinuria in experimental diabetic nephropathy. Vitamin D 
supplementation reduces podocyte loss and proteinuria in vitro and in vivo. 
Therefore, we hypothesize that vitamin D reduces proteinuria by reduction of 
glomerular heparanase expression. Adriamycin-exposed rats developed proteinuria 
and showed increased heparanase expression, which was reduced by 1,25-
dihydroxyvitamin D3 (1,25-D3) treatment. In vitro, adriamycin treatment increased 
heparanase mRNA expression in the podocyte, which could be corrected by 1,25-D3 
treatment. In addition, 1,25-D3 treatment reduced transendothelial albumin passage 
after adriamycin stimulation. In line with these results, we showed direct binding of 
the vitamin D receptor to the heparanase promoter, which dose-dependently reduced 
heparanase promoter activity. Finally, 1,25-D3-deficient 25-hydroxy-1α-hydroxylase 
knockout mice developed proteinuria, and showed increased heparanase 
expression, which was normalized by 1,25-D3 treatment. Our data suggest that the 
protective effect of vitamin D on the development of proteinuria is mediated by 
inhibiting heparanase expression in the podocyte.  
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Introduction 
The glomerular filtration barrier (GFB), composed of glomerular endothelial cells 
covered with a glycocalyx, the glomerular basement membrane (GBM) and 
podocytes, is responsible for the charge- and size-selective filtration of the blood. The 
charge-selective filtration of the GFB has been attributed to the presence of 
negatively charged molecules in the GFB, of which heparan sulfate (HS) is the most 
abundant. Heparan sulfate proteoglycans (HSPGs) consist of a core protein to which 
one or more HS side chains are covalently attached. Loss of HS expression in the 
GFB is associated with the development of proteinuria [1, 2]. During the last decade, 
the primary role of HS in the glomerular basement membrane in charge-selective 
filtration was refuted [2, 3]. However, in patients proteinuria is associated with a 
reduction in glomerular HS expression, which suggest that the presence of HS in the 
endothelial glycocalyx is key in dictating the charge-selective properties of the GFB 
[2].    
The decreased glomerular HS expression in patients with proteinuria could be 
attributed to an increased glomerular expression of the HS-degrading enzyme 
heparanase, the only known mammalian enzyme that can cleave HS [4]. The 
expression of heparanase is increased in many experimental and human glomerular 
diseases [2-6]. Inhibition of heparanase in experimental passive Heymann nephritis 
by a polyclonal anti-heparanase antibody or the heparanase inhibitor PI-88 reduced 
proteinuria, suggesting that heparanase is important for the development of 
proteinuria [7, 8]. Recently, we showed that heparanase is essential for the 
development of proteinuria in experimental diabetic nephropathy [9]. In response to 
streptozotocin-induced type 1 diabetes, heparanase knockout mice, unlike their 
wildtype littermates, failed to develop proteinuria and diabetic nephropathy, and 
diabetic heparanase knockout mice had a normal renal function. In addition, 
treatment with the heparanase inhibitor SST0001 reduced proteinuria and renal 
function loss [9].  
Proteinuria is an independent risk factor for the progression of renal failure. Current 
treatment of patients with proteinuria is blockade of the renin-angiotensin-aldosterone 
system (RAAS) by angiotensin-converting enzyme (ACE) inhibitors or angiotensin 
receptor blockers (ARBs). This treatment only partly reduces proteinuria, and 
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therefore there is a need for additional anti-proteinuric agents. Recent findings 
suggest anti-proteinuric effects of vitamin D analogues in experimental and human 
glomerular diseases. Vitamin D is a steroid hormone that is involved in the regulation 
of calcium and phosphate homeostasis. Vitamin D3 (cholecalciferol) is taken up from 
the diet and produced in the skin from 7-dehydrocholesterol by exposure to ultraviolet 
radiation. Subsequently, vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver 
and to 1,25-dihydroxyvitamin D3 (1,25-D3), the active form of vitamin D3, in the 
kidney. Vitamin D binds to the vitamin D receptor (VDR). The VDR then interacts with 
the retinoid X receptor to form a heterodimer that binds to vitamin D responsive 
elements in the promoter regions of vitamin D-responsive genes [10]. As a result of 
renal damage, many patients with chronic kidney disease (CKD) develop a 
progressive 1,25-D3 deficiency [11]. Several clinical studies showed that proteinuria 
in CKD patients, in addition to ACE inhibitors or ARBs, could be further reduced by 
treatment with 1,25-D3 [12-18]. In experimental animal models for focal segmental 
glomerulosclerosis (FSGS) such as adriamycin nephropathy and 5/6 nephrectomy, 
proteinuria and podocyte loss were decreased by treatment with 1,25-D3 [19-21].  
Since heparanase is a key mediator in the development of proteinuria and vitamin D 
seems beneficial in reducing proteinuria and kidney injury, we hypothesize that 
vitamin D regulates glomerular heparanase expression. In the current study, we 
evaluated the effects of vitamin D on the glomerular heparanase and HS expression 
in animal models of FSGS or 1,25-D3 deficiency. In addition, we evaluated whether 
vitamin D was able to directly regulate heparanase expression in cultured mouse 
glomerular endothelial cells and mouse podocytes.  
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Methods 
Animals  
Animals were housed in a temperature-controlled room with a 12-hour light/dark 
cycle with ad libitum access to food and water. All animal experiments were approved 
by the Animal Ethical Committee of the Radboud University Nijmegen. 
Rats. Adriamycin nephropathy (AN) was induced in 8-week-old Wistar rats (Charles 
River Laboratories, Wilmington, MA) by an intravenous injection of 5 mg/kg body 
weight of adriamycin (Sigma-Aldrich, St. Louis, MO), as described previously [21]. 
Rats were treated with daily i.p. injections of 2.5 µg/kg bodyweight of 1,25-D3 (Sigma-
Aldrich Chemie, Zwijndrecht, The Netherlands) or vehicle. After 6 weeks, rats were 
placed in metabolic cages for 24 hours to collect urine, and sacrificed to collect 
kidneys and blood.  
Mice. 1,25-D3-deficient 25-hydroxy-1α-hydroxylase knockout (KO) mice were 
generated and genotyped as described [22]. 5-week-old KO mice and their wildtype 
(WT) littermates received daily i.p. injections of 500 pg/g bodyweight of 1,25-D3 
(Sigma-Aldrich) or vehicle. After 6 weeks, mice were housed in metabolic cages for 
24 hours to collect urine. Subsequently, mice were sacrificed and kidneys and blood 
were collected.   
 
Immunofluorescence staining 
Glomerular heparanase and HS expression was determined by immunofluorescence 
staining as described [23]. Primary antibodies included anti-heparanase (HPA1, 
ProsPecTany, Rehovot, Israel) and the VSV-tagged single chain variable fragment 
(scFv) antibody HS4C3 (N-, 2-O, 3-O and 6-O sulfation) [24]. Bound antibodies were 
detected with goat anti-rabbit IgG Alexa 488 (Invitrogen Life Technologies, Breda, 
The Netherlands) for heparanase and anti-VSV-Cy3 (Sigma-Aldrich) for HS4C3. 
Twenty five glomeruli per section were scored for staining intensities of heparanase 
and HS on a scale between 0 and 10 (0= no staining, 5= 50% staining, 10= 100% 
staining), which was performed by two independent investigators on blinded sections.  
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Heparanase activity assay 
Heparanase activity in kidney cortex was determined using a commercially available 
assay (AMS Biotechnology, Abingdon, UK) according to the manufacturer’s 
instruction. 
 
Cell culture  
Conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) and 
mouse podocytes (MPC-5) were cultured as described previously [25, 26]. Silencing 
of heparanase in MPC-5 was achieved after transfecting a heparanase shRNA 
construct (Qiagen, Venlo, The Netherlands) and subsequent selection with G418 
(Sigma-Aldrich). Where indicated, differentiated mGEnC-1 and MPC5 were 
stimulated with vehicle or 0.25 µg/ml adriamycin (Sigma-Aldrich) and treated with 
different concentrations of 1,25-D3 (10 nmol/L, 100 nmol/L, and 1 µmol/L; Sigma-
Aldrich).  
 
Transendothelial albumin passage 
Differentiated mGEnC-1 seeded on polyester membranes (0.4 µm pore size) in 
tissue culture inserts (Corning Incorporated, NY, USA) were treated with adriamycin 
and/or 100 nmol/L 1,25-D3 as outlined. In addition, mGEnC-1 were treated with a 1:1 
mix of medium supplemented with adriamycin and/or 100 nmol/L 1,25-D3 and 
conditioned culture supernatant of podocytes also treated with adriamycin and/or 100 
nmol/L 1,25-D3. After 16 hours, medium in the insert was replaced by serum free 
medium (SFM) containing 0.5 mg/ml FITC-labeled BSA (Sigma) and medium in the 
well was replaced by SFM. After 1, 2 and 3 hours, aliquots were removed from the 
well and replaced with SFM. Fluorescence of the aliquots was measured on a 
fluorometer with excitation at 495 nm and emission at 520 and the amount of albumin 
passing the endothelial cell monolayer was determined by a set of standard dilutions.    
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RNA isolation and real-time PCR 
Total RNA was extracted from kidney cortex, podocytes and mGEnC-1 using the 
RNeasy mini kit (Qiagen, Venlo, The Netherlands). RNA (1 µg) was reverse 
transcribed into cDNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo 
Scientific, Waltham, MA, USA). The mRNA levels of heparanase were quantified on 
the CFX real-time PCR system (Bio-Rad Laboratories, Hercules, CA, USA) using 
SYBR Green SuperMix (Roche Diagnostics, Mannheim, Germany) with gene-specific 
primers (Isogen Life Science, De Meern, The Netherlands). Heparanase (HPSE): 
forward 5’-GAGCGGAGCAAACTCCGAGTGTATC-3’, reverse 5’-
GATCCAGAATTTGACCGTTCAGTT-3’, and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH): forward 5’-AGAAACCTGCCAAGTATGATGAC-3’, reverse 
5’-TCATTGTCATACCAGGAAATGAG-3’. Gene expression levels of heparanase 
were quantified by the delta-delta CT method using GAPDH as the housekeeping 
gene.  
 
Determination of HS expression on mGEnC-1 by ELISA 
mGEnC-1 were differentiated for 7 days in 96-wells plates and stimulated with vehicle 
or adriamycin in the absence or presence of 1,25-D3 for 16 hours. Cells were washed 
and incubated with the VSV-tagged scFv antibody HS4C3 [24]. Cells were washed 
and incubated with anti-VSV-G-peroxidase (Sigma-Aldrich). Finally, cells were 
washed and incubated with tetramethylbenzidine (TMB) substrate (Biolegend, 
London, UK). Reaction was stopped with 2 M H2SO4 and absorption was measured 
at 450 nm.  
 
Transfection and luciferase activity assay 
A pGL3 luciferase reporter vector containing the 3.5 kb promoter region of the human 
HPR1 (heparanase) gene was generated previously [27]. Opossum Kidney (OK) cells 
were cultured in 12-well plates as described previously [28]. Cells were treated with 
different concentrations of 1,25-D3 (100 nmol/L and 1 µmol/L; Sigma-Aldrich) and 
transfected using the following mixture: either pGL3-HPR1 promoter construct or 
pGL3-basic empty vector with 50 ng of pRL-CMV (Promega Corp., Fitchburg, WI) as 
control for transfection efficiency, and 1,25 µL lipofectamin in 120 µL Opti-MEM 
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medium (Invitrogen, Carlsbad, CA). Twenty-four hours after transfection cells were 
harvested and luciferase activity was determined using the Dual-Luciferase reporter 
assay (Promega) following manufacturer’s instructions.  
 
Chromatin Immunoprecipitation (ChIP) 
OK cells were transfected with the HPR1 promoter construct or the empty vector as 
outlined above and treated with 1 µmol/L 1,25-D3. Four hours after transfection, the 
ChIP assay was performed according to manufacturer’s protocol (Merck Millipore, 
Billerica, MA). Briefly, cells were treated with formaldehyde to crosslink proteins to 
DNA, lysed and sonicated twice on melting ice. Samples were incubated with protein 
A magnetic beads and 5.0 µg of the rabbit polyclonal anti-VDR antibody (ab3508; 
Abcam Inc., Cambridge, MA) or the normal rabbit IgG antibody as a negative control. 
Subsequently, protein-DNA cross-links were reversed and DNA was isolated. Real-
time PCR analysis was performed using specific primers for the HPR1 promoter 
region (forward 5’-TGTTCCTCCTTCCTATGTATCC-3’, reverse 5’-
TTGGCTGAGATCTTGCTCCT-3’). Amplified DNA samples were resolved by 2% 
agarose gel electrophoresis and visualized by ethidium bromide. 
 
Statistical analysis 
Values are expressed as mean ± SEM. Significance was evaluated by an one-way 
ANOVA and post hoc analysis with Tukey’s multiple comparison test. Comparison of 
expression between two different groups was evaluated using the Student’s t-test. A 
2-way repeated measures ANOVA with Bonferroni post-test was used to evaluate 
significance for the transendothelial albumin passage experiments. Statistical 
analysis was performed using GraphPad Prism 5.03 (GraphPad Software, Inc., San 
Diego, CA, USA). A P-value of ≤ 0.05 was considered statistically significant.  
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Results 
Adriamycin-induced heparanase expression is attenuated by 1,25-D3 in 
podocytes 
To study the in vivo effects of 1,25-D3 treatment on heparanase and HS expression, 
AN (an animal model for FSGS) was induced in rats, which were subsequently 
treated with either 1,25-D3 or vehicle for 6 weeks. As shown previously, these AN 
rats develop proteinuria, which could be ameliorated by treatment with 1,25-D3 [21]. 
Induction of AN resulted in an increased cortical heparanase mRNA expression 
(Figure 1A), glomerular heparanase protein expression (Figure 1B,E) and cortical 
heparanase activity (Figure 1C). Heparanase expression and activity were reduced 
by treatment with 1,25-D3, although this was not significant for heparanase protein 
expression (Figure 1A-C,E). Heparanase mRNA expression was also significantly 
reduced by 1,25-D3 treatment in control rats (Figure 1A), suggesting that endogenous 
heparanase expression is regulated by 1,25-D3. In addition, glomerular HS 
expression was reduced in AN rats, but significantly increased by treatment with 
1,25-D3 (Figure 1D,F).  
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Figure 1: 1,25-D3 treatment reduces heparanase expression and increases HS expression in 
rats with AN. 
 By induction of AN in Wistar rats, (A) cortical heparanase mRNA expression, (B,E) 
glomerular heparanase protein expression, and (C) cortical heparanase activity were 
significantly increased, whereas (D,F) glomerular HS expression was significantly reduced. 
Daily treatment with 2.5 µg/kg bodyweight of 1,25-D3 for 6 weeks reduced heparanase 
mRNA expression and activity and increased glomerular HS expression. In addition, 
treatment with 1,25-D3 alone also reduced heparanase mRNA expression. (E) 
Representative images showing glomerular heparanase protein expression and (F) 
glomerular HS expression as determined by immunofluorescence staining (magnification x 
400). 8 rats per group were used for analysis. *P<0.05 and **P<0.01 versus VEH CTRL, 
#P<0.05 versus VEH AN. VEH, vehicle; CTRL, control; AN, adriamycin nephropathy.    
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To extend the in vivo findings of 1,25-D3 on glomerular heparanase expression in AN, 
we evaluated the effects of adriamycin and 1,25-D3 on heparanase expression in 
cultured mouse podocytes and mGEnC-1. Stimulation of mouse podocytes with 
adriamycin resulted in an increased heparanase mRNA expression (Figure 2).  
 
Figure 2: Adriamycin-induced heparanase mRNA expression is attenuated by 1,25-D3 in 
podocytes.  
Cultured mouse podocytes were stimulated with vehicle (VEH) or adriamycin (ADRIA) in the 
absence or presence of different concentrations of 1,25-D3 for 24 hours. By stimulation with 
adriamycin, heparanase mRNA expression was increased. Heparanase mRNA expression 
was dose-dependently reduced by treatment with 1,25-D3 in both injured and uninjured 
podocytes. *P<0.05, **P<0.01 and ***P<0.001 versus VEH CTRL, #P<0.05 versus VEH 
ADRIA. CTRL; control.  
 
Treatment with increasing concentrations of 1,25-D3 dose-dependently reduced 
heparanase expression in both adriamycin-injured and uninjured podocytes (Figure 
2). Stimulation of mGEnC-1 with adriamycin initially increased heparanase mRNA 
expression, but reduced heparanase mRNA expression after 16 hours (Figure 3A-B). 
Importantly, adriamycin decreased HS expression on mGEnC-1 (Supplementary 
Figure 3C). 1,25-D3 treatment did not affect heparanase mRNA expression and HS 
expression on mGEnC-1 (Figure 3B-C). 
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Figure 3: 1,25-D3 treatment did not affect heparanase mRNA expression and HS expression 
on mouse glomerular endothelial cells. 
(A) Cultured mouse glomerular endothelial cells (mGEnC-1) were stimulated with vehicle 
(VEH) or adriamycin (ADRIA) for several time points. Stimulation of mGEnC-1 with 
adriamycin increased heparanase mRNA expression after 4-6 hours, but reduced 
heparanase mRNA expression after 16 hours. (B) mGEnC-1 were stimulated with VEH or 
ADRIA in the absence or presence of different concentrations of 1,25-D3 for 16 hours. By 
stimulation with adriamycin, heparanase mRNA expression was reduced. Heparanase 
mRNA expression was not affected by treatment with 1,25-D3. (C) mGEnC-1 were stimulated 
with VEH or ADRIA in the absence or presence of 1 µM 1,25-D3 for 16 hours. By stimulation 
with adriamycin, HS expression was reduced. HS expression was not affected by treatment 
with 1,25-D3. *P<0.05 and ***P<0.001 versus VEH CTRL. CTRL; control.  
  
Heparanase as vitamin D target 
 
 
 
 
 
139 
1,25-D3 directly regulates heparanase promoter activity 
Our in vivo and in vitro data show that heparanase mRNA expression is reduced by 
treatment with 1,25-D3. To determine whether 1,25-D3 directly regulates heparanase 
transcription, a luciferase reporter assay was performed using the luciferase HPR1-
3.5 promoter construct [27]. OK cells were transfected with the HPR1-3.5 construct or 
the empty vector, i.e. without heparanase promoter, and treated with vehicle, 100 nM 
1,25-D3 or 1 µM 1,25-D3 for 24 hours. Treatment with 1,25-D3 resulted in a decrease 
in heparanase promoter activity, whereas the luciferase activity in cells with empty 
vector was very low and not affected by treatment (Figure 4A).  
To evaluate whether this effect of 1,25-D3 on heparanase promoter activity is 
mediated by direct binding of the VDR to the heparanase promoter, a ChIP assay 
was performed. By real-time PCR analysis we showed an 8-fold enrichment of the 
heparanase promoter when precipitated with the anti-VDR antibody compared to the 
rabbit IgG isotype control (Figure 4B).  
Figure 4: 1,25-D3 directly regulates heparanase promoter activity. 
(A) Heparanase promoter activity determined by a luciferase reporter assay revealed a 40% 
and 55% decrease in heparanase promoter activity when OK cells transiently transfected 
with the luciferase HPR1-3.5 promoter construct were treated with 100 nM or 1 µM 1,25-D3, 
respectively. The luciferase activity of cells with the empty vector, without promoter, was 
unaltered. (B) A ChIP assay was performed to determine whether the VDR binds directly to 
the heparanase promoter. Real-time PCR analysis showed an 8-fold enrichment of the 
heparanase promoter using the anti-VDR antibody (anti-VDR lane) compared with the 
isotype control (IgG lane). As a control, 2% of the chromatin used for the 
immunoprecipitation is shown (input lane). *P<0.05 and **P<0.01 versus VEH (vehicle). 
VDR: Vitamin D receptor. 
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1,25-D3 treatment reduces transendothelial albumin passage in the presence of 
podocyte-conditioned culture medium 
To study the effects of 1,25-D3 treatment on transendothelial albumin passage, 
mGEnC-1 were stimulated with vehicle or adriamycin in the presence or absence of 
100 nM 1,25-D3. Transendothelial albumin passage was increased by stimulation 
with adriamycin, but 1,25-D3 treatment did not have an effect on transendothelial 
albumin passage (Figure 5A). Since 1,25-D3 treatment also did not have an effect on 
heparanase and HS expression in mGEnC-1, but reduced heparanase mRNA 
expression in mouse podocytes, we added culture supernatant of mouse podocytes 
treated with either vehicle or adriamycin, in the presence or absence of 1,25-D3, to 
the mGEnC-1 monolayer. In the presence of podocyte culture supernatant, 
transendothelial albumin passage was increased after adriamycin stimulation, and 
normalized by 1,25-D3 treatment of cultured podocytes (Figure 5B). To show that this 
effect was really mediated by heparanase, heparanase expression in MPC5 
podocytes was completely silenced with shRNA, since no heparanase mRNA 
expression could be measured (HPSE KD). Stimulation of mGEnC-1 with culture 
supernatant of adriamycin-stimulated podocytes containing a scrambled shRNA 
increased transendothelial albumin passage, whereas stimulation of mGEnC-1 with 
culture supernatant of adriamycin-stimulated HPSE KD podocytes did not have an 
effect on transendothelial albumin passage (Figure 5C), indicating that the effect of 
adriamycin on transendothelial albumin passage is completely heparanase-
dependent.  
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Figure 5: 1,25-D3 treatment reduces transendothelial albumin passage in the presence of 
podocyte-conditioned culture medium.  
Cultured mGEnC-1 were stimulated with vehicle (VEH) or adriamycin (ADRIA) in the 
absence or presence of 100 nM 1,25-D3 for 16 hours. Cumulative passage of FITC-labeled 
albumin across the mGEnC-1 monolayer was determined over time. (A) Stimulation of 
mGEnC-1 with adriamycin increased the passage of albumin compared to vehicle treated 
cells. Combined treatment of adriamycin with 1,25-D3 did not reduce transendothelial 
albumin passage. (B) mGEnC-1 were treated with a 1:1 mix of medium supplemented with 
vehicle or adriamycin in the absence or presence of 100 nM 1,25-D3, and culture supernatant 
of podocytes also treated with vehicle or adriamycin in the absence or presence of 100 nM 
1,25-D3. Stimulation of mGEnC-1 with culture supernatant of adriamycin-stimulated 
podocytes increased transendothelial albumin passage. Passage of albumin across the 
mGEnC-1 monolayer was reduced after combined treatment of adriamycin with 1,25-D3 only 
in the presence of podocyte cell culture supernatant. (C) mGEnC-1 were treated with a 1:1 of 
medium supplemented with vehicle or adriamycin and culture supernatant of scrambled or 
HPSE KD podocytes treated with vehicle or adriamycin. Stimulation of mGEnC-1 with culture 
supernatant of adriamycin-stimulated scrambled podocytes increased transendothelial 
albumin passage, whereas stimulation of mGEnC-1 with culture supernatant of adriamycin-
stimulated HPSE KD podocytes did not have an effect on transendothelial albumin passage. 
***P<0.001 versus VEH, ###P<0.001 versus ADRIA. mGEnC-1; mouse glomerular endothelial 
cells, CTRL; control. 
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1,25-D3 deficiency leads to increased glomerular expression of heparanase that 
can be corrected by treatment with 1,25-D3 
To evaluate the effects of 1,25-D3 deficiency on heparanase expression in vivo, 1,25-
D3-deficient 25-hydroxy-1α-hydroxylase knockout (KO) mice were used. These mice 
lack the enzyme 1α-hydroxylase in the kidney, and therefore are not able to produce 
the active form of vitamin D3. 5-week-old KO mice were daily treated with 1,25-D3 for 
6 weeks. Heparanase mRNA expression (Figure 6A), protein expression (Figure 6B-
C) and activity (Figure 6D) were increased in the untreated KO mice, which showed a 
significant proteinuria (Figure 6E). Proteinuria was corrected by daily 1,25-D3 
treatment, which was accompanied by a normalized heparanase expression and 
activity (Figure 6A-E). 
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Figure 6: Vitamin D deficiency leads to increased glomerular expression of heparanase that 
can be corrected by treatment with 1,25-D3. 
(A) Cortical heparanase mRNA expression, (B,C) glomerular heparanase protein expression, 
(D) cortical heparanase activity and (E) proteinuria were significantly increased in 11-week-
old 1,25-D3-deficient 25-hydroxy-1α-hydroxylase knockout (KO) mice. Daily treatment with 
500 pg/g bodyweight of 1,25-D3 for 6 weeks normalized proteinuria and heparanase 
expression and activity. (C) Representative images showing glomerular heparanase protein 
expression as determined by immunofluorescence staining (magnification x 400). 10 WT, 8 
KO and 5 KO+1,25-D3 mice were used for analysis. *P<0.05 and **P<0.01 versus WT, 
#P<0.05 versus KO. WT; wildtype. 
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Discussion 
Our in vivo and in vitro data show that 1,25-D3 regulates heparanase expression in 
cultured podocytes and in animal models for FSGS and 1,25-D3 deficiency. 
Consistent with our previous studies [6, 29], glomerular heparanase expression was 
increased and glomerular HS expression reduced in AN in vivo. These effects were 
attenuated by treatment with 1,25-D3, suggesting that these effects are, at least in 
part, mediated by 1,25-D3. This is supported by the in vitro data, where we showed 
that adriamycin induced heparanase expression in podocytes, which could be 
normalized by treatment with 1,25-D3. 1,25-D3 treatment also reduced 
transendothelial albumin passage, which was dependent on conditioned medium of 
podocytes. Moreover, we demonstrated that the VDR directly binds to the 
heparanase promoter region and that 1,25-D3 treatment inhibits heparanase 
promoter activity. Finally, 1,25-D3-deficient mice developed proteinuria and showed 
increased heparanase expression and activity, which both could be normalized by 
treatment with 1,25-D3. Taken together, we showed that vitamin D reduced 
heparanase expression in in vitro and in vivo podocyte injury, possibly through a 
direct effect on heparanase promoter activity.  
The present study is the first study that shows that heparanase promoter activity and 
expression are regulated by the steroid hormone vitamin D. By binding of vitamin D 
to the VDR, the VDR interacts with the retinoid X receptor to form a heterodimer that 
binds to vitamin D responsive elements in the promoter regions of vitamin D-
responsive genes [10]. In this study we showed that the VDR indeed binds to the 
heparanase promoter. Most genes regulated by vitamin D are positively regulated. 
Heparanase is one of the few genes that are negatively regulated by vitamin D, which 
also include the genes encoding parathyroid hormone, renin, and, as we recently 
reported, the transient receptor potential cation channel C6 (TRPC6) [21, 30-32].    
The importance of heparanase in the development of proteinuria was recently 
demonstrated in heparanase-deficient mice, which failed to develop proteinuria and 
had a normal renal function after induction of type 1 diabetes [2, 9]. Moreover, 
proteinuria and renal function loss were limited when diabetic WT mice were treated 
with the heparanase inhibitor SST0001. In addition to its essential role in the 
development of proteinuria in diabetic nephropathy, heparanase has also been 
Heparanase as vitamin D target 
 
 
 
 
 
145 
suggested to play a role in the development of proteinuria in other glomerular 
diseases. Treatment with the heparanase inhibitor PI-88 reduced proteinuria in rats 
with Passive Heymann Nephritis [7] and treatment with an anti-heparanase antibody 
reduced proteinuria in anti-glomerular basement membrane disease in rats [8]. 
Moreover, the expression of heparanase is increased in many experimental and 
human glomerular diseases [2-6], suggesting that heparanase may play an important 
role in the development of proteinuria in many glomerular diseases.  
A recent paper suggests that heparanase may play a nephroprotective role in the 
development of AN [33]. Transgenic heparanase overexpressing mice developed 
only mild albuminuria and failed to develop renal damage after induction of AN. We 
previously showed that transgenic overexpression of heparanase did not result in 
proteinuria, which we explained by the lack of induced pathology [34]. Results in the 
paper by Assady et al. seem in contrast to previous studies that showed a 
pathological role of heparanase in models for diabetic nephropathy, minimal change 
disease, accelerated anti-GBM disease and membranous glomerulopathy [2, 3, 7-9]. 
Unfortunately, the study by Assady et al. does not provide a mechanism for the 
observed nephroprotective effect of transgenic heparanase overexpression. 
However, it may be possible that transgenic heparanase overexpression since birth 
makes the mice more resistant to develop AN. It is known that enzymatically inactive 
heparanase promotes vascular endothelial growth factor (VEGF) expression, which 
promotes endothelial health and survival [35, 36]. A recent study showed that 
endothelial dysfunction precedes podocyte injury in AN [37]. Therefore, heparanase 
overexpression since birth may increase endothelial health, thereby making these 
mice more resistant to develop AN. Nevertheless, additional research is needed to 
evaluate the protective role of heparanase on endothelial cells in AN.  
In the present study, we showed that 1,25-D3 treatment significantly reduced 
proteinuria and heparanase expression and activity in AN in vivo. In addition, we 
used 1,25-D3-deficient 25-hydroxy-1α-hydroxylase KO mice to further evaluate the 
importance of 1,25-D3. These 1,25-D3-deficient mice developed proteinuria and 
showed increased heparanase expression and activity, which both could be 
normalized by treatment with 1,25-D3. Although current data demonstrate that 
heparanase expression and proteinuria are regulated by 1,25-D3 treatment, and 
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previous studies indicate that heparanase is associated with the development of 
proteinuria, it does not rule out that simultaneous regulation of other genes by vitamin 
D also plays a role in the development of proteinuria. We recently reported that the 
expression of TRPC6, a slit diaphragm protein expressed by podocytes, is regulated 
by vitamin D [21]. The expression of TRCP6 is increased in several acquired 
proteinuric diseases, suggesting that TRPC6 also plays a role in the pathogenesis of 
podocyte injury in proteinuric diseases [38]. In addition to TRPC6, renin is negatively 
regulated by vitamin D. Renin plays an important role in the biosynthesis of 
angiotensin II, and the latter can even be produced locally by the podocyte itself. 
Finally, 1,25-D3 also negatively regulates the expression of the proinflammatory 
cytokine tumor necrosis factor-α (TNF-α) [39, 40]. We and others previously showed 
that both angiotensin II and TNF-α can induce heparanase expression [29, 41, 42], 
suggesting that the reduction of renin or TNF-α expression may also be involved in 
the reduced heparanase expression after 1,25-D3 treatment.  
AN in rats has mainly been regarded as a podocyte-injury model for FSGS. However, 
glomerular endothelial cells also play a role in the pathogenesis of AN, as adriamycin 
reduces the thickness of the endothelial glycocalyx by 80% in mice [43]. We 
observed similar effects in vitro, where HS expression on mouse glomerular 
endothelial cells was decreased after stimulation with adriamycin. Our data, however, 
suggest that 1,25-D3 treatment only has a direct protective effect on the podocyte. No 
direct effect of 1,25-D3 treatment was observed on mouse glomerular endothelial 
cells. This could be expected, since the VDR is expressed only at very low 
concentrations by the glomerular endothelium, whereas it is expressed at much 
higher levels by podocytes [44]. In line with this, 1,25-D3 treatment did not have an 
effect on transendothelial albumin passage for adriamycin injured glomerular 
endothelial cells. Interestingly, when conditioned culture supernatant of mouse 
podocytes treated with vehicle or adriamycin, in the presence or absence of 1,25-D3, 
was added to the mouse glomerular endothelial cells, we observed a reduction in 
transendothelial albumin passage by 1,25-D3 treatment after adriamycin stimulation. 
This further demonstrates that 1,25-D3 treatment mainly affects podocytes and 
suggests that crosstalk between cells in the glomerulus is involved in the 
pathogenesis of proteinuria.  
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We previously showed that heparanase is mainly expressed in the podocyte in AN in 
vivo, as heparanase was expressed on the outside of the GBM and colocalized with 
synaptopodin [6]. Only minimal heparanase staining was observed inside the 
capillary loops. This is in line with our current in vitro data, where we observed a 
marked increase in heparanase expression by adriamycin in mouse podocytes, 
whereas a slight increase followed by a reduced heparanase expression was 
observed in mouse glomerular endothelial cells. Loss of heparanase expression in 
the podocyte prevents the increased passage of albumin across the endothelial 
monolayer induced by adriamycin, suggesting that heparanase is the permeability 
factor in the conditioned medium of podocytes that is regulated by1,25-D3. Future 
research should reveal how podocyte-derived heparanase crosses the GBM in vivo. 
VEGF and endothelin are other examples of podocyte-derived proteins that need to 
cross the GBM to reach the endothelium. 
In conclusion, in this report we provide further mechanistic evidence for the potential 
benefits of vitamin D treatment in patients with glomerular disease. We add 
heparanase as a target regulated in experimental glomerular disease. Our current in 
vivo and in vitro results show that the protective effect of vitamin D on the 
development of proteinuria in AN could be mediated by reduction of the increased 
heparanase expression in the podocyte.  
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Abstract 
Transient receptor potential channel C6 gain-of-function mutations and increased 
TRPC6 expression in podocytes induces glomerular injury and proteinuria. 
Previously, it has been shown that Sildenafil (Viagra®) reduces TRPC6 expression 
and activity in non-renal cell types, although the mechanism is not elucidated. 
Peroxisome proliferator-activated receptor gamma (PPARy) was described as a 
downstream target of sildenafil via the cyclic guanosine monophosphate (cGMP)-
activated protein kinase G (PKG) axis. PPARγ agonists like pioglitazone appear to be 
antiproteinuric. We hypothesized that sildenafil inhibits TRPC6 expression in 
podocytes, with PPARγ as central mediator, thereby counteracting podocyte injury 
and proteinuria. 
Podocyte injury-induced TRPC6 expression was dose-dependently downregulated by 
sildenafil, the cGMP derivative 8-bromoguanosine 3′,5′-cyclic monophosphate 
sodium salt (8-Br-cGMP) and pioglitazone. PKG or PPARγ antagonists enhanced 
TRPC6 expression in podocytes, and counteracted the effects of sildenafil and 8-Br-
cGMP. Similar results were demonstrated for TRPC6 promoter activity and TRPC6-
dependent calcium influx. Chromatin immunoprecipitation showed PPARγ binding to 
the TRPC6 promoter. Rats treated with a PPARy antagonist developed proteinuria 
and increased podocyte TRPC6 expression, as did podocyte-specific PPARγ knock-
out mice. Proteinuria and increased TRPC6 expression in adriamycin-induced 
nephropathy could be prevented by sildenafil and pioglitazone treatment. Sildenafil is 
approved for clinical use, and therefore would be ideal to initiate clinical trials for its 
anti-proteinuric effect.  
Thus, amelioration of podocyte injury by sildenafil involves the cGMP- and PKG-
dependent binding of PPARγ to the TRPC6 promoter, thereby inhibiting TRPC6 
promoter activity, expression and activity. We identified sildenafil as a bona fide novel 
antiproteinuric agent, which inhibits deleterious TRPC6-mediated intracellular 
podocyte signaling.  
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Introduction 
Sildenafil, also known as Viagra®, was originally developed to treat angina pectoris 
and hypertension. However, the first clinical trials were disappointing, and currently 
sildenafil is primarily used to treat erectile dysfunction as well as pulmonary arterial 
hypertension. In this study, we explore the mechanism of a potential antiproteinuric 
effect of sildenafil in glomerular disease. 
Sildenafil increases intracellular cyclic guanosine monophosphate (cGMP) levels by 
inhibiting the enzyme phosphodiesterase 5A (PDE-5A), which converts cGMP to 
GMP [1]. cGMP is a second messenger which gives rise to numerous (intra)cellular 
effects, leading to stimulation of glycogenolysis, apoptosis, smooth muscle relaxation 
and vasodilatation. The raised cGMP levels also activate protein kinase G (PKG), 
which can stimulate the nuclear receptor and transcription factor peroxisome 
proliferator-activated receptor gamma (PPARy). Upon stimulation, PPARy 
heterodimerizes with retinoid X receptors (RXR) and regulates gene transcription of 
various target genes [2]. Several PPARy agonists, i.e. the thiazolidinediones (TZDs) 
class of antidiabetic drugs, such as pioglitazone and rosiglitazone have been 
suggested to be renoprotective [3, 4].  
One of the possible transcriptional targets of PPARy is the Transient Receptor 
Potential Channel C6 (TRPC6), a non-specific calcium (Ca2+) conducting ion channel 
that is expressed in pulmonary vascular and penile corporal smooth muscle cells, but 
also in renal glomerular podocytes [5, 6]. Gain-of-function mutations in TRPC6 lead 
to focal segmental glomerular sclerosis (FSGS), which is characterized by podocyte 
foot process effacement, proteinuria, and eventually end-stage-renal-disease (ESRD) 
[7, 8]. Importantly, we and others have shown that in acquired human and 
experimental glomerular diseases, TRPC6 expression in the podocyte is increased 
[9-11]. Podocytes are glomerular epithelial cells covering the outside of the 
glomerular capillaries with their intertwined foot processes, thereby creating a sieve 
or slit diaphragm in the glomerular filtration barrier. Ca2+ influx through TRPC6 
activates several pathways in the podocyte, including the deleterious feed-forward 
calcineurin/NFAT pathway, which decreases expression of slit diaphragm-associated 
proteins such as nephrin, induces podocyte injury and eventually proteinuria [12-14]. 
Hall et al. previously showed that PKG affects TRPC6 phosphorylation at Thr69 in 
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podocytes, which reduces TRPC6 functional channel activity [15]. In addition, pre-
treatment of podocytes with a PKG agonists or a PDE5 inhibitor decreased TRPC6 
Thr69 phosphorylation and inhibited TRPC6-dependent podocyte motility. Importantly, 
it has been described that sildenafil, by activating PKG and PPARy, affects TRPC6 
expression in the pulmonary vasculature, which is relevant to its therapeutic effect in 
pulmonary hypertension, whereas a dominant-negative TRPC6 mutant was recently 
shown to restore erectile dysfunction in diabetic rats, [5, 6]. We hypothesize that 
sildenafil activates PPARy and reduces TRPC6 expression in the podocyte, which 
may decrease proteinuria, thereby contributing to the suggested renoprotective 
action of sildenafil (Figure 1). 
 
Figure 1: Hypothesis that links TRPC6 to sildenafil.  
Sildenafil inhibits phosphodiesterase 5A (PDE5A), thereby indirectly increasing cellular cyclic 
guanosine monophosphate (cGMP) levels. Cyclic GMP signaling activates protein kinase G-
1 (PKG-1) and subsequently peroxisome proliferating-activated receptor gamma (PPARγ), 
which inhibits Transient Receptor Potential Channel C6 (TRPC6) transcription and 
expression. This leads to reduced TRPC6 channel expression at the membrane of the 
podocyte, thereby reducing TRPC6-mediated calcium influx and eventually podocyte injury in 
the context of glomerular disease. We propose that this pathway can be modulated by 
blocking PKG-1 with KT5823, activating PPARγ with pioglitazone or inhibiting PPARy with 
GW9662.  
 
Sildenafil prevents podocyte injury via PPARγ-mediated TRPC6 inhibition 
 
 
 
 
 
155 
In the current study we determined whether sildenafil inhibits TRPC6 promoter 
activity and expression, whether this affects TRPC6 channel activity, and whether 
this is a PPARy-dependent effect. In addition, we investigated whether these effects 
also have an in vivo significance. Elucidating these signaling processes will reveal 
more mechanistic insights into sildenafil or PPARy agonists as therapeutic agents 
that could ameliorate renal injury and proteinuria in patients.  
 
Results 
Sildenafil dose-dependently downregulates TRPC6 expression in injured 
podocytes by affecting TRPC6 promoter activity 
We addressed our proposed hypothesis (Figure 1), by exposing adriamycin-injured 
MPC-5 immortalized mouse podocyte cultures to different concentrations of sildenafil 
or the cell-permeable cGMP derivative 8-bromoguanosine 3′,5′-cyclic 
monophosphate sodium salt (8-Br-cGMP), with or without the protein kinase G-1 
(PKG-1) inhibitor KT5823. TRPC6 expression in adriamycin-treated podocytes was 
increased compared to untreated control cells, which could be dose-dependently 
downregulated by sildenafil treatment (Figure 2a). The cell-permeable cGMP 
derivative 8-Br-cGMP also downregulated TRPC6 expression in injured podocytes 
(Figure 2b). The PKG-1 antagonist KT5823 prevented downregulation of TRPC6 
expression by sildenafil and 8-Br-cGMP in injured podocytes (Figure 2c). We 
performed a luciferase-based TRPC6 promoter activity assay to determine whether 
the above described effects were mediated by inhibition of TRPC6 transcription. 
Importantly, both sildenafil (Figure 2d) and 8-Br-cGMP (Figure 2e) inhibited TRPC6 
promoter activity. Moreover, the PKG antagonist KT5823 prevented the effects of 
both sildenafil and 8-Br-cGMP on TRPC6 promoter activity (Figure 2f). 
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Figure 2: Sildenafil and 8-Br-cGMP concentration-dependently downregulate TRPC6 
expression in injured podocytes by affecting TRPC6 promoter activity. 
Cultured podocytes were injured by adriamycin (ADRIA) application and treated with different 
concentrations of sildenafil (A) or 8-Br-cGMP (B), with or without PKG-1 antagonist KT5823 
(C). OK cells expressing a TRPC6 promoter luciferase construct were treated with the same 
concentrations of sildenafil (D) or 8-Br-cGMP (E) with or without KT5823 (F). Firefly/Renilla 
ratio was calculated and normalized for vehicle treated cells. * p < 0.05 vs vehicle-treated 
cells, # p < 0.05 vs adriamycin-treated cells. N = 4-8, in at least 2 independent experiments. 
Statistical significance was determined using ANOVA followed by Bonferroni post hoc test.  
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Downregulation of TRPC6 expression by sildenafil leads to reduced TRPC6-
mediated Ca2+ influx into the podocyte 
Subsequently, we determined whether the reduced transcription and expression of 
TRPC6 also resulted in a reduced TRPC6-mediated Ca2+ influx using Fura-2 
intracellular Ca2+ measurements. We pretreated podocytes stably transfected with a 
scrambled and TRPC6 knockdown (KD) construct with sildenafil and 8-Br-cGMP, 
either with or without co-treatment with the PKG-1 antagonist KT5823, and thereafter 
determined TRPC6-mediated 1-oleoyl-2-acetyl-sn-glycerolin (OAG)-activated Ca2+ 
influx in the absence of aforementioned compounds. Compared to non-pretreated 
control podocytes, significantly less Ca2+ influx was measured in podocytes 
pretreated with sildenafil or 8-Br-cGMP, an effect that could be prevented by 
inhibiting PKG-1 by pretreatment with KT5823 (Figure 3a). Importantly, in TRPC6 KD 
cells Ca2+ influx was almost absent, and was not influenced by any pretreatment 
regimen (Figure 3b). 
 
PPARy agonists and antagonists influence TRPC6 promoter activity, TRPC6 
expression and channel activity 
To evaluate whether PPARγ activation, as we hypothesize (Figure 1), is able to 
downregulate TRPC6 expression, we treated cultured mouse podocytes with 
pioglitazone to activate PPARy. Indeed, this treatment inhibited adriamycin-induced 
TRPC6 overexpression (Figure 4a). Moreover, when uninjured podocytes were 
treated with the PPARy inhibitor GW9662, TRPC6 expression increased (Figure 4b). 
Accordingly, a concentration-dependent inhibition of pioglitazone on TRPC6 
promoter activity was evident (Figure 4c), while PPARy antagonism with GW9662 
increased TRPC6 promoter activity (Figure 4d). Importantly, using a chromatin 
immunoprecipitation (ChIP) assay, we demonstrated that PPARy directly binds to 
theTRPC6 promoter using a TRPC6 promoter construct transfected into Opossum 
Kidney (OK) cells (Figure 4e), as well as to the endogenous TRPC6 promoter in 
cultured podocytes (Figure 4f). The decreased TRPC6 expression due to PPARy 
activation resulted in reduced TRPC6-mediated Ca2+ influx into podocytes, while the 
opposite occurred upon pretreatment with GW9662 (Figure 4g). Again, Ca2+ influx 
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was almost absent and not influenced by pioglitazone or GW9662 pretreatment in 
TRPC6 KD podocytes (data not shown). 
 
 
 
 
 
 
 
 
Figure 3: Downregulation of TRPC6 expression by sildenafil leads to reduced TRPC6-
mediated Ca2+ influx into the podocyte. 
Intracellular Ca2+ concentration was determined by Fura-2 ratiometry. Cultured podocytes 
transfected with a scrambled siRNA construct were pretreated with sildenafil or 8-Br-cGMP, 
with or without the PKG-1 antagonist KT5823 for 24 hours. After removal of the specific 
media, cells were exposed to 100 µM 1-oleoyl-2-acetyl-sn-glycerolin (OAG) to activate the 
TRPC6 ion channel (A). The same experimental setup was tested in TRPC6 knockdown 
(KD) podocytes (B). * p < 0.05 vs vehicle-treated cells. N = 5, in 2 independent experiments. 
Statistical significance was determined using a repeated measurement test.  
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Figure 4: PPARy agonism and antagonism affect TRPC6 promoter activity, TRPC6 
expression and Ca2+ influx into the podocyte. 
Cultured podocytes were injured by adriamycin application, treated with different 
concentrations of the PPARy agonist pioglitazone, and TRPC6 expression was determined 
(A). In addition, TRPC6 expression was determined in uninjured podocytes treated with 
various concentrations of the PPARy antagonist GW9662 (B). A luciferase assay was 
performed to determine TRPC6 promoter activity in OK cells treated with pioglitazone (C) 
and GW9662 (D). TRPC6/GAPDH and Firefly/Renilla ratio was calculated and normalized for 
vehicle-treated cells. A chromatin immunoprecipition (ChIP) assay was performed to 
determine whether PPARy directly binds to either the TRPC6 promoter in using a promoter 
construct transfected into OK cells (E) or the endogenous TRPC6 promoter in cultured 
mouse podocytes (F). Cultured podocytes stably transfected with scrambled siRNA were 
pretreated with sildenafil or 8-Br-cGMP, with or without KT5823 for 24 hours. After removal of 
the specific media, cells were exposed to 100 µM OAG to activate the TRPC6 ion channel 
(G). Intracellular Ca2+ concentration was determined by Fura-2 ratiometry. * p < 0.05 vs 
vehicle-treated cells, # p < 0.05 vs adriamycin-treated cells. N = 4-8, in at least 2 independent 
experiments. Statistical significance was determined using ANOVA followed by Bonferroni 
post hoc test (A-D) or repeated measurement test (G).  
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PPARy antagonist abrogates the effect of sildenafil on TRPC6 promoter 
activity, TRPC6 expression and channel activity  
To determine the suggested role of PPARy in the sildenafil and cGMP-induced 
inhibition of TRPC6 promoter activity, expression and functionality as demonstrated 
above, adriamycin-injured podocytes were treated with sildenafil or 8-Br-cGMP in 
combination with the PPARy inhibitor GW9662. GW9662 abolished the inhibitory 
effect of sildenafil and 8-Br-cGMP on TRPC6 expression (Figure 5a). In line with the 
above, the effects of sildenafil and 8-Br-cGMP on TRPC6 promoter activity were also 
abolished when co-treated with GW9662 (Figure 5b). These TRPC6 transcriptional 
and expressional changes also had functional effects, as GW9662 pretreatment 
completely blocked the effects of sildenafil and 8-Br-cGMP on Ca2+ influx (Figure 
5c). Again, OAG-stimulated Ca2+ influx was virtually absent and unaffected by any 
pretreatment in control TRPC6 KD podocytes (data not shown). 
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Figure 5: PPARy antagonism abrogates the effect of sildenafil on TRPC6 promoter activity, 
TRPC6 expression and channel activity.  
Cultured podocytes were injured by adriamycin application and treated with sildenafil or 8-Br-
cGMP, with or without PPARy antagonist GW9662 and TRPC6 expression expression was 
determined (A). TRPC6 promoter activity was measured using a luciferase promoter assay in 
OK cells, treated with sildenafil or 8-Br-cGMP, with or without GW9662 (B). Firefly/Renilla 
ratio was calculated and normalized for vehicle treated cells. Cultured podocytes stably 
transfected with scrambled siRNA were pretreated with sildenafil or 8-Br-cGMP, with or 
without GW9662 for 24 hours. After removal of the specific media, cells were exposed to 100 
µM OAG to activate the TRPC6 ion channel (C). Intracellular Ca2+ concentration was 
determined by Fura-2 ratiometry.* p < 0.05 vs vehicle-treated cells, # p < 0.05 vs adriamycin-
treated cells. N = 4-7, in at least 2 independent experiments. Statistical significance was 
determined using ANOVA followed by Bonferroni post hoc test (A-B) or repeated 
measurement test (C).   
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Podocyte-specific PPARy KO mice show increased glomerular TRPC6 
expression 
To determine the in vivo role of PPARy expressed by the podocyte in the regulation 
of TRPC6 expression, we determined TRPC6 expression in a podocyte-specific 
PPARy KO mouse model. Podocyte-specific PPARy KO mice were previously shown 
to be more susceptible than their wildtype littermates to develop albuminuria when 
challenged with e.g. adriamycin [16]. Importantly, glomerular TRPC6 expression was 
significantly increased in podocyte-specific PPARy KO mice (Figure 6a) compared to 
wild-type littermates, which was accompanied by increased expression of the 
podocyte injury marker desmin (Figure 6b), and decreased expression of the central 
slit diaphragm protein nephrin (Figure 6c). 
 
 
Figure 6: Podocyte-specific PPARy deficient mice showed increased glomerular TRPC6 
expression.  
Glomerular TRPC6 (A), desmin (B) and nephrin (C) expression was determined in podocyte-
specific PPARγ deficient (KO) mice as well as their wild-type littermates. Protein expression 
is depicted relative to the mean expression in wild-type mice. * p < 0.05 vs wildtype 
littermates. N = 4 animals per group. Statistical significance was determined using an 
unpaired student t-test.  
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Pharmacological inhibition of PPARy in rats leads to glomerular and podocyte 
injury 
To study whether pharmacological inhibition of PPARy also increases TRPC6 
expression in vivo, we treated Wistar rats with vehicle or the PPARy antagonist 
GW9662 (10 mg/kg bodyweight) for six weeks. Indeed, GW9662 treatment increased 
glomerular TRPC6 expression (Figure 7a), as well as desmin expression (Figure 
7b), while nephrin expression was downregulated compared to untreated control rats 
(Figure 7c). Rats treated with GW9662 demonstrated a significantly increased 
urinary albumin/creatinine ratio (Figure 7d) and IgG (Figure 7e) excretion. 
 
Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in 
adriamycin-induced nephropathy  
To evaluate whether the PPARy agonist pioglitazone has renoprotective properties 
associated with regulation of TRPC6 expression in vivo, we induced adriamycin 
nephropathy in rats after which treatment with pioglitazone (12mg/kg bodyweight) 
was immediately started and continued for six weeks. Pioglitazone prevented 
upregulation of TRPC6 (Figure 8a) and desmin (Figure 8b) expression in adriamycin 
nephropathy. Accordingly, nephrin expression was reduced in adriamycin-treated 
rats, and normalized when these rats were treated with pioglitazone (Figure 8c). 
Adriamycin-exposed rats had an increased urinary albumin (Figure 8d) and IgG 
excretion (Figure 8e), which was remarkably ameliorated by pioglitazone treatment.  
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Figure 7: Pharmacological inhibition of PPARy in rats increases glomerular TRPC6 
expression and leads to podocyte injury and proteinuria.  
Wistar rats were treated with the PPARy antagonist GW9662 (10 mg/kg bodyweight) for 6 
weeks, after which animals were sacrificed and glomerular TRPC6 (A), desmin (B) and 
nephrin (C) expression was determined. Protein expression is depicted as percentage 
relative to the mean expression in vehicle-treated rats. In addition, urinary albumin/creatinine 
ratio (µg/mM) (D) and IgG/creatinine ratio (µg/mM) (E) was assessed. * p < 0.05 vs control 
rats. N = 8 animals per group. Statistical significance was determined using an unpaired 
student t-test.  
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Figure 8: Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the 
adriamycin-induced nephropathy rat model for FSGS.  
Adriamycin-induced nephropathy was induced in rats, after which control and adriamycin 
nephropathy rats were treated with the PPARy agonist pioglitazone (12 mg/kg bodyweight) 
for 6 weeks. Thereafter, animals were sacrificed and glomerular TRPC6 (A), desmin (B) and 
nephrin (C) expression was determined. Protein expression is depicted as percentage of 
vehicle-treated rats. In addition, urinary albumin/creatinine ratio (µg/mM) (D) and 
IgG/creatinine ratio (µg/mM) (E) were assessed. * p < 0.05 vs vehicle-treated control rats, # p 
< 0.05 vs adriamycin-treated control rats. N = 8 animals per group. Statistical significance 
was determined using ANOVA followed by Bonferroni post hoc test.  
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Sildenafil prevents TRPC6 overexpression and podocyte injury in the 
adriamycin-induced nephropathy rat model for FSGS  
To determine whether sildenafil treatment also inhibits injury-induced TRPC6 
expression in vivo and has an antiproteinuric effect, we induced adriamycin 
nephropathy in rats and started with 5 mg/kg bodyweight oral sildenafil treatment for 
six weeks. Adriamycin increased glomerular TRPC6 expression (Figure 9a), which 
was accompanied by increased expression of the podocyte injury marker desmin 
(Figure 9b), and a downregulation of nephrin expression (Figure 9c). These 
expressional changes were all normalized by sildenafil treatment. Importantly, 
adriamycin treatment resulted in a significant urinary albumin (Figure 9d) and IgG 
excretion (Figure 9e), which was significantly reduced by sildenafil exposure. 
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 Figure 9: Sildenafil treatment prevents TRPC6 overexpression and podocyte injury in the 
adriamycin-induced nephropathy rat model for FSGS. 
Adriamycin-induced nephropathy was induced in rats, after which control and adriamycin 
nephropathy rats were treated with sildenafil (5mg/kg bodyweight) for 6 weeks. Thereafter, 
animals were sacrificed and glomerular TRPC6 (A), desmin (B) and nephrin (C) expression 
was determined. Protein expression is depicted as percentage of vehicle-treated rats. In 
addition, urinary albumin/creatinine ratio (µg/mM) (D) and IgG/creatinine ratio (µg/mM) (E) 
were assessed. * p < 0.05 vs vehicle-injected control rats, # p < 0.05 vs adriamycin-treated 
control rats. N = 8 animals per group. Statistical significance was determined using ANOVA 
followed by Bonferroni post hoc test.  
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Discussion 
This study demonstrates that sildenafil reduces TRPC6 promoter activity, TRPC6 
channel expression and, thereby, prevents deleterious TRPC6-mediated Ca2+ influx 
in cultured podocytes. In addition, we showed that PPARy (ant)agonism affects 
podocyte TRPC6 expression, probably by modulating the binding of PPARy to the 
TRPC6 promoter. Both PKG-1 inhibition and PPARy antagonism inhibited the effects 
of sildenafil and cGMP on TRPC6 expression and activity in the podocyte. Therefore, 
we propose a mechanism of action in which a sildenafil-induced rise in cGMP levels 
activates PKG-1 and subsequently PPARy, which then directly binds to the TRPC6 
promoter and downregulates its expression (as depicted in Figure 1). Activation of 
the suggested pathway, thereby inhibiting TRPC6 dependent Ca2+ influx, could 
contribute to podocyte viability, and thereby protect the glomerulus from injury. 
Indeed, both podocyte-specific PPARy KO mice as well as rats treated with a PPARy 
antagonist showed increased glomerular TRPC6 expression, signs of podocyte injury 
and increased proteinuria. Importantly, both sildenafil and pioglitazone treatment 
prevented the increased TRPC6 expression in adriamycin nephropathy, a model for 
human FSGS, which was accompanied by a reduction in podocyte injury and 
amelioration of proteinuria.  
Renoprotective effects of sildenafil were suggested before, albeit mainly in an 
ischemia/reperfusion model [17-19]. The effects of sildenafil in ischemia/reperfusion 
were postulated to involve vascular effects, as dilatation of afferent arterioles for 
instance promotes a transient increase in glomerular filtration in renal transplant 
recipients receiving a single dose of sildenafil. However, we could not detect TRPC6 
in the renal vasculature, and our study provides pre-clinical proof, as well as a novel 
mechanism, for a specific antiproteinuric effect of sildenafil mediated by PPARy 
activation in the podocyte. Our data particularly show that sildenafil affects TRPC6 
transcription and expression, and thereby alters TRPC6-mediated Ca2+ influx into the 
podocyte. A previous study by Hall et al. suggested that PDE5 inhibition induces 
phosphorylation of TRPC6 at Thr69, and thereby inhibits channel function directly 
[15]. This could in turn also affect TRPC6 expression. We have previously shown that 
TRPC6-dependent Ca2+ influx into the podocyte activates the calcineurin/NFAT 
pathway, which eventually increases TRPC6 expression [12]. Therefore, direct 
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inhibition of TRPC6 channel signaling could lead to TRPC6 downregulation via the 
latter mechanism. However, in the current study we have shown that sildenafil-
dependent activation of PPARy by PKG-1 plays a significant direct transcriptional role 
in the downregulation of TRPC6 expression. We could demonstrate effects of PKG-1 
and PPARy on TRPC6-mediated Ca2+ influx in the absence of sildenafil or 8-Br-
cGMP. Moreover, sildenafil or 8-br-cGMP did not significantly affect Ca2+ influx when 
combined with a PPARy antagonist, which affects TRPC6 at the level of transcription. 
Therefore, we conclude that in vitro, the cGMP-PKG-PPARy pathway seems to be 
more important in downregulating TRPC6 expression, compared to a possible 
indirect effect through reduced TRPC6 channel function resulting from Thr69 
phosphorylation. A direct inhibition of TRPC6 channel function by sildenafil could, 
however, still contribute to its in vivo antiproteinuric effect, by limiting the deleterious 
Ca2+ influx through TRPC6. In this manner, sildenafil could successfully interrupt 
deleterious TRPC6-mediated signaling in the podocyte at multiple levels.  
Sildenafil is currently used to treat pulmonary hypertension, where its main 
mechanism of action has been described to reduce intracellular Ca2+ levels in 
pulmonary arterial smooth muscle cells, leading to vasorelaxation in the pulmonary 
vasculature [20]. Recently, it was shown that also in these cells, sildenafil inhibits 
TRPC6 expression, which could be prevented by application of a PKG-1 or PPARy 
inhibitor [21]. In this way, sildenafil prevented hypoxia-induced TRPC6 and TRPC1 
expression, which led to vasoconstriction, in pulmonary arterial smooth muscle via 
the same cGMP-PKG-PPARγ axis. We are the first to demonstrate that his 
mechanism not only plays a role in the beneficial effect of sildenafil in pulmonary 
hypertension, but also in proteinuric diseases. 
Our in vivo data showed that treatment with the PPARy agonist pioglitazone 
normalized TRPC6, desmin and nephrin expression, and ameliorated proteinuria in 
adriamycin nephropathy. The antiproteinuric effect of pioglitazone has been 
previously shown in adriamycin nephropathy as well as human proteinuric disease, 
and several hypotheses on the podocyte-protective effect of PPARy were postulated 
[22, 23]. Among these were anti-apoptotic effects, blockade of angiotensin 
production, as well as improved mitochondrial function reducing the level of reactive 
oxygen species (ROS) [24-27]. Importantly, we and others described the role of 
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angiotensin and local angiotensin production by the podocyte in the regulation of 
TRPC6 expression during podocyte injury [12, 28]. Of note, TRPC6-mediated Ca2+ 
influx has previously been linked to podocyte apoptosis and ROS production [27, 29]. 
Thus, identification of TRPC6 as a direct PPARy target in the podocyte could also 
provide a mechanistic link between PPARy agonists and their previously described 
effects on oxidative stress and cell fate.  
It was previously determined that the podocyte-specific PPARγ KO mice are 
particularly susceptible to podocyte injury by e.g. adriamycin or nephrotoxic serum 
[16]. This predisposition is reminiscent of the apparent podocyte susceptibility which 
leads to late-onset FSGS in patients with TRPC6 gain-of-function mutations [7, 8]. 
The potential of PPARy agonists as treatment modalities for several renal diseases, 
such as diabetic nephropathy, was already previously demonstrated [30]. Beneficial 
effects of PPARγ were suggested in tubular epithelial cells as well as glomerular 
mesangial cells, endothelial cells, and podocytes in the context of diabetic 
nephropathy [31-33].  
In conclusion, we have shown that in vitro as well as in vivo, treatment with a PDE5 
inhibitor or PPARy agonist reduces podocyte injury and ameliorates the associated 
proteinuria. Amelioration of podocyte injury by sildenafil appears to involve 
stimulation of cGMP- and PKG-dependent binding of PPARy to the TRPC6 promoter, 
thereby inhibiting TRPC6 promoter activity, TRPC6 expression and, ultimately, 
channel activity. In vivo, blocking this cGMP-PKG-PPARy pathway induces 
proteinuria, whereas its stimulation by sildenafil and pioglitazone treatment reduces 
glomerular injury and proteinuria. These data identify sildenafil as a novel 
antiproteinuric agent, which acts by inhibiting deleterious TRPC6-mediated 
intracellular podocyte signaling. 
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Concise methods 
Animal studies 
Mice, 12-14 weeks of age, with a podocyte-specific deletion of PPARy were created 
using the NPHS2-Cre recombinase (podocin-Cre) mouse [16]. Podocyte-specific 
disruption of PPARy alleles was achieved by crossing podocin-Cre positive mice with 
the B6.129S6-Ppargtm1.1Mgn/Mmmh strain obtained from the Mutant Mouse 
Regional Resource Center at the University of Missouri (stock number 012035-MU) 
on a C57BL6/J background. Wild-type littermates were used as age-matched 
controls.  
Adriamycin nephropathy was induced in Wistar rats (Charles River Laboratories, 
Wilmington, MA) and treated with sildenafil or pioglitazone or GW9662. After six 
weeks of treatment rats were housed in metabolic cages for 24 hours, hereafter 
urine, blood and kidneys were collected. Urinary albumin, IgG and creatinine 
concentrations were determined. 
All animal procedures were approved by the Animal Ethics Committee of the 
Radboud University and the INSERM local Ethic Review Board at Paris Descartes 
University, in accordance with both the guidelines of the Dutch Council for Animal 
Care and the European Communities Council Directive (86/609/EEC). 
 
Immunohistochemistry 
Frozen kidney cortex was cut and stained for TRPC6 (Abcam, Cambridge, UK), 
nephrin (R&D, Minneapolis, USA) and desmin (Santa Cruz, Santa Cruz, USA). 
Subsequently, the mean fluorescent intensity was determined, as described 
previously [10, 11]. 
 
Cell culture studies 
Conditionally immortalized mouse podocytes (MPC-5) cells were cultured as 
described previously [34]. Differentiated cells were treated with vehicle or adriamycin, 
in combination with vehicle or various concentrations of sildenafil, pioglitazone, 8-Br-
cGMP, KT5823 or GW9662. The TRPC6 promoter activity assay was performed as 
described previously [10]. Intracellular Ca2+ was visualized using fura-2 fluorescent 
Ca2+ as previously described [11]. 
Chapter 7 
 
 
 
 
 
172 
Chromatin immunoprecipitation  
Chromatin immunoprecipitation (ChIP) was performed according to the 
manufacturers protocol. OK cells were transfected using lipofectamin with TRPC6 
promoter construct and untransfected podocytes were treated with pioglitazone, after 
which ChIP was performed (Magna ChIP A Chromatin Immunoprecipitation kit, 
Upstate Millipore) using an antibody directed against PPARγ (Santa Cruz, Santa 
Cruz, USA) and the appropriate isotype control. The enrichment of the TRPC6 
promoter compared to the isotype control was evaluated using real-time PCR with 
specific primers corresponding to the TRPC6 promoter region. 
 
Real-time quantitative PCR analysis 
RNA was isolated from kidney cortex or cultured MPC-5 cells for real-time PCR. 
Glyceraldehyde-3-phosphate dehydrogenase was used as housekeeping gene. 
 
Statistics 
All results are depicted as mean ± SEM. Student t-test or ANOVA was used to test 
for significance using SPSS software (IBM, New York, USA) followed by a Bonferroni 
post-hoc test. P values less than 0.05 were considered significant. 
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Summary 
Podocytes play a crucial role in the glomerular filtration barrier. Podocyte foot 
processes are connected by the glomerular slit diaphragm complex that contains 
specialized proteins. The proteins in the glomerular slit diaphragm complex are 
closely connected to the podocyte actin skeleton and play an important role in cell 
signaling. Injury to the podocyte can lead to cytoskeletal changes, podocyte foot 
process effacement and podocyte apoptosis, eventually leading to proteinuria and 
chronic renal function loss. Various studies suggest that podocyte injury plays a 
crucial initiating role in several hereditary and acquired proteinuric diseases, including 
focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy. Gain-of-
function mutations in the cation channel Transient Receptor Potential Channel C6 
(TRPC6), which is expressed by the podocyte, cause autosomal dominant FSGS. In 
acquired proteinuric renal disease, glomerular TRPC6 expression is increased. 
Currently it is well-established that increased calcium (Ca2+) influx through TRPC6 is 
important in the pathogenesis of podocyte injury. Therefore, the hypothesis of this 
thesis was that TRPC6 is a key pathogenic mediator in podocyte injury, the 
subsequent development of proteinuria, glomerulosclerosis and eventually loss of 
kidney function. The data described in the individual chapters of this thesis provide 
further insight into the role of TRPC6 in the molecular pathophysiology of podocyte 
injury, in particular by demonstrating the effect of high glucose and AngII in diabetic 
nephropathy, a downstream mechanism coupling TRPC6 activity to cytoskeletal 
rearrangement, effects of vitamin D deficiency and vitamin D analog treatment.  
Diabetic nephropathy is a major complication of diabetes mellitus and one of the 
leading causes of chronic renal failure, which in particular is epidemic in type 2 
diabetes. Podocyte injury due to high intrarenal levels of AngII and/or hyperglycemia 
were suggested to play a crucial role in the initiation of podocyte injury in diabetic 
nephropathy. The experiments described in chapter 2 demonstrate that high glucose 
levels can activate a local renin-angiotensin system in the podocyte, leading to 
increased TRPC6 expression, which enhances TRPC6-mediated Ca2+ influx. These 
glucose-induced effects could be ameliorated using angiotensin receptor blockers or 
angiotensin converting enzyme inhibitors. In vivo an increased glomerular TRPC6 
expression was observed in a rat model of diabetic nephropathy. These data 
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suggested that regulation of TRPC6 expression could be an important factor in 
podocyte injury due to chronic hyperglycemia, while the antiproteinuric effect of 
angiotensin receptor blockers or angiotensin converting enzyme inhibitors in diabetic 
nephropathy could be explained by downregulation of TRPC6 expression. 
Increased TRPC6 expression and activation has been associated with podocyte 
cytoskeletal rearrangement, which might eventually lead to podocyte apoptosis. 
However, the exact downstream effectors, i.e. how TRPC6-mediated Ca2+ influx 
leads to cytoskeletal changes, were not fully elucidated yet. In chapter 3 we describe 
a novel intracellular mechanism in which TRPC6-dependent Ca2+ influx leads to 
activation of the protease calpain-1 in the podocyte, which cleaves the vital podocyte 
cytoskeleton-associated protein talin-1, as well as the slit diaphragm protein nephrin. 
Importantly, calpain inhibition resulted in less podocyte injury and proteinuria in the 
adriamycin nephropathy model for human FSGS. We concluded that TRPC6-
dependent activation of calpain-1 might be a key mechanism in the initiation and 
progression of podocyte injury in glomerular diseases, thereby suggesting that this 
TRPC6-calpain mechanism constitutes a potential therapeutic target in proteinuric 
patients. 
Clinical and pre-clinical studies suggested that treatment with vitamin D analogs 
could potentially reduce proteinuria and podocyte loss. Cholecalciferol is taken up in 
the gastrointestinal tract or synthesized in the skin, after which it is converted into 25-
hydroxyvitamin D3 in the liver and, subsequently, into 1,25-dihydroxyvitamin D3 (1,25-
D3) in the proximal tubular cells of the kidney. 1,25-D3 is classically defined as the 
active form of vitamin D, which plays a central role in Ca2+ and PO43- metabolism. 
With the progression of renal insufficiency, deficiency of 1,25-D3 ensues. However, 
1,25-D3 deficiency may not only be a consequence of, but 1,25-D3 deficiency itself 
could also be the cause of renal injury. In chapter 4 we describe how podocyte injury 
induced TRPC6 expression and increased TRPC6 dependent Ca2+ influx, which 
could be attenuated by vitamin D analog application. We demonstrated that the 
vitamin D receptor directly binds to the TRPC6 promoter region, thereby reducing 
TRPC6 transcription and TRPC activity. Moreover, vitamin D treatment prevented 
proteinuria, podocyte injury and TRPC6 upregulation in a rat model for human FSGS. 
These results suggested that this TRPC6 downregulation could contribute to the 
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suggested antiproteinuric effect of vitamin D3. Importantly, we observed proteinuria in 
vitamin D3-deficient mice. We detailed the renal phenotype of both genetically 1,25-
D3 deficient mice as well as acquired 1,25-D3 deficient rats in chapter 5. These 
vitamin D3-deficient animals showed enhanced glomerular TRPC6 expression, 
glomerular and tubular injury, podocyte foot process effacement and proteinuria that 
were independent of concomitant changes in Ca2+/PO43- homeostasis. When treated 
with vitamin D2 and D3 analogs, both glomerular and tubulointerstitial injury could be 
reversed. Heparan sulfate (HS) expression in the glomerular filtration barrier is 
reduced in the majority of patients with proteinuria, which is associated with an 
increased glomerular expression of the HS-degrading enzyme heparanase. 
Previously, data from our lab showed that heparanase is essential for the 
development of proteinuria in experimental diabetic nephropathy. Interestingly, in 
similar models described in chapters 4 and 5, heparanase was similarly regulated 
compared to TRPC6, as described in chapter 6. This might suggest an (in)direct link 
between both proteins and co-regulation of their gene expression. When the results 
of these vitamin D studies are translated to and confirmed in human subjects, this 
could have implications for clinical practice. Patients with glomerular diseases and/or 
proteinuria should be actively examined for vitamin D3 deficiency, and additional 
treatment with vitamin D analogs might be considered, whether or not vitamin D 
deficiency is present. 
Sildenafil, better known by its brand name Viagra®, was primarily developed to treat 
hypertension and angina pectoris. However, the first clinical trials were disappointing 
and currently it is used to treat erectile dysfunction and pulmonary hypertension. 
Sildenafil appeared to reduce TRPC6 expression and activity in cells of the 
pulmonary vascular smooth musculature and corpus cavernosum. Peroxisome 
proliferator-activated receptor gamma (PPARy) was described as a downstream 
target of sildenafil via the cyclic guanosine monophosphate (cGMP)-activated protein 
kinase G (PKG) axis. Interestingly, PPARγ agonists like pioglitazone were suggested 
to be antiproteinuric in sporadic animal studies. We hypothesized that sildenafil could 
inhibit TRPC6 expression in podocytes, with PPARγ as a central mediator. In 
chapter 7 we demonstrated that podocyte injury-induced TRPC6 expression was 
dose-dependently downregulated by sildenafil, the cGMP analog 8-Br-cGMP and 
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pioglitazone mediated by direct binding of PPARy to the TRPC6 promoter, thereby 
inhibiting its expression and activity. PKG or PPARγ antagonists enhanced TRPC6 
expression in podocytes, and counteracted the effects of sildenafil and 8-Br-cGMP. 
Similar regulatory effects were demonstrated for TRPC6 promoter activity and 
TRPC6-dependent Ca2+ influx. Rats treated with a PPARy antagonist developed 
proteinuria and increased podocyte TRPC6 expression. Similarly, podocyte-specific 
PPARγ knock-out mice showed enhanced glomerular TRPC6 expression and 
increased susceptibility to develop proteinuria. Both sildenafil and pioglitazone 
treatment could prevent proteinuria in adriamycin-induced nephropathy. These data 
identified sildenafil as a novel antiproteinuric agent, which acts by inhibiting 
deleterious TRPC6-mediated intracellular podocyte signaling.  
 
Taken all data together, the role of TRPC6 as a central mediator of podocyte injury 
during proteinuric diseases was elucidated in this thesis. Importantly, we have shown 
that angiotensin inhibition, vitamin D analogs, PPARy agonism and sildenafil-induced 
rise in cGMP, all downregulate TRPC6 expression, thereby inhibiting its channel 
activity and reducing glomerular and podocyte injury. Notably, we elucidated a novel 
downstream pathway of TRPC6, the activation of calpain-1, linking TRPC6-
dependent Ca2+ influx to podocyte cytoskeletal changes. Given the central role of 
TRPC6 in linking multiple pathways and factors leading to podocyte injury and 
proteinuria, as described in this thesis, TRPC6 should be considered as novel 
treatment target for glomerular diseases. 
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Future perspectives 
In this thesis, potential antiproteinuric properties of sildenafil and vitamin D were 
described. Both agents are approved for clinical use in other diseases, and therefore 
would be readily available to initiate clinical trials to test their renoprotective and 
antiproteinuric effects in humans. In clinical practice vitamin D is currently only 
supplemented to prevent and treat hyperparathyroidism occurring in later stages of 
renal insufficiency. While the clinical antiproteinuric effect of vitamin D 
supplementation was already previously assessed, results and interpretation of 
studies are not unambiguous. The presumed pluripotent effects of vitamin D in kidney 
disease crosses the field of proteinuria, possibly by reducing renal fibrosis in CKD 
progression and putative immune-modulatory effects. Importantly, we demonstrated 
that vitamin D deficiency could also contribute to both glomerular and tubulointerstitial 
injury which can be reversed by supplementation with vitamin D. A reduced 
proteinuria has already been shown in patients that received vitamin D analogs in 
combination with the current standard therapy on proteinuria and progressive renal 
injury, which was confirmed by the experimental data described in this thesis. 
Therefore, it would be vital to monitor vitamin D levels in proteinuric patients in the 
clinics, and to treat these patients with vitamin D supplementation to improve renal 
outcome. 
Moreover, we have shown that sildenafil has beneficial effects on proteinuria in an 
animal model for human FSGS model. First and foremost, the effect of sildenafil 
treatment after the occurrence of proteinuria should be further detailed in animal 
studies. There is, to our knowledge, currently no data available regarding the 
renoprotective potential of sildenafil in humans. The few clinical trials performed with 
sildenafil in the field of nephrology are focused on restoration of erectile dysfunction 
after transplantation, and did not assess proteinuria. Therefore, one could start by 
assessing proteinuria in patients receiving continued sildenafil treatment, e.g. for 
pulmonary hypertension. Eventually, only randomized controlled trials can ultimately 
demonstrate whether sildenafil reduces proteinuria and ameliorates renal outcome 
compared to placebo treatment. 
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We found that heparanase activity and expression was similarly increased 
comparable to TRPC6 expression in proteinuric disease and vitamin D deficiency. Of 
note, heparanase is essential for the development of proteinuria in experimental 
diabetic nephropathy, while TRPC6 deficient animals are protected against 
angiotensin II-mediated albuminuria. This could imply that TRPC6 and heparanase 
are functionally linked. This interaction might be facilitated by syndecan proteins. 
Recently, syndecans were described to influence TRPC6 activity, while syndecan 
activity, localization and function are affected by heparanase and vice versa. 
Elucidating the mechanisms potentially linking these two important proteins in 
podocyte injury could enhance our knowledge of glomerular injury and identify more 
specific therapeutic targets.  
Previously, it was shown that Ca2+ influx through TRPC6 activates the deleterious 
feed-forward calcineurin/NFAT pathway, which is associated with a decreased 
expression of slit diaphragm-associated proteins such as nephrin, thereby inducing 
podocyte injury and proteinuria. We now demonstrated that, alongside of this 
downstream pathway, TRPC6-dependent Ca2+ influx activates calpain-1. 
Interestingly, calpains are described to activate calcineurin as well, providing the 
possibility that calpain-1 is the mediator between TRPC6 and calcineurin activation. 
On the other hand, calpain-1 was also shown to be involved in TRPC6 proteolysis in 
the brain, thereby affecting TRPC6 cell membrane abundance. Moreover, calpains 
are able to recruit cathepsins, including cathepsin V (homologous to cathepsin-L in 
mice) from lysosomes. Cathepsin V activates heparanase, which provides again a 
possible link between TRPC6 and heparanase. Our current data showed that 
calpain-1 inhibition in adriamycin nephropathy rats led to TRPC6 mRNA 
downregulation, while TRPC6 protein expression was still increased. Notably, in 
neurons it was shown that calpains were able to cleave and subsequently degrade 
TRPC6 protein. Since the TRPC6-calcineurin/NFAT pathway was described as a 
deleterious feed-forward loop, one could hypothesize that either calpain-1 proteolysis 
or cathepsin-mediated degradation of TRPC6 could form the elusive negative 
feedback loop controlling TRPC6 expression in the podocyte, which should be 
addressed in future studies. As our initial data suggests, the potential pathway of 
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TRPC6-mediated calpain-1 activation could be very relevant to establish whether and 
how calpain inhibition could be a novel therapeutic target during proteinuric disease. 
Currently, TRPC6 is associated with podocyte injury and proteinuria. To determine 
whether TRPC6 is indeed a valuable in vivo target experiments have to be performed 
in transgenic knockout (KO) animals. Indeed, it has been shown that angiotensin II-
induced proteinuria is ameliorated in TRPC6 KO mice. However, the currently 
available systemic non-conditional TRPC6 KO mouse model has several drawbacks. 
Since TRPC6 systemic KO mice have no renal or podocyte phenotype, one could 
reason that TRPC6-targeted therapy can be tolerated without inducing specific renal 
injury. This is rather unexpected given the central role of TRPC6 in the podocyte. 
Moreover, the TRPC6 KO was generated to investigate its role in vascular smooth 
muscle cell (VSMC) contraction and, therefore, was expected to show hypotension. 
Surprisingly, hypertension occurred, due to replacement of TRPC6 by the related 
constitutively active TRPC3 channel in VSMCs. Compensatory mechanisms could 
take place in podocytes as well. In addition, the classical TRPC6 KO is not 
representative of the clinical situation where one would want to pharmacologically 
induce TRPC6 loss-of-function during/after renal injury. Then, it is yet unknown 
whether systemic TRPC6 inhibition would have beneficial, or rather more side-effects 
over local, podocyte-targeted therapy. Finally, because of the potential compensatory 
effects and the lack of tissue-specificity, the classical systemic TRPC6 KO is not 
helpful in further delineating the physiological role of TRPC6 in the podocyte. 
Therefore, there is need for an inducible, podocyte-specific, TRPC6 KO model. The 
inducible KO model could be used to study the effects of acquired functional TRPC6 
loss in podocyte injury and glomerular disease. Furthermore, it could be used to 
investigate the physiological role of TRPC6 in the podocyte, which is yet incompletely 
understood, and confirm TRPC6-dependency of certain processes and mechanisms 
in health and disease in vivo. 
Although this thesis focuses on the role of TRPC6 in the podocyte in the 
development of podocyte injury and proteinuria, future research should also address 
TRPC6 in other cell types in the filtration barrier, in particular glomerular endothelial 
cells, but also mesangial cells and parietal epithelial cells. Since there is important 
cross-talk between podocytes and endothelial cells, studying TRPC6 in co-cultures of 
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podocytes and endothelial cells is another future perspective. Several in vitro studies 
could be performed in these co-cultures, thereby evaluating the same cell signaling 
pathways and TRPC6 regulators and TRPC targets as outlined in this thesis.  
When the importance of TRPC6 in the podocyte has been proven during proteinuric 
diseases in the podocyte specific inducible KO animals, it is important to determine 
whether specific TRPC6 inhibitors might reduce proteinuria in vivo. Interestingly, 
recently, SAR7334 has been described as potent TRPC6 blocker. Pharmacokinitic 
studies determined SAR7334 was suitable for chronic oral administration. Therefore, 
studies with SAR7334 should be performed that could possibly improve renal 
outcome in in vivo nephropathy models. Eventually, if successful in vivo, SAR7334 
could be tested in clinical trials, paving the way to a more specific treatment of 
proteinuric patients by inhibiting TRPC6 channels. 
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Translational aspects 
The work described in this thesis mainly used in vitro and in vivo methods to 
determine the role of TRPC6 during podocyte injury and how TRPC6 expression and 
activity can be modulated to decrease podocyte injury. When translated to the clinic, 
we hypothesize that treatment with vitamin D and sildenafil supplements potentially 
can be used as add-on therapy to the conventional antiproteinuric treatment. In the 
case of treatment with vitamin D analogs, there are indeed already indications in 
literature that this could be effective in proteinuric human patients. Importantly, in this 
thesis we describe that genetic as well as acquired vitamin D deficiency in rodents 
leads to the development of spontaneous proteinuria. Therefore, we suggest that it 
could be important to test vitamin D status of renal patients, and if necessary correct 
it, irrespective of for example secondary hyperparathyroidism being present. In 
general, increasing knowledge on podocyte injury pathways from preclinical studies, 
such as described in this thesis, might translate into new personalized treatment 
options for renal patients in the future. 
Therefore, this thesis also suggests that the TRPC6 ion channel itself, or the 
podocyte injury signaling pathways TRPC6 is involved in, could be future therapeutic 
targets in podocyte injury and proteinuric human disease. To further substantiate the 
potential of such targeted therapy in patients, it is particularly important to try to 
understand how and what other mechanisms link into TRPC6-mediated signaling, 
and to specifically address the potential of (TRPC6-)targeted therapy. Of note, cation 
channels like TRPC6 are highly amenable to (pharmacological) modulation. 
However, many TRP-type channel blockers are non-specific with regard to the 
channels and tissues targeted, and therefore have serious potential for unwanted 
side-effects in humans. However, the pharmaceutical industry has been working on 
more specific channel blockers, suggesting that TRPC6-specific pharmacological 
inhibition could be a real prospective in the near future. In addition, tissue or even 
cell-specific targeting of compounds is increasingly being achieved in preclinical 
studies. In the coming years, we should use the in vitro and in vivo experimental 
models we have established and plan to develop, including podocyte-specific 
inducible TRPC6 knockout mice, to provide proof-of-principle of TRPC6-targeted 
therapy in proteinuria. If confirmed, we will be able to take the step towards 
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specifically targeting TRPC6 in humans and proteinuric patients, taking the TR(i)P 
into clinical practice. 
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Nederlandse samenvatting 
Podocyten spelen een cruciale rol in de glomerulaire filtratiebarrière. Podocytvoetjes 
zijn onderling verbonden met het glomerulaire filtratiespleetdiafragma, welke 
gespecialiseerde eiwitten bevat. De eiwitten in het glomerulaire 
filtratiespleetdiafragma complex zijn nauw verbonden met het actine cytoskelet van 
de podocyt en spelen een belangrijke rol tijdens celsignalering. Beschadiging van de 
podocyten kan leiden tot veranderingen in het cytoskelet, podocytvoetjes versmelting 
en uiteindelijk tot proteïnurie en chronisch nierfunctie verlies. Verschillende studies 
suggereren dat podocytschade een belangrijke rol speelt tijdens de initiatie van 
verschillende genetische en verworven proteïnurische ziekten, bijvoorbeeld focale 
segmentale glomerulosclerose (FSGS) en diabetische nefropathie. Het cation 
geleidend ion-kanaal Transient Receptor Potential Channel C6 (TRPC6) bevindt zich 
in het filtratiespleetdiafragma complex. Mutaties in het gen dat codeert voor TRPC6 
kunnen leiden tot een toegenomen activiteit van het kanaal, wat vervolgens leidt tot 
autosomale dominante FSGS. In verworven proteïnurische nierziekten is de 
glomerulaire TRPC6 expressie toegenomen. Inmiddels is aangetoond dat door 
TRPC6 gemedieerde calcium (Ca2+) influx een pathogeen sleutelmechanisme is voor 
het ontstaan van podocytschade, de hieruit voortvloeiende proteïnurie, glomerulaire 
sclerose en het uiteindelijke verlies van nierfunctie. De data beschreven in de 
verschillende hoofdstukken van dit proefschrift geven meer inzicht in de rol van 
TRPC6 in de moleculaire pathofysiologie van podocytschade. Specifiek kon worden 
aangetoond dat hoge concentraties glucose en angiotensine II (AngII) tijdens 
diabetische nefropathie een verhoogde TRPC6 activiteit koppelen aan veranderingen 
in het cytoskelet. Daarnaast kon worden aangetoond dat vitamine D deficiëntie leidt 
tot verhoogde TRPC6 activiteit en proteïnurie, wat kon worden behandeld met 
vitamine D analogen. 
Diabetische nefropathie is een frequente complicatie van diabetes mellitus en één 
van de voornaamste oorzaken van chronisch nierfalen, wat voornamelijk voorkomt bij 
patiënten met type 2 diabetes. Hoge intrarenale AngII concentraties en/of 
hyperglycemie spelen een cruciale rol tijdens de initiatie van podocytschade tijdens 
diabetische nefropathie. De data beschreven in hoofdstuk 2 tonen aan dat hoge 
glucose concentraties het locale renine-angiotensine systeem kunnen activeren in de 
podocyt, wat leidt tot een hogere TRPC6 expressie en TRPC6 gemedieerde Ca2+ 
influx. Deze glucose geïnduceerde effecten kunnen worden voorkomen door 
behandeling met angiotensine receptor blokkers of angiotensine I converterend 
enzym remmers. In een rat model voor diabetische nefropathie werd een 
toegenomen glomerulaire TRPC6 expressie gevonden. Deze data suggereren dat de 
regulatie van TRPC6 expressie een belangrijke factor is bij het ontstaan van 
podocytschade. In diabetische nefropathie wordt deze schade veroorzaakt door 
chronische hyperglycemie terwijl behandeling met angiontensine receptor blokkers of 
remmers van het angiotensine I converterend enzym tijdens diabetische nefropathie 
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zorgt voor verminderde proteïnurie. Deze verminderde podocytschade kan worden 
uitgelegd door afname van glomerulaire TRPC6 expressie. 
Toegenomen TRPC6 expressie en activiteit zijn geassocieerd met veranderingen in 
het cytoskelet, wat uiteindelijk kan leiden tot de dood (apoptose) van de podocyt. 
Echter, de exacte moleculaire effectoren die verklaren hoe TRPC6 gemedieerde 
Ca2+ influx kan leiden tot cytoskelet veranderingen, zijn niet volledig bekend. In 
hoofdstuk 3 wordt een belangrijke nieuwe intracellulair mechanisme beschreven 
waarin TRPC6 afhankelijke Ca2+ influx leidt tot activatie van de protease calpain-1 in 
de podocyt. Calpain-1 breekt vervolgens de cruciale eiwitten talin-1 en het nefrine af 
in de podocyt. Calpain inhibitie resulteert in verminderde podocytschade en 
proteïnurie in adriamycine nefropathie ratten die model staan voor humane FSGS. 
Hieruit kan worden geconcludeerd dat TRPC6-afhankelijke activatie van calpain-1 
een sleutelmechanisme kan zijn bij de initiatie en progressie van podocytschade 
tijdens glomerulaire ziekten. Daarmee zou het TRPC6-calpaine mechanisme een 
mogelijke therapeutisch aangrijpingspunt vormen in de behandeling van 
proteïnurische patiënten. 
Klinische en preklinische studies suggereren dat een behandeling met vitamine D 
analogen mogelijk kan leiden tot een verminderde proteïnurie en minder verlies van 
podocyten. Cholecalciferol wordt opgenomen in de darm of gemaakt in de huid. 
Vervolgens wordt het omgezet naar 25-hydroxyvitamine D3 in de lever en uiteindelijk 
naar 1,25-dihydroxyvitamine D3 (1,25-D3) in de proximale tubulaire cellen van de 
nier. Klassiek gezien is 1,25-D3 de actieve vorm van vitamine D, welke een 
belangrijke rol speelt in de Ca2+ en fosfaat (PO43-) huishouding. Tijdens progressieve 
nierinsufficiëntie zal de patiënt vitamine D deficiënter worden. Echter, 1,25-D3 
deficiëntie is mogelijk niet alleen een gevolg van nierschade maar kan ook een 
oorzaak zijn. In hoofdstuk 4 wordt beschreven hoe toegenomen podocytschade, 
TRPC6 expressie en TRPC6 afhankelijke Ca2+ influx kan worden voorkomen door 
behandeling met verschillende vitamine D analogen. We tonen aan dat de vitamine D 
receptor direct bindt in de TRPC6 promoter regio, en daarbij TRPC6 transcriptie en 
activiteit vermindert. Behandeling van adriamycine nefropathie ratten, een model 
voor humane FSGS, met vitamine D voorkwam proteïnurie, podocytschade en 
toegenomen TRPC6 expressie. Hieruit kan worden geconcludeerd dat vermindering 
van TRPC6 kan bijdragen aan het antiproteïnurische effect van vitamine D3. Tijdens 
deze studie werd geheel onverwacht ook proteïnurie in genetisch vitamine D3-
deficiënte muizen gevonden. In hoofdstuk 5 wordt het nierfenotype van deze muizen 
en van verkregen vitamine D3-deficiënte ratten beschreven. Beide diermodellen 
vertoonden een verhoogde glomerulaire TRPC6 expressie, glomerulaire en tubulaire 
schade, podocytvoetjes versmelting en proteïnurie, waarbij deze effecten 
onafhankelijk waren van de veranderingen in serumconcnetraties van Ca2+ en PO43-. 
Behandeling met vitamine D2 en D3 analogen normaliseerde de glomerulaire en 
tubulointerstitiële schade.  
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Heparansulfaat (HS) expressie in de glomerulaire filtratie barrière is afgenomen in de 
meeste patiënten met proteïnurie. Tevens is proteïnurie in patiënten geassocieerd 
met een toegenomen glomerulaire expressie van het HS-afbrekend enzym 
heparanase. Voorgaande experimenten van onze groep lieten zien dat heparanase 
essentieel is bij het ontstaan van proteïnurie tijdens diabetische nefropathie. In 
vergelijkbare modellen die gebruikt zijn in hoofdstukken 4 en 5 kon worden 
aangetoond dat heparanase en TRPC6 op een zelfde manier worden gereguleerd 
door vitamine D, zoals beschreven in hoofdstuk 6. Dit zou kunnen suggereren dat er 
een (in)direct verband tussen TRPC6 en heparanase, en mogelijk co-regulatie van 
genexpressie bestaat.  
 
Wanneer de resultaten van deze vitamine D studies zijn vertaald en bevestigd in 
patiëntenstudies, dan kan dit gevolgen hebben voor de klinische praktijk. Vitamine D 
deficiëntie zou in patiënten met glomerulaire ziekten en/of proteïnurie actief moeten 
worden gescreend en een additionele behandeling met vitamine D analogen kan dan 
worden overwogen. 
 
Sildenafil, beter bekend onder de merknaam Viagra®, is oorspronkelijk ontwikkeld om 
hypertensie en angina pectoris te behandelen. Echter, de eerste klinische trials 
waren teleurstellend. Nu wordt Sildenafil gebruikt om erectiestoornissen en 
longhypertensie te behandelen. Sildenafil vermindert TRPC6 expressie en activiteit in 
bepaalde cellen van de long en de penis. Peroxisome proliferator-activated receptor 
gamma (PPARγ) is beschreven als een aangrijpingspunt van sildenafil via de 
cyclisch guanosine monofosfaat (cGMP) geactiveerde proteïne kinase G (PKG) 
route. Antiproteïnurische effecten van PPARγ agonisten zoals pioglitazone worden 
beschreven in een klein aantal dierstudies. Onze hypothese is dat sildenafil TRPC6 
expressie kan verminderen in podocyten, waarbij PPARγ een centrale mediator is. In 
hoofdstuk 7 wordt aangetoond dat podocytschade geïnduceerde toename van 
TRPC6 concentratie-afhankelijk kan worden verminderd door sildenafil, de cGMP 
analoog 8-Br-cGMP en pioglitazone. Deze effecten worden gemedieerd door directe 
binding van PPARγ aan de TRPC6 promoter, waardoor de expressie en activiteit van 
TRPC6 vermindert. PKG en PPARγ antagonisten verhogen de TRPC6 expressie in 
podocyten en neutraliseren de effecten van sildenafil en 8-Br-cGMP. Vergelijkbare 
resultaten werden gevonden met TRPC6 promoteractiviteit en TRPC6 afhankelijke 
Ca2+ influx. Ratten behandeld met een PPARγ antagonist ontwikkelden proteïnurie 
en vertoonden een verhoogde glomerulaire TRPC6 expressie. Ook podocyt-
specifieke PPARγ deficiënte muizen vertoonden een toegenomen glomerulaire 
TRPC6 expressie en waren gevoeliger voor het ontwikkelen van proteïnurie. Zowel 
behandeling met sildenafil als pioglitazone kan proteïnurie voorkomen in ratten met 
adriamycine geïnduceerde nefropathie. Deze data identificeren sildenafil als een 
nieuw anti-proteinurische middel, dat werkt door inhibitie van de schadelijke TRPC6-
gemedieerde intracellulaire signaleringscascade. 
Samenvatting, toekomstperspectieven en translationele aspecten 
 
 
 
 
 
191 
Samengevat, in dit proefschrift wordt de centrale rol van TRPC6 in het ontstaan van 
podocytschade tijdens proteïnurische ziekten beschreven. Er is aangetoond dat 
angiotensine remming, vitamine D analogen, PPARγ agonisten en sildenafil allen 
geïnduceerde TRPC6 expressie kunnen verlagen en daarmee de kanaalactiviteit, 
glomerulaire- en podocytschade kunnen verminderen. Er is een nieuw mechanisme 
opgehelderd waarin verhoogde TRPC6 activiteit calpain-1 activeert wat vervolgens 
leidt tot podocytaire cytoskelet veranderingen. Door de centrale rol van TRPC6 in het 
verbinden van verschillende signaaltransductieroutes en factoren die leiden tot 
podocytschade en proteïnurie, zoals beschreven in dit proefschrift, zou TRPC6 
overwogen moeten worden als nieuw aangrijpingspunt voor het behandelen van 
glomerulaire ziekten. 
  
Chapter 9 
 
 
 
 
 
192 
Toekomstperspectieven 
In dit proefschrift worden de potentiële antiproteïnurische eigenschappen van 
sildenafil en vitamine D beschreven. Beide stoffen zijn al goedgekeurd voor klinisch 
gebruik voor andere ziekten en kunnen daarom direct gebruikt worden in klinische 
onderzoeken om de nierbeschermende en antiproteïnurische effecten in patiënten te 
bestuderen. In de kliniek wordt vitamine D gebruikt om hyperparathyroidisme, een 
ziektebeeld in latere stadia van nierinsufficiëntie, te voorkomen of te behandelen. 
Ondanks dat het antiproteïnurische effect van vitamine D suppletie in eerdere 
klinische studies was onderzocht, waren de resultaten niet eenduidig. Het 
veronderstelde pluripotente effect van vitamine D tijdens nierziekten heeft het veld 
van proteïnurie gekruist, mogelijk door het verminderen van renale fibrose in CKD 
progressie en een veranderde immuun-modulatie. Wij hebben in dit proefschrift 
aangetoond dat vitamine D deficiëntie ook kan bijdragen aan glomerulaire- en 
tubulointerstiële schade, welke behandeld kunnen worden door vitamine D suppletie. 
Het was al bekend dat proteïnurische patiënten die vitamine D analogen krijgen 
bovenop de standaard medicatie tegen progressieve nierschade en proteïnurie, een 
verminderde proteïnurie optreedt. Deze klinische data worden nu onderbouwd door 
de experimentele modellen beschreven in dit proefschrift. Daarom is het van groot 
belang dat in de kliniek vitamine D waarden in proteïnurische patiënten worden 
bepaald en er wordt behandeld met vitamine D analogen voor een betere uitkomst 
van de nierziekte.  
Daarnaast hebben we laten zien dat sildenafil gunstige effecten heeft op proteïnurie 
in een diermodel voor humane FSGS. Het is van groot belang om in toekomstige 
dierstudies te bestuderen wat het effect is van sildenafil behandeling op het ontstaan 
van proteïnurie. Zover wij kunnen nagaan bestaan er geen data over de 
nierbeschermende effecten van sildenafil in mensen. Het kleine aantal klinische 
onderzoeken dat is uitgevoerd met sildenafil met betrekking tot niergerelateerde 
onderwerpen beperkt zich tot het herstel van erectiestoornissen na een 
niertransplantatie, waarbij niet gekeken is naar proteïnurie. Daarom zou proteïnurie 
bestudeerd kunnen worden in patiënten die een continue behandeling van sildenafil 
krijgen, zoals patiënten met longhypertensie. Uiteindelijk kunnen alleen 
gerandomiseerde gecontroleerde klinische onderzoeken uitwijzen of sildenafil 
proteïnurie en nierschade kan verminderen in vergelijking met een placebo 
gecontroleerde groep. 
We hebben gevonden dat heparanase en TRPC6 activiteit en expressie vergelijkbaar 
waren verhoogd in proteïnurische ziekten en vitamine D deficiëntie. Heparanase is 
essentieel voor het ontstaan van proteïnurie in experimentele diabetische 
nefropathie, terwijl TRPC6-deficiënte dieren beschermd zijn tegen angiotensine II 
gemedieerde albuminurie. Dit kan betekenen dat TRPC6 en heparanase functioneel 
zijn gekoppeld. Deze interactie zou gefaciliteerd kunnen worden door syndecan 
eiwitten. Recent is aangetoond dat syndecans TRPC6 activiteit kunnen beïnvloeden, 
terwijl syndecan activiteit, lokalisatie en functie worden beïnvloed door heparanase 
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en visa versa. Het ontrafelen van de mogelijke interacties tussen deze twee 
belangrijke met podocytschade geassocieerde eiwitten kan onze kennis over 
glomerulaire schade vergroten en mogelijk leiden tot een specifieker 
aangrijpingspunt voor therapeutische interventie.  
 
Eerder is aangetoond dat TRPC6 afhankelijke Ca2+ influx het zichzelf amplificerende 
en schadelijke calcineurin/NFAT mechanisme activeert. Activatie van dit mechanisme 
gaat gepaard met een verlaagde expressie van de glomerulaire 
filtratiespleetdiafragma eiwitten, waaronder nefrine, podocytschade en proteïnurie. In 
dit proefschrift laten we zien dat naast dit mechanisme, TRPC6 afhankelijke Ca2+ 
influx leidt tot activatie van calpain-1. Het is beschreven dat calpains calcineurin 
kunnen activeren, waarbij mogelijk calpain-1 de mediator is tussen TRPC6 en 
activatie van calcineurin. Aan de andere kant is calpain-1 betrokken bij de proteolyse 
van TRPC6 in de hersenen, waarbij het invloed heeft op de hoeveelheid TRPC6 die 
aanwezig is op de celmembraan. Ook kunnen calpains cathepsins rekruteren uit de 
lysosomen, waaronder cathepsin V (een homoloog van cathepsin L in muizen). 
Cathepsin V kan heparanase activeren en draagt hiermee bij aan een mogelijke 
interactie tussen TRPC6 en heparanase. In dit proefschrift beschrijven we dat 
calpain-1 inhibitie in adriamycine nefropathie ratten leidt tot afname van TRPC6 
mRNA expressie, terwijl de TRPC6 eiwitexpressie nog was verhoogd. Zoals eerder 
beschreven wordt het TRPC6 eiwit in neuronen afgebroken door calpain-1. Omdat 
het TRPC6-calcineurin/NFAT mechanisme zichzelf amplificeert en daardoor 
schadelijk is, kan worden voorgesteld dat TRPC6 proteolyse door calpain-1 of 
cathepsins de nog onbekende remmende factor is. Dit zal echter in toekomstige 
studies moeten worden uitgezocht. Onze initiële data suggereren dat het relevant is 
om te bepalen of remming van calpain kan dienen als nieuw therapeutisch 
aangrijpingspunt voor de behandeling van proteïnurische ziekten. 
Tegenwoordig is TRPC6 geassocieerd met podocytschade en proteïnurie. Om te 
bepalen of TRPC6 regulatie werkelijk een waardevol in vivo aangrijpingspunt is, 
moeten er experimenten worden uitgevoerd in transgene ‘knockout’ (KO) dieren. 
Eerder is aangetoond dat angiotensine II geïnduceerde proteïnurie is verminderd in 
TRPC6 KO muizen. Echter, deze systemische, niet-conditionele, TRPC6 KO dieren 
hebben een aantal nadelen. De TRPC6 KO dieren hebben bijvoorbeeld geen renaal- 
of podocytair fenotype, dus zou er geconcludeerd kunnen worden dat TRPC6 
remmende therapie getolereerd kan worden zonder specifieke negatieve gevolgen 
voor de nier. Dit lijkt onwaarschijnlijk omdat TRPC6 een centrale rol speelt in de 
podocyt. De TRPC6 KO muizen zijn ontwikkeld voor onderzoek naar de contractie 
van vasculaire gladde spiercellen (VGSC) en er was verwacht dat er hypotensie zal 
ontstaan in deze TRPC6 KO dieren. Tegen de verwachting in vertoonden deze 
TRPC6 KO dieren hypertensie, welke was ontstaan omdat TRPC3, een altijd actief 
en aan TRPC6 gerelateerd ion-kanaal, de plaats van TRPC6 had ingenomen op de 
VGS cellen. Deze compensatoire mechanismen kunnen ook optreden in de podocyt. 
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Daarnaast is de klassieke TRPC6 KO niet representatief voor de klinische situatie 
waarin tijdens of na de nierschade pas farmacologische TRPC6 remming gewenst is. 
Daarbij is het onbekend of systemische TRPC6 remming voordelen biedt, of meer 
bijwerkingen, dan locale podocyt-specifieke therapie. Door de mogelijke 
compensatoire effecten en gebrek aan weefselspecificiteit, is de originele TRPC6 KO 
niet geschikt om de fysiologische rol van TRPC6 in de podocyt te achterhalen. 
Daarom is er een grote behoefte aan een induceerbaar podocyt-specifieke TRPC6 
KO muismodel. Dit induceerbare KO model kan worden gebruikt om de effecten van 
TRPC6 verlies tijdens podocytschade en glomerulaire ziekten aan te tonen. Ook zou 
dit induceerbare KO model kunnen worden gebruikt om de nog niet geheel bekende 
fysiologische rol van TRPC6 in de podocyt verder te onderzoeken, terwijl bekende 
TRPC6-afhankelijke effecten en mechanismen in vivo kunnen worden bevestigd.  
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Translationele aspecten 
Het werk beschreven in dit proefschrift maakt voornamelijk gebruik van in vitro en in 
vivo methoden om de rol van TRPC6 tijdens podocytschade te achterhalen, alsmede 
hoe TRPC6 expressie en activiteit kan worden beïnvloed om podocytschade te 
verminderen. Vertaald naar de kliniek, denken we dat behandeling met vitamine D en 
sildenafil supplementen mogelijk gebruikt kan worden als ondersteunende therapie 
bovenop de bestaande antiproteïnurische behandeling. In het geval van behandeling 
met vitamine D analogen zijn er inderdaad al indicaties in de literatuur dat deze een 
antiproteïnurisch effect kunnen bewerkstelligen in patiënten. In dit proefschrift 
beschrijven we dat zowel genetisch als verkregen vitamine D deficiëntie in 
knaagdieren leiden tot het ontstaan van spontane proteïnurie. Daarom lijkt het 
belangrijk om de vitamine D status van nierpatiënten te bepalen, en als dit nodig is te 
corrigeren, onafhankelijk van bijvoorbeeld het bestaan van een secundaire 
hyperparathyreoidie. De in deze preklinische studies verkregen kennis over 
mechanismen van podocytschade kunnen in de toekomst mogelijk vertaald worden 
naar nieuwe gepersonaliseerde behandelopties voor nierpatiënten. 
De resultaten beschreven in dit proefschrift suggereren ook dat het TRPC6 ionkanaal 
zelf, of de TRPC6 geassocieerde intracellulaire podocytschademechanismen, 
mogelijk een toekomstig therapeutisch doel vormen bij podocytschade in humane 
proteïnurische ziekten.  
Om de potentie van TRPC6 gerichte therapie voor de klinische praktijk te toetsen is 
het belangrijk om te begrijpen welke andere signaaltransductiemechanismen 
beïnvloed worden door TRPC6 expressie en/of activiteit, en om specifiek het effect 
van (TRPC6) gerichte therapie te onderzoeken. Van kationkanalen zoals TRPC6 is 
bekend dat hun activiteit relatief makkelijk farmacologisch te beïnvloeden is. Helaas 
zijn veel TRP-type kanaal blokkers niet kanaal- en weefselspecifiek, en hierdoor 
zouden potentieel bijwerkingen kunnen optreden. De farmaceutische industrie werkt 
momenteel echter aan steeds specifieker kanaalblokkers, hetgeen mogelijk al in de 
nabije toekomst kan leiden tot TRPC6 specifieke farmaca. Daarbij komt dat er 
methoden in ontwikkeling zijn die het in preklinische studies mogelijk maken om 
geneesmiddelen weefsel- of zelfs celspecifiek toe te dienen. In de aankomende jaren 
zullen we de in dit proefschrift beschreven in vitro en in vivo experimentele modellen 
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gebruiken, alsmede nieuwe modellen ontwikkelen zoals een podocyt specifieke 
induceerbare TRPC6 knockout muis, om te bevestigen dat TRPC6 specifieke 
behandeling bij proteïnurie van nut kan zijn. Op dat moment komt antiproteïnurische 
behandeling middels gerichte therapie in zicht, zodat we de TR(i)P naar de klinische 
praktijk kunnen ondernemen. 
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Ramon Sonneveld werd op 27 december 1985 geboren te Brummen. In 2003 
behaalde hij zijn HAVO diploma op het Isendoorn College te Warnsveld, en twee jaar 
later zijn VWO diploma op het Stedelijk Dalton College te Zutphen. Hetzelfde jaar 
begon hij aan de opleiding Biomedische Wetenschappen aan de Radboud 
Universiteit Nijmegen met als major Pathobiologie, minor Neurowetenschappen en 
Griekse mythologie als bijvak. Hij deed onderzoeksstages op de afdelingen 
Neurologie, Matrix Biochemie en Antropogenetica van het Radboudumc. In 2010 
werd deze studie met goed gevolg afgerond en is hij vervolgens direct gestart als 
promovendus op de afdelingen Nierziekten en Fysiologie van het Radboudumc op 
het project “Role of the novel slit diaphragm-associated channel TRPC6 in glomerular 
disease”, onder begeleiding van Dr. Tom Nijenhuis, Dr. Johan van der Vlag, Prof. Dr. 
Jo Berden en Prof. Dr. Joost Hoenderop, dat uitmondde in het in dit proefschrift 
beschreven onderzoek. Hierbij werd ook een bijdrage geleverd aan het onderwijs aan 
studenten van de opleidingen Moleculaire Levenswetenschappen en Medische 
Biologie. Tijdens zijn promotie is hij 4 jaar commissielid geweest van het landelijk 
Platform AIO’s/Post-docs Nefrologie en daarbij verschillende evenementen 
georganiseerd, waaronder een ééndaags nefrologiecongres in Nijmegen. Sinds 
december 2014 werkt Ramon als post-doctoraal onderzoeker op de afdeling 
Nierziekten van het Radboudumc waarin hij verder werkt aan de TRPC6 
onderzoekslijn. 
  
Chapter 10 
 
 
 
 
 
200 
 
Chapter 11 
 
 
 
Dankwoord 
 
 
  
Chapter 11 
 
 
 
 
 
202 
Nu het boekje klaar is, is het tijd om de mensen die hebben bijgedragen aan dit 
proefschrift te bedanken.  
 
Tegen de standaard gebruiken in wil ik allereerst mijn co-promotoren bedanken.  
Beste Tom en Johan, bedankt voor de kans die jullie mij hebben gegeven om dit 
promotietraject te kunnen volgen en uiteindelijk zelfs het onderzoek voort te kunnen 
zetten als post-doc. Ik had het voorrecht om co-promotoren te hebben met een 
onderzoeks dan wel klinische achtergrond, die elkaar fantastisch aanvullen! Jullie 
staan altijd open voor nieuwe ideeën en invalshoeken, waarvan het calpaine verhaal 
een succesvol voorbeeld is. Tijdens de werkbesprekingen hadden we goede 
discussies over de data, implicaties hiervan of gerelateerde onderwerpen. Hierdoor 
duurden deze vaak iets langer dan gepland, waardoor ik regelmatig door collega’s al 
een ‘goed weekend’ werd gewenst voordat we waren begonnen.  
Tom, zonder de subsidies die je hebt binnengehaald was het niet mogelijk geweest 
om dit promotietraject te kunnen starten. En ondanks je klinische taken maak je veel 
tijd vrij voor de wetenschap. Zo ben je altijd supersnel met het nakijken van 
presentaties en manuscripten en heb je vaak tijd om even kort te overleggen. Tom, 
heel erg bedankt! 
Johan, ook jij hebt me de kans gegeven om dit traject te starten. Ik vind het prachtig 
dat je, ondanks je overvolle agenda en duizelingwekkende ‘to do list’, altijd de tijd kan 
vinden om mensen te helpen en persoonlijke verhalen te delen. Johan, dank je wel! 
 
Niet te onderschatten was natuurlijk de betrokkenheid van de promotoren. 
Beste Joost, het is bewonderingswaardig hoe punctueel en efficiënt je bent. Bij jou 
stond de deur altijd open voor vragen of advies. Tijdens werkbesprekingen en de 
FLM had je vaak goede ideeën, waaruit onder andere het promoter-construct is 
voortgekomen. Dank je wel Joost! 
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Beste Jo, ik vind het mooi om te zien hoe betrokken je nog bent bij, en hoeveel inzet 
je nog toont voor de afdeling, ondanks dat je inmiddels de eretitel emeritus professor 
draagt. Hierdoor was het mogelijk om deze promotie op zo’n korte termijn te kunnen 
realiseren. Ik denk dat ik hierbij ook voor de hele afdeling nierziekten spreek, heel erg 
bedankt. 
 
Geachte manuscriptcommissieleden, ik wil jullie bedanken voor het beoordelen van 
mijn proefschrift. 
 
En dan mijn collega’s... 
Ik denk dat er weinig afdelingen zijn waarbij zoveel koekjes worden weggewerkt, en 
waarbij we allemaal nog door de deur van het lab passen. Ik weet dat sommige 
mensen het heel graag zouden willen (Mathijs, Jasper), maar ik ga niet iedereen 
apart noemen. Ik wil jullie allemaal bedanken voor de levendige discussies aan de 
koffietafel en ongelofelijk gezellige sfeer! 
 
Hierbij wil ik ook de collega’s van de afdeling fysiologie bedanken. Ik kwam vaak 
even langs om te ‘shoppen’ of voor jullie expertise. 
 
Tijdens mijn onderzoek heb ik vele proefdieren gebruikt en daarom wil ik de 
medewerkers van het CDL bedanken.  
 
Natuurlijk wil ik de co-auteurs bedanken die allen een zeer belangrijke bijdrage 
hebben geleverd aan dit boekje! 
 
Lars en Maurice, jullie waren mijn eerste twee studenten. Ik hoop dat jullie net zoveel 
van mij hebben geleerd als ik van jullie. 
 
Mijn mentor, beste Frank, ondanks dat we elkaar ongeveer eens per jaar zagen heb 
je me van goed advies voorzien. Dank je wel. 
Marinka en Marijke, wat is het fijn om jullie als paranimf te hebben! Jullie hebben me 
ongelofelijk geholpen bij het opzetten en uitvoeren van dit project.  
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Ook wil ik mijn vrienden bedanken. Jullie zorgden voor ontspanning na het werk. 
Vooral de, tot diep in de nacht durende, gamedagen met Jørn en Mark moeten we 
erin houden! 
 
Lieve pappa en mamma, ik weet zeker dat jullie nog trotser zijn dan ikzelf. Dankzij de 
opvoeding die jullie me hebben gegeven, met de onvoorwaardelijke liefde en steun, 
ben ik zo geworden zoals ik nu ben. Ik kan me geen betere ouders wensen. Dank 
jullie wel. 
 
Allerliefste Nienke, we hebben de afgelopen vijf jaar veel meegemaakt, een huis 
gekocht, getrouwd en een dochter gekregen. Je hebt me altijd gesteund tijdens mijn 
promotietraject, en je hebt me geholpen de laatste spelfouten uit het dankwoord te 
halen. Dank je wel voor alles, ik houd van je. 
 
Allerlaatst wil ik Vera bedanken, onze prachtige dochter. Je hebt inhoudelijk niets 
bijgedragen aan dit proefschrift, maar je voetje staat wel vereeuwigd op de voorkant. 
